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The observation that several RTKs can act as promoters of tumor development and growth has 
brought a revolution in the study of new targets, in the hope of developing more specific anticancer 
drugs: the Insulin-like Growth Factors system is among the most studied. 
The role of this system in the development and progression of a large number of malignancies is 
well documented. Hence the development of different classes of compounds that can affect this 
system, in particular directly targeting the type 1 receptor (IGF-1R). Some of these compounds, both 
monoclonal antibodies (mAbs) against the receptor or small molecules that inhibit the TK activity of 
IGF-1R, are already undergoing clinical trials, because of their effectiveness in inhibiting the signal. 
Unfortunately, cancer cells show a high degree of plasticity and redundancy in the proliferative and 
anti-apoptotic signals, which may contribute to the creation of resistance to specific inhibitors: the 
identification of these mechanisms, and their overcome, are two key goals in the development of 
these drugs. 
Within this study, we encountered a similar problem: our experiments show that the compound in 
use, NVP-AEW541 (a specific, low molecular weight inhibitor of IGF-1R catalytic activity), is perfectly 
capable of inhibiting the signal transduced by the receptor following stimulation with IGF-1, but it 
appears to lose effectiveness following stimulation with IGF-2. Starting from the observation that IGF-
2 seems to be the key factor in this resistance, literature search showed us a growing number of 
experimental evidences in support of the role of variant A of the insulin receptor (IR-A) in the 
maintenance of a proliferative signal similar to that classically attributed to IGF-1R: our experiments 
confirmed the activation of this receptor following exposure to IGF-2, justifying the loss of 
effectiveness of NVP-AEW541 in regard of the migratory potential of MDA-231 cell line. While the 
dual inhibition of IGF-1R and IR could overcome this redundancy in the signal, it remains to consider 
the problems that may occur due to the inhibition of a receptor as essential for cellular metabolism as 
IR. 
A different and probably more practicable strategy would be the inhibition of the key player in the 
dual activation, IGF-2. The one proposed is a strategy that reflects the physiological mechanism of 
controlling the levels of IGF-2: in fact normal cells are able to control the levels of circulating IGF-2 by 
binding the ligand to IGF-2R, followed by its subsequent transport to lysosomes for degradation. 
During this study we then concentrated also on IGF-2R, observing no significative differences 
between the cell lines in study. 
Following the ligand-based targeting of the IGF system, which effectiveness seems to be proven 
by an ongoing phase I clinical trial using MEDI-573, actually the only mAb in clinical testing that exerts 
its effects by neutralizing not only IGF-2 but also IGF-1, we used a neutralizing antibody against IGF-
2 (MAB292), making it impossible for it to bind both IGF-1R and IR-A. The use of MAB292 proved to 
be effective both in combination with NVP-AEW541 and alone: MDA-231 cells seem in fact unable to 
respond to stimulation with IGF-2 and almost completely lose the ability to migrate. 
This strategy could be particularly effective especially considering that, in hypoxic conditions (pO2 
<2.5%), stabilization of HIF-1α leads to an increase in the levels of IGF-2. This increase in fact results 
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in the resistance of MDA-231 to NVP-AEW541, while MAB292 still retain its effectiveness. We also 
observed the lack of a direct and defined relationship between HIF-1α and IGF-2R levels: cells 
seemed not able to compensate to IGF-2 increase by increasing also the receptor levels.  
From this observation it’s therefore evident that another strategy to overcome the resistance to 
IGF-1R inhibitors may be the combination with HIF-1α inhibitors. At the present days, the fundamental 
problem is the lack of specific inhibitors: many chemotherapic drugs, in fact, have a complete or 
partial inhibitory activity of HIF-1α, that is however accompanied by a number of off-target effects. 
One of these compounds is Topotecan, a Top-1 poison in use in the treatment of ovarian and small 
cell lung cancer that inhibits HIF-1α translation by a Top1-dependent but DNA damage-independent 
mechanism, suggesting that its effect as HIF-1α inhibitor could be mechanistically distinguished from 
those characterizing its cytotoxic activity. In our case the dual inhibition was obtained with success 
through the use of Topotecan in combination with NVP-AEW541. 
We also introduced the combination between NVP-AEW541 and Luteolin, a compound of natural 
origin belonging to the flavonoid class that possess anti-proliferative and anti-migratory activity. 
Despite the more complex comprehension of its effect on HIF-1, which resulted only slightly 
decreased, the most interesting feature of this compound resulted to be its anti-migratory potential: 
the use of Luteolin in fact completely inhibited migration in MDA-231. 
As a last point in our study, we focused our attention on the metabolic alteration determined by the 
modulation of insulin/IGF system. Since deregulation of cellular energy metabolism is considered an 
increasingly important hallmark of cancer, IR and its related metabolic syndromes have become 
another major focus in the breast cancer research and treatment field. Preliminary analysis of the 
oxidative and glycolitic profiles of three cell lines showed in first stance an interesting difference at the 
basal level as well as a modulation of the two processes after treatment with NVP-AEW541 together 
with MAB292 or with Luteolin. Further experiments would be needed to assess the effective impact of 
these compounds on cellular metabolism, as well as the metabolic processes and responses in 
hypoxia. 
In conclusion we can say that the dual targeting of IGF-1R and HIF-1 appears to be an interesting 
therapeutic strategy in breast cancer, especially given the close relationship between these two 
systems. 
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Structure of the breast 
 
The mammary gland is an organ unique to the class Mammalia, with the specific function in the 
female to synthesize, secrete, and deliver milk to the newborn upon demand for its optimal 
nourishment, protection, and development (Medina, 1996). In humans, the life cycle of the female 
mammary gland is epitomized by drastic changes in composition, architecture, and functionality, 
mediated by marked changes in gene expression, that characterize its physiological stages of 
development, all of which are aimed at allowing it to perform its function as a milk-producing organ 
with the birth of the infant. The key mammary developmental stages include fetal growth, infant 
(prepubertal) growth, pubertal expansion, pregnancy and lactation-associated remodeling, and post-
lactational and post-menopausal involution (Russo and Russo, 2004). A sound knowledge of the 
development, anatomy, physiology, and regulation of the breast is integral in the understanding of 
both the normal biology and function of this organ and its benign or malignant pathologies and their 
successful treatment. 
Breast development during life follows a time course of distinct phases. Beginning with the 
formation of the mammary crest and subsequent primitive mammary buds during embryonic life, it 
continues with minimal growth during infancy followed by a rapid growth phase at puberty in the 
female. Unlike most other organs of the body, which develop to a relatively mature state during 
embryonic life, breast development culminates during the pregnancy and lactation cycle (PLC) when 
the mammary gland undergoes complete remodeling, maturating into a functional milk-secretory 
organ. Regression of PLC-induced growth is initiated as weaning is commenced and is completed 
after involution when the breast regresses to a resting state. Remarkably, the PLC-induced mammary 
growth and subsequent involution can be repeated at multiple pregnancies during the reproductive life 
of a female. The cycle is completed with a further phase of involution post-menopause (Hassiotou 
and  Geddes, 2012). 
An understanding of the gross anatomy of the breast and its variations has many clinical 
applications ranging from breastfeeding/lactation support to the detection, diagnosis, and removal of 
benign and malignant lesions. In this context, the epithelial cells lining the duct walls are at the origin 
of the majority of breast malignancies (Li et al, 2003), underscoring the importance of a thorough 
understanding of the anatomy of the breast. Current descriptions of breast anatomy are based on 
Cooper’s dissections of lactating breasts (Cooper, 1840). However, there is renewed interest in 
investigating breast anatomy, particularly that of the ductal system, with the aim of better 
understanding the origins of breast cancer and the potential of localized intra-ductal therapies (Going 
and Mohun, 2006).  
The breast is composed of glandular (secretory) and adipose (fatty) tissue supported by a loose 
framework of fibrous connective tissue called Cooper’s ligaments. The secretory tissue is drained by 
a ductal system that stores and transports milk to the nipple during lactation. The resting breast 
consists of ductal epithelial tissue embedded within a fibrous stroma. Each duct wall is lined by two 
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layers of epithelial cells: an inner layer that encapsulates the ductal lumen, and which contains 
cuboidal epithelial cells, some of which (typically those of the terminal duct) have the potential to 
further differentiate into milk-secretory cells (lactocytes) during lactation; and a basal/outer layer of 
contractile myoepithelial cells that tightly surround the luminal layer and have properties of smooth 
muscle cells. The basal layer lies on the basement membrane (Hassiotou and  Geddes, 2012). 
Particular anatomical structures of the mammary gland are: 
Nipples. The nipple is composed of longitudinal and horizontal smooth muscle fibers relating to the 
nipple base. These muscles either remain separate or are intermixed with longitudinal fibers often 
associated with the nipple ducts with horizontally orientated muscles located distally and which 
provide a sphincter-like function (Tezer et al, 2011).  
Breast ductal system. Standard textbook descriptions depict the ductal system as numerous small 
ductules that drain the alveoli merging to culminate in one main duct that dilates slightly to form a 
lactiferous sinus. The main duct then narrows before it passes through the nipple and opens onto the 
nipple surface (Rusby et al, 2007). 
Lobes. In women, the glandular tissue is composed of lobes that comprise lobules containing 10–
100 alveoli. Each breast lobe is generally considered to exist as a single entity (Love and Barsky, 
2004). The arrangement and volume of tissue associated with each lobe within the breast has been 
confirmed to be highly variable, showing up to 20–30-fold differences in lobe volume (Moffat and 
Going, 1996). 
 
 
Figure 1 Anatomy of the human mammary gland (Nature Rev Cancer, 2002) 
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Breast cancer 
 
Cancer is increasingly a global problem and breast cancer is not only the most common incident 
form of cancer in women worldwide, but is the first or second most common in all regions of the world, 
and responsible for 1.4 million new cases annually (Boyle, 2006). The incidence of breast cancer is 
increasing almost everywhere throughout the world, although the mortality rate from breast cancer is 
declining in many high income countries (Boyle, 2012). 
Only a decade ago, breast cancer was considered a relatively ‘simple’ disease in many respects, 
with focus essentially on quantifying whether a tumour was, or was not, estrogen dependent—a 
situation that had lasted for a century (Beatson, 1896). It develops following multiple alterations in the 
molecular signatures, function, and structure of the affected cells and is therefore characterized by 
various stages. These include cellular immortality, hyperplasia, tumorigenicity, and invasiveness and 
are structurally evident as an initial epithelial hyperplasia, which develops into cellular atypia and 
occlusion of the duct, intra-ductal carcinoma, and progression to a locally invasive carcinoma, which 
can metastasize to various organs, such as the lung, bone, and liver (Medina, 1996; Lu et al, 2009; 
Oskarsson et al, 2011). 
In fact in modern times breast cancer is recognized as a heterogeneous disease encompassing a 
variety of entities, which are molecularly, morphologically and clinically distinct. Epidemiologic studies 
employing cDNA microarrays and immunohistochemical markers resulted in breast cancers being 
classified into five distinct sub-types (Nielsen et al, 2004; Perou et al, 2000): 
Luminal A. Estrogen receptor (ER) positive and/or progesterone receptor (PR) positive, human 
epidermal growth factor receptor 2 (HER2) negative; 
Luminal B. ER positive and/or PR positive, HER2 positive;  
HER2 overexpressing. ER negative, PR negative, HER2 positive;  
Basal-like. ER negative, PR negative, HER2 negative, cytokeratin 5/6 positive and/or epidermal 
growth factor receptor positive; 
Normal breast-like tumours. 
However, the most modern definition of breast cancer has evolved, with triple-negative breast 
cancer (TNBC) defined as ER negative, PR negative and lacking overexpression of HER2; luminal-A 
cancers are defined as ER positive and histologically low grade; luminal-B cancers are also mostly 
ER positive but may express low levels of hormone receptor and are often high grade; HER2-positive 
cancers show amplification and high expression of the HER2 gene (Sotiriou and Pusztai, 2009; Boyle, 
2012). 
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Triple Negative Breast Cancer (TNBC) 
The definitional hallmark of TN breast cancer is their negative status for both ER and PR and the 
lack of over-expression and amplification of the HER2 gene: they represent around 15%-20% of 
newly diagnosed breast cancer cases. Unfortunately, a consensus on what constitutes a negative 
hormone receptor status is still lacking: this makes it very difficult to compare data stemming from 
different studies (Reis-Filho and Tutt, 2008; Viale and Bottiglieri, 2009). 
Comparing TN with non-triple negative breast cancers, several clinical differences are noticeable. 
First of all, TN tumours reportedly affect younger (mean age 47–55 years) women, are more 
prevalent in the population of women carrying BRCA-1 mutations, their average size at diagnosis is 
larger than for non-TN tumours, and the prevalence of lymph node metastases is higher. Interestingly, 
for TN tumours there is no apparent correlation between tumour size and nodal status, and even 
small tumours with a triple negative phenotype have a higher rate of nodal positivity than non-TN 
tumours. TN tumours are more common in the African-American population, often manifest clinically 
as “interval” cancer between consecutive mammograms, and are more likely to be diagnosed by 
clinical examination, probably due to a more rapid growth rate (Atchley et al, 2008; Viale and 
Bottiglieri, 2009). 
The clinical course of the disease is particularly aggressive, with a tendency to early dissemination 
to distant organs (particularly in the lungs and brain, less frequently in the bones) irrespective of the 
axillary lymph node status, and the time between the appearance of distant recurrence to death is 
much shorter in this type of malignancy than in other types of breast cancer (Diaz et al, 2007). The 
appearance of distant metastases is rarely preceded by a local recurrence, and if a local relapse 
occurs it is not predictive of systemic metastases. Moreover, the risk of recurrence is particularly high 
during the first 3 to 5 years after diagnosis, and it decreases thereafter. Overall survival is shorter 
than for other breast malignancies, and most deaths occur within the first 5 years after diagnosis. 
Histologically, TN tumours are more commonly high-grade neoplasms, which lack tubule formation, 
have prominent nuclear abnormalities and high mitotic count. They have broad pushing tumour 
borders, and are often characterized by large areas of central or geographic necrosis and fibrosis, 
often associated with a ribbon-like tumour architecture, and show a prominent lymphocytic infiltrate 
(Viale and Bottiglieri, 2009). These necrosis and fibrosis have long been identified as a peculiar 
feature of some high-grade invasive ductal carcinomas with a poor prognosis and early appearance 
of pulmonary and cerebral metastases. More recently, the biological and clinical implications of the 
fibrotic foci in breast cancers have been extensively investigated. These foci have been considered 
as surrogate markers of hypoxia and neoangiogenesis (Van Den Eynden et al, 2007).  
The immunohistochemical profile of TN breast cancer has been extensively investigated (Kreike et 
al, 2007; Reis-Filho and Tutt, 2008; Lerma et al, 2007) and it is characterised by the variable 
expression of several markers, including cytokeratins 5,14 and 17 (at least one of these cytokeratins 
is expressed in the vast majority of TN tumours), vimentin (55%), P-cadherin (93%), EGFR (27−37%), 
PDGFR (31%), IGF-1R (36%), c-kit (11−38%), S-100 protein (22%), p63 (10%), smooth-muscle actin 
(8%) and by the nuclear accumulation of p53 (50−56%). Cyclin D1 is overexpressed in as many as 
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51% of the tumours, whereas down-regulation of p27 expression and loss of PTEN has been 
documented in 56% and 14% of the TN tumours, respectively. The median Ki-67 labelling index is 
35% (range 10−90%), and only 20% of the tumours have Ki-67 labelling indexes less than 20% 
(Lerma et al, 2007). 
Approximately 75% of TNBCs express basal markers and, consequently, the triple-negative sub-
type is frequently, and erroneously, taken as a surrogate marker for the basal-like sub-type (Atchley 
et al, 2008). “Basal-like” breast carcinomas have been identified by the hierarchical clustering of the 
variations in the expression of 496 genes (“intrinsic” gene subset). Basal-like carcinomas show an 
aggressive clinical course and a poor outcome (Perou et al, 2000). Due to the clinical, biological and 
histological similarities with TN breast cancers, it has been tempting to consider the triple negative 
phenotype as the immunohistochemical surrogate for the molecularly-defined basal-like tumours 
(Kreike et al, 2007). This view, however, is oversimplistic (Viale and Bottiglieri, 2009). 
 
 
Breast Cancer Therapy 
 
Breast cancer therapy is today based on surgical removal of the primary tumour, postoperative 
radiation followed by adjuvant endocrine and/or chemotherapy (Lundgren et al, 2007). As already 
stated, expression of both the ER and PR, as well as the oncogene HER2/neu, are being used to 
define the most prominent breast cancer subtypes in a clinical context. This is particularly clinically 
relevant since these three markers represent important predictive markers for systemic therapies to 
allow for a personalized therapeutic approach. Also, increasing knowledge of the molecular pathology 
of breast cancer has resulted in the development and validation of a number of therapeutic targets 
that are currently and increasingly being exploited as part of an individualized targeted therapeutic 
approach. Targeted agents largely consist in either targeted antibodies or small molecules (Liedtke 
and Kiesel, 2012). Despite impressive advances in the treatment of patients with breast cancer, there 
are still patients within each subtype that do not benefit from current therapeutic strategies; therefore, 
overcoming resistance against these highly efficacious agents is of major importance. Instead, 
patients with TNBC suffer from a lack of targeted therapies, since endocrine and HER2-targeted 
agents cannot be used. 
 
Endocrine Therapy 
HR-positive breast cancer represents the most common breast cancer subtype and is present in 
more than 3/4 of patients with breast cancer. Most HR-positive breast cancers are classified as 
luminal breast cancer when examined using complex gene expression analyses. Luminal breast 
cancers are divided into luminal A and B breast cancer, the latter comprising a more aggressive 
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phenotype that may require additional chemotherapy (Liedtke and Kiesel, 2012). The most 
established targeted therapeutic approach for patients with breast cancer consists in endocrine 
therapy through the use of agents such as tamoxifen of aromatase inhibitors (Forbes et al, 2008; 
Goss et al, 2007). More recently, agents targeted against the HER2/neu oncogene (i.e. the 
humanized antibody Trastuzumab or the small molecule Lapatinib), against EGFR (i.e. the chimeric 
monoclonal antibody Cetuximab or the small-molecule Tyr-kinase inhibitor Gefitinib) or against VEGF 
(i.e. the humanized monoclonal antibody Bevacizumab) have been developed and are being used as 
part of clinical routine in a number of countries worldwide (Conte and Guarnieri, 2012). Nevertheless, 
there is an urgent need to develop novel (targeted) therapies that overcome (primary and secondary) 
endocrine resistance: newer biologic agents like Pertuzumab (a humanized monoclonal antibody that 
blocks HER2 dimerization) and T-DM1 (an antibody-drug conjugate that uses Trastuzumab to 
specifically deliver a cytotoxic antimicrotubule agent to HER2+ cells), as well as multikinase inhibitors 
(i.e. Sorafenib, Sunitinib and Dasatinib) and mTOR inhibitors (i.e. Everolimus) are currently 
undergoing different phases of clinical trial (Liedtke and Kiesel, 2012; Conte and Guarneri, 2012). 
 
TNBC Therapy 
TNBC is the most clinically relevant given that patients lacking the predictive markers ER/PR and 
HER2 cannot benefit from endocrine and HER2-targeted therapy. Patients with TNBC suffer from an 
adverse prognosis which is in contrast of an increased probability of deriving benefit from 
chemotherapy (Liedtke et al, 2008). Therefore, in the development of novel and optimization of 
current therapeutic concepts for patients with TNBC there are several issues that are of particular 
importance:  
(1) Identification of patients with intrinsic resistance against current chemotherapy regimens that 
should be offered alternative approaches, if available; 
(2) Optimization of response to current chemotherapy regimens, for instance through the use of 
alternative chemotherapy substances or dosages (Isakoff et al, 2011); 
(3) Development of novel (targeted) agents. 
Possible targets already in study are VEGF (the use of Bevacizumab in TNBC patients is 
undergoing clinical trial) and PARP (at least in TNBC also BRAC1/2 negative; Iniparib and Olaparib 
showed promising results in phase II trial, which unfortunately could not be reproduced in phase III). 
Other therapeutic targets with potential indication for patients with TNBC are MET, mTOR, IGF-1R, 
SRC, NOTCH, FGFR and ADAM17 (Liedtke and Kiesel, 2012). 
 
Metastatic breast cancer (MBC) therapy 
Despite improvements in adjuvant treatment of early breast cancer, about 20% of patients initially 
diagnosed with regional disease are eventually diagnosed with metastases (Beslija et al, 2009). 
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Unfortunately, tumors in most patients with metastatic breast cancer (MBC) eventually become 
unresponsive to systemic therapy. The heterogeneity in the clinical behavior of MBC—as it relates to 
tumor burden, distribution of metastatic sites, rate of disease progression, and degree of symptoms—
indicates the need for flexibility in therapeutic strategies (Alvarez et al, 2010; Guarneri and Conte, 
2009). Indeed, the heterogeneous molecular pathways involved in breast cancer provide numerous 
potential targets for therapeutic intervention. Several targeted agents have been introduced into 
chemotherapy regimens for MBC in recent years, complementing the existing options (Sánchez-
Muñoz et al, 2009; Beslija et al, 2009), and numerous other targeted agents are in preclinical or early 
clinical stages of development. Treatment of MBC is aimed at stabilizing disease, improving survival, 
and maintaining quality of life with manageable toxicities; earlier and more aggressive use of 
traditional chemotherapeutic agents, such as anthracyclines and taxanes, has decreased the number 
of treatment options in the metastatic setting. However various new approaches to combination 
therapy are being investigated, including classic and novel cytotoxic agents and targeted therapies 
(Alvarez et al, 2010). The latter have the potential to improve outcomes in MBC, and their use has 
increased dramatically over recent years. Overall, single-agent use of targeted therapies has failed to 
produce dramatic benefit in patients with advanced breast cancer; however significant benefit has 
been achieved by their use in combination with cytotoxic chemotherapy. One strategy that appears 
particularly promising is the combination of hormonal therapy with a targeted agent as demonstrated 
by a significant improvement in PFS of patients with HR_ recurrent advanced breast cancer treated 
with exemestane in combination with everolimus compared with exemestane alone. Another 
promising approach is multitarget inhibition as illustrated by the CLEOPATRA trial showing that the 
addition of pertuzumab to trastuzumab and docetaxel resulted in significantly prolonged PFS as first-
line treatment for HER2_ MBC. Despite all these studies, treatment of TNBC remains a major 
challenge (Conte and Guarneri, 2012). 
 
First-Line Treatment 
Anthracyclines: doxorubicin, epirubicin, liposomal doxorubicin, or anthracyline-
based combinations 
Taxanes: paclitaxel, docetaxel, albumin-bound paclitaxel 
Other agents: gemcitabine, capecitabine, vinorelbine, ixabepilone/capecitabine 
After Anthracycline Resistance or Failure 
Taxane monotherapy (docetaxel every 3 weeks, paclitaxel every 3 weeks or 
weekly, or nab-paclitaxel every 3 weeks) 
Later-Line Treatment 
Capecitabine, gemcitabine, liposomal doxorubicin, ixabepilone, eribulin, or 
vinorelbine as monotherapy or in combination with other cytotoxic agents 
HER2-Overexpressing Tumors 
Trastuzumab and non–anthracycline-based chemotherapy 
Lapatinib in combination with capecitabine as second-line treatment 
 
Table 1 Standard cytotoxic chemotherapy in breast cancer 
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Resistance to breast cancer therapy 
As already stated, despite the advances in the treatment of patients with breast cancer there are 
still patients within each subtype that do not benefit from current therapeutic strategies. For instance, 
patients with both luminal (i.e. hormone receptor positive) early breast cancer and those with 
HER2/neu-positive disease experience resistance to endocrine or HER2/neu-targeted therapy in a 
significant number of cases (Forbes et al, 2008; Goss, 2007).  There is an urgent need to develop 
novel (targeted) therapies that overcome (primary and secondary) endocrine resistance (Liedtke and 
Kiesel, 2012).  
Intracellular signal transduction is characterized by a network of (often redundant) signaling 
pathways that mediate mechanisms essential for cellular function and survival. It is well known that 
there is a close and reciprocal crosslink between growth factor receptor and hormone receptor 
signaling with regard to mediation of tumor cell stimulation (Schiff et al, 2004). Therefore, it seems 
plausible that combined use of growth factor receptor inhibitors and endocrine therapy may be used 
to overcome endocrine resistance. In fact, a number of proof-of-principle studies have been 
conducted, demonstrating that combination of endocrine and growth-factor targeted therapies may be 
feasible and effective (Osborne et al, 2011).  
Another mechanism of endocrine resistance is mediated through the phosphatidylinositol 3-kinase 
(PI3K)–Akt– mammalian target of rapamycin (mTOR) signaling pathway (Burstein, 2001; Johnston, 
2006). In preclinical models, the use of Everolimus, an mTOR inhibitor, in combination with 
aromatase inhibitors inhibits proliferation and induces apoptosis The results of these studies 
demonstrate that dual endocrine and mTOR blockade may result improved endocrine response 
among patients with HR-positive breast cancer, particularly among those individuals with metastatic 
disease. Hence, using mTOR inhibition may be a mechanism of overcoming endocrine resistance, 
particularly among advanced cases. Further substances in this context may be worth exploring 
(Efeyan and Sabatini, 2010). 
One major milestone in the therapy of patients with HER2/neu-positive breast cancer certainly is 
the development and establishment of the humanized monoclonal antibody Trastuzumab for patients 
with HER2/neu-positive breast cancer of all disease-stages. In the pivotal registration trial, patients 
with metastatic HER2/neu-positive breast cancer were randomized to receive either chemotherapy 
alone or chemotherapy in combination with Trastuzumab. Treatment with Trastuzumab resulted in a 
significant increase in overall survival, however, even in the combination arm, median OS was still 
25.1 months, demonstrating that those patients had eventually experienced either primary or 
secondary resistance (Slamon et al, 2001).  
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A great number of mechanisms have been suggested to explain the development of trastuzumab 
resistance: reduced bioavailability; CNS metastases; loss of Trastuzumab binding capacity (Scaltriti et 
al, 2007); loss of the HER2 extracellular domain (p95); mutation of the Trastuzumab binding domain; 
downregulation of HER2 expression; activation of downstream signal transduction (Nahta et al, 2009); 
activating PI3K-mutations; loss of PTEN; activation of alternative signal transduction/growth factor 
receptors like IGF-R, HER3, MET, etc. (Nahta et al, 2009). The study of these different  mechanisms 
of resistance has lead to the introduction of a number of novel substances to treat patients with 
Trastuzumab-resistant breast cancer (i.e. Lapatinib, Pertuzumab and T-DM1) (Liedtke and Kiesel, 
2012). 
 
 
The insulin/IGF system 
 
Insulin is conventionally described in medical textbooks as a hormone that plays key roles in the 
regulation of carbohydrate metabolism, while the insulin-like growth factors are described as 
important regulators of pre- and post-natal growth. In fact, an insulin-like signal transduction system is 
present in simple organisms such as C. elegans, where it regulates fundamental cellular processes 
including longevity and energy metabolism (Dong et al, 2007). The emergence of distinct insulin and 
IGF receptors and the use of these signaling systems to regulate blood glucose concentration is a 
relatively recent evolutionary development (Pollak, 2008). 
The lack of structural variation of insulin and IGFs throughout phylogeny1-3 speaks to their 
importance in the control of  growth and metabolism in multicellular organisms. A key lesson learned 
from phylogenetic and physiological studies is that metabolism and growth are tightly coupled through 
Figure 2 Approaches to optimize therapy among patients with distinct breast 
cancer subgroups. (Maturitas, 2012) 
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a single signaling receptor in invertebrates, while vertebrates have uncoupled the process of growth 
and metabolism by separating growth from metabolism into IGF and insulin signaling pathways, 
respectively (Froesch et al, 1985; Maki, 2010). 
As previously stated, the insulin-like growth factor (IGF) system comprises a phylogenetically 
ancient family of peptides involved in mammalian growth, development and metabolism, as well as in 
cellular processes such as proliferation, survival, cell migration and differentiation. This family 
includes three ligands (IGF-1, IGF-2 and insulin), their cell surface receptors [the IGF-1 receptor (IGF-
1R), the mannose 6-phosphate/IGF-2 receptor (M6P/IGF-2R), two different isoforms of the insulin 
receptor (IR-A and IR-B) and the hybrid IR/IGF-1R], six high affinity binding proteins (IGFBP-1 to 6) 
and their proteases. Moreover, it includes the proteins involved in intracellular signaling distal to IGF-
1R, such as the insulin receptor substrate (IRS) family and AKT (Le Roith, 2003; Annunziata et al, 
2011). 
 
Ligands 
IGF-1 was first identified as a serum factor induced by the pituitary growth hormone (GH) that 
mediated GH-induced sulfate uptake into the cartilage and was initially referred to as ‘‘sulfation factor’’ 
(Salmon and Daughaday, 1957). In 1972, the more general term ‘‘somatomedin’’ was proposed to 
designate a substance in the serum considered to be the intermediary of somatotropin (GH) action on 
its target tissues. In the meantime, a new factor with insulin-like effects was found in human serum, 
whose activity could not be suppressed by addition of anti-insulin antibodies: this insulin-like factor 
was also shown to possess growth-promoting effects. Later, IGF-1 and IGF-2 were purified, and IGF-
1 was found to be identical to somatomedin. Both substances were termed ‘‘insulin-like growth 
factor,’’ for their close homology with insulin and because their effects on cell and tissue growth 
predominate over those on metabolism (Daughaday et al, 1987). Insulin expression is confined to 
specialized pancreatic β-cells, and under normal circumstances it is tightly regulated by the level of 
circulating glucose. In contrast to epidermal growth factor and other tissue growth factors that are 
relevant to neoplastic disease, insulin functions as a classic hormone, influencing tissues remote from 
its site of production (Pollak, 2012).  IGF-1 has characteristics of both circulating hormone and tissue 
growth factor. Most IGF-1 found in the circulation is produced by the liver. Regulation of hepatic IGF-1 
production is complex, and GH has a dominant role in upregulating IGF-1 gene expression. GH, in 
turn, is produced by the pituitary gland under the regulation of the hypothalamic factors somatostatin 
and growth hormone-releasing hormone (GHRH). Initially, it was supposed that virtually all IGF-1 
originated in the liver and was transported by endocrine mechanisms to sites of action, but it is now 
recognized that IGF-1 is also synthesized in other organs where it exerts autocrine or paracrine 
effects (Annunziata et al, 2011). Similarly to IGF-1, IGF-2 is also expressed both in the liver and in 
extrahepatic tissues, but is not tightly regulated by GH (Clemmons, 2006). 
The human IGF-1 gene is located on the long arm of the chromosome 12. It has a complex 
structure with multiple promoters and contains six exons, four of which are subjected to alternative 
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splicing; the alternative transcripts generate different precursors, without altering the structure of the 
mature peptide (Tricoli et al, 1984; Rotwein et al, 1986). IGF expression is finely regulated at the level 
of transcription, RNA processing and translation, and the final product is a precursor protein that 
undergoes proteolytic processing at both ends (Sussenbach et al, 1992). The mature IGF-1 is a 
single chain 7.5 kDa, 70-amino acid peptide, cross-linked by 3 disulfide bridges.  
Since its first characterization, it was evident that IGF-1 displays high degree of homology with 
insulin, having 48% amino acid identity, identical disulfide bonding and similar tertiary structure. The 
major structural difference between the IGFs and insulin is that the IGFs retain the C-peptide region 
that is cleaved from proinsulin, and there is a small D extension to the A chain in the IGF molecules 
(Blundell et al, 1983). A second important difference is that specific amino acids at positions 3, 4, 15 
and 16 within the IGF-1 molecule, which are not present in insulin, confer binding to a family of six 
high affinity binding proteins (IGFBPs). Therefore, while most insulin circulates in a free form, more 
than 75% IGF-1 is confined to the vascular compartment as a 150 kDa ternary complex with the acid 
labile subunit (ALS) and IGFBP-3, the most abundant circulating IGFBP (Firth and Baxter, 2002). 
IGF-2 is a 67-aminoacid protein produced by post-translational removal of the COOH-terminal E 
domain from the precursor molecule, pro-IGF-2 (Duguay et al. 1998); its structure resembles that of 
IGF-1. Partial cleavage of the E domain results in big IGF-2 (two isoforms; 1-104 or 1-87) which, 
along with pro-IGF-2, are also found in the circulation. Mature IGF-2 itself can be processed to 
generate des(37-40) IGF-2 (also known as vesiculin). Little is known about the signaling properties 
and function of these IGF-2 variants (Marks et al, 2011, Harris and Westwood, 2012). In humans, 
evidence for the importance of IGF-2 comes from the observation that Igf2 is maternally imprinted 
(Giannoukakis et al. 1993). Relaxation of imprinting leads to Beckwith–Wiedemann syndrome (BWS) 
in which excess IGF-2 is associated with foetal overgrowth. IGF-2 can interact with a number of cell-
surface receptors but it binds to the type 1 IGF receptor with highest affinity and therefore it is likely 
that this receptor mediates much of IGF-2 effect on cellular proliferation, survival, differentiation and 
migration. However, IGF-1 also binds to IGF-1R and in general, elicits the same effects with greater 
potency, which has led to some speculation about the specific purpose of IGF-2. In recent years, this 
has been clarified through the use of receptor inhibitors and a better understanding of the pathways 
downstream of the type 2 IGF receptor and also, the A isoform of the insulin receptor (IR-A), both of 
which bind IGF-2 with greater affinity than IGF-2 (Harris and Westwood, 2012). 
 
Receptors 
An ancestral insulin-like receptor arose early in evolution and has important roles in Drosophila 
melanogaster and C. elegans (Dong et al, 2007; Teleman et al, 2008). The need to regulate cellular 
uptake of glucose independently of cell survival and proliferation probably led to the evolution of 
distinct IGFRs and insulin receptors in more complex animals. In humans, IGF-1R and insulin 
receptor (IR) are widely expressed on normal tissues: both types of receptors are members of the 
tyrosine kinase class of membrane receptors and have tetrameric structures, characterized by two 
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‘half receptors’, each of which in turn comprises a predominately extracellular α-chain that is involved 
in ligand binding and a predominately intracellular β chain that includes the tyrosine kinase domain 
(De Meyts, 2004). Cells that co-express the two receptor genes present not only insulin and IGF-1R, 
but also ‘hybrid receptors’ formed by an insulin half receptor and an IGF-1 half receptor (Belfiore et al, 
2009). These hybrid receptors appear to bind IGF-1 and IGF-2 with high affinity, similarly to IGF-1R. 
Conversely, insulin is bound with low affinity, which is tenfold lower than that of classical insulin 
receptors and 20-fold lower than the affinity of hybrids for IGF-1. The biological response elicited by 
these hybrid receptors can vary, depending on the ligands involved and the specific IR isoforms. 
However, their physiological role is still unclear (Belfiore et al, 2009). 
The biosynthesis and trafficking of the receptors involves the chaperone protein heat shock protein 
90 (HSP90), therefore implying that IR and IGF-1R are among the targets of the HSP90-targeting 
agents that are currently being evaluated for antineoplastic activity (Pollak, 2009).  
The insulin receptor exists in two splice variant isoforms, depending on the absence or presence 
of exon 11 splicing (Belfiore et al, 2009). IR-A (short form) is a fœtally expressed isoform that lacks a 
region within exon 11. The ‘B’ isoform only recognizes insulin, but the ‘A’ isoform, which is the isoform 
most commonly expressed by tumours, recognizes both insulin and IGF-2 (Pollak, 2012). Insulin is 
the canonical ligand for IR and most potently activates IR homodimers. However, as already stated, 
the ability of IGF-2 to activate IR is also well established (Belfiore et al, 2009). Interestingly, affinity of 
IGF-2 for IR-A is 5-fold tighter than IR-B homodimers. As a result, in addition to its role in metabolic 
signaling in tissues involved in glucose homeostasis, IR can also promote cell proliferation and 
survival (Buck et al, 2010). 
IGF-1R gene encodes for a single chain 180 kDa 1,367 amino acid precursor. Cleavage of the 
precursor generates α and β subunits which are glycosylated and proteolytically processed to yield 
the mature α2β2 receptor (Ullrich, 1986). IGF-1R is closely related to the IR, sharing 70% amino acid 
identity overall and 84% identity within the catalytic domain (Lawrence et al, 2007) Following ligand 
binding, the intracellular tyrosine kinase domain autophosphorylates specific tyrosines that act as 
docking sites for signaling proteins, such as the insulin receptor substrate (IRS) family of proteins 
(IRS-1 through -4). These proteins then recruit other substrates leading to activation of different 
signaling cascades, including the phosphatidylinositol 3-kinase (PI3K)–AKT– TOR pathway and the 
RAF–MAPK pathway, that stimulate cell proliferation and survival (Annunziata et al, 2011). 
At the cellular level, signaling downstream of insulin receptors and hybrid receptors is similar but 
not identical. In each case, the kinase activity of the receptor leads to phosphorylation of members of 
the insulin receptor substrate (IRS) family of proteins, and this leads to activation of PI3K, AKT and 
various downstream networks. However, different cell types use this control system to regulate 
different processes. For example, a major consequence of pathway activation in the liver is the 
inhibition of gluconeogenesis and the activation of glycogen storage. By contrast, epithelial cells do 
not express gluconeogenic enzymes and consequences of pathway activation include the stimulation 
of proliferation and the inhibition of apoptosis (Belfiore et al, 2009).  
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IGF-2R is structurally unrelated to either IGF-1R or IR as it consists of just a single, primarily 
extracytoplasmic, polypeptide chain. This receptor binds IGF-2 with greater affinity than IGF-1 and 
whilst it does not accept insulin as a ligand (El-Shewy and Luttrell, 2009), it does have high affinity for 
the sugar mannose-6-phosphate (M-6-P), and can therefore bind lysosomal enzymes and other 
growth factors and cytokines. Cloning of the type 2 IGF receptor cDNA (Morgan et al, 1987) led to the 
realisation that this receptor was also the cation-independent receptor for M-6-P; given the well-
documented role of this receptor in the intracellular transport of lysosomal enzymes, it was suggested 
that rather than mediating IGF-2 effects, it might be important for clearing IGF-2 from the circulation 
(Harris and Westwood, 2012). However, although IGF-2R contains neither tyrosine kinase activity nor 
an autophosphorylation site, it seems to be linked to G-proteins which provides a mechanism for 
signal transduction (El-Shewy and Luttrell, 2009). 
 
IGFBPs 
The bioactivity of IGFs is furthermore modulated by IGFBPs, which have high affinity for both IGF-
1 and IGF-2. In general, IGFBPs limit IGFs access to IGF-1R, thereby attenuating the bioactivity of 
these growth factors (Firth and Baxter, 2002). The tumour suppressor p53, as well as many growth 
inhibitors including vitamin D, anti-estrogens, retinoids, and transforming growth factor-β (TGFβ), 
reduce IGF bioactivity by increasing the secretion of IGFBPs. It is of interest that the circulating 
concentration of insulin (~0.5 nmol per litre) is considerably lower than that of IGF-1 (~20 nmol per 
litre) or IGF-2 (~90 nmol per litre). This is compatible with the view that insulin has direct access to its 
receptor, whereas IGF-1 faces binding competition from the IGFBPs, and IGF-2 from both IGFBPs 
and IGF-2R (Pollak, 2009). However, in certain contexts, overexpression of IGFBPs is associated 
with increased rather than decreased IGF action, with adverse effects on cancer prognosis and with 
loss of function of PTEN (So et al, 2008). The mechanisms involved in this aspect of IGFBP 
physiology remain incompletely described, but are the subject of intense investigation: one hypothesis 
is that the secretion of these high-affinity IGFBPs increases the concentration of ligands in the tumour 
microenvironment; whereas these bound ligands are initially in an inactive state, they may be 
released as continuously bioavailable ligands owing to the action of IGFBP proteases that are 
secreted by neoplastic cells. The concept that IGFBPs have biological activities that are independent 
of their IGF binding properties is not new (Firth and Baxter, 2002). A recent study suggests that 
certain IGFBPs modulate Wnt signalling in a manner that is influenced by the local concentration of 
IGF ligands. This finding deserves follow-up as it implies the existence of a network linking two 
important signal transduction pathways. Adding further to the complexity of IGFBP activity is the 
finding of proteolytic cleavage fragments of IGFBPs in serum; it is unclear if the fragments have 
biologic activity as well (Maki, 2010). 
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Biological effects of IGF-1 and IGF-2 
The IGF system is involved in pleiotropic actions, at endocrine, paracrine and autocrine levels. It is 
activated during fetal development with growth-promoting effects, especially in bone, mammary 
gland, prostate and muscle, but it is also implicated in postnatal growth and tissue remodeling. For 
example in the adulthood, IGFs play a key role in skeletal muscle regeneration and hypertrophy and 
in mammary gland cell proliferation and survival during puberty, pregnancy and lactation. In addition, 
IGF-1 is a trophic and survival factor for neuronal cells, and it may exert neuroprotective effects in 
pathologic conditions such as Huntington’s disease and Alzheimer. Moreover, the IGF system plays a 
role in neuronal plasticity and cognitive functions (Annunziata et al, 2011). IGFs also have protective 
functions in the heart, as assessed by in vitro and in vivo studies. Indeed, low serum IGF-1 levels are 
associated with increased risk of ischemic heart disease and stroke (Colao, 2008). IGF-1 is also a 
mitogen and antiapoptotic factor for vascular cells, including smooth muscle and endothelial cells, and 
exerts regulatory functions on the immune system. As a net result, IGF-1 seems to have 
atheroprotective effects. At the cellular level, IGF-1 proliferative effects can be followed by induction 
of differentiation: it is a renowned mitogen, as expected by its role in promoting somatic growth. 
Besides its role in somatic growth, IGF-1 exerts metabolic effects. Indeed, it can mediate the anabolic 
effects of GH by stimulating protein synthesis and preventing proteolysis. Because of its anabolic 
effects in adults, IGF-1 has been implicated in the treatment of catabolic states associated with illness 
(Le Roith, 2003). However, IGF-1 and GH have divergent effects on carbohydrate metabolism. While 
GH has insulin-antagonistic properties and its excess causes insulin resistance, IGF-1 has insulin-like 
Figure 3 The major components of the IGF axis (the IGF-1R/IR-B hybrid receptors are not represented). 
(Cancer Res, 2012) 
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effects and improves insulin sensitivity. Several evidence indicate that IGF-1 contributes to glucose 
homeostasis and insulin sensitivity (Clemmons, 2006). Low circulating IGF-1 levels are associated 
with insulin resistance, as found in individuals with IGF-1 gene deletion. In vivo and in vitro evidence 
indicate that IGF-1 can stimulate glucose transport, particularly in skeletal muscle cells, exerting direct 
glucose-lowering effects via either the IGF-1R or the hybrid receptor. IGF-1 can enhance insulin 
actions also by inhibiting GH secretion from the pituitary, and therefore preventing its diabetogenic 
effects, via a negative feedback mechanism (Annunziata et al, 2011). 
IGF-2 exhibits proliferative and antiapoptotic actions similar to those of IGF-1: it plays a 
fundamental role in embryonic and foetal growth, as proven by studies performed on IGF-2 knockout 
mice, which survive but remain smaller than their wild-type littermates (Maki, 2010). IGF-2 is not 
expressed in mice after birth, while it is expressed throughout life in humans, where its activity is 
regulated by genomic imprinting, the gene being inactive on the chromosome inherited from the 
mother in most normal tissues (Harris and Westwood, 2012). IGF-2 affects foetal growth by 
influencing placental development and function (through modulation of trophoblast turnover and 
migration, as well as nutrient transport) and appears to be an important modulator of muscle growth 
and differentiation, especially in early cardiac development, myogenesis and vasculogenesis. 
 
 
The insulin/IGF system in cancer 
 
The evolving consensus that insulin and IGFs physiology are relevant to neoplasia arises from 
converging results from independent lines of investigation. Population studies have provided evidence 
that relate circulating ligand levels as well as polymorphic variation of relevant genes to cancer risk 
and prognosis. Laboratory models have provided further evidence that is consistent with the 
population studies as well as experimental validation of various therapeutic targeting approaches 
(Pollak, 2009).  
Laboratory studies. Experimental investigations of the function of insulin in neoplasia preceded 
those focusing on the functions of IGFs. Early studies not only showed that insulin at physiologically 
relevant concentrations stimulates DNA synthesis in breast cancer cells, but also provided evidence 
that insulin deficiency is associated with less aggressive cancer proliferation in vivo (Osborne et al, 
1976). Until the recent resurgence of interest, however, little attention was given to following up on 
these observations made more than 30 years ago, probably because of the assumption that any 
attempt to reduce insulin-stimulated signalling in cancers would have severe metabolic consequences 
for the host. IGF-1R targeting strategies were first proposed over 20 years ago, when IGF-1R 
(overexpression?) was detected in human cancers (Pollak et al, 1987). Many subsequent in vitro and 
in vivo models provide, overall, convincing evidence for a role of IGF1R in neoplasia. Initial in vitro 
experiments demonstrated dose-dependent increases in neoplastic cell proliferation with increasing 
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IGF-1 concentration. Following studies showed that the transforming action of many oncogenes 
required, or was facilitated by, IGF signalling. In vivo models using naturally occurring mutations 
associated with low IGF-1 levels, or genetic manipulations that influence ligand levels showed that in 
vivo tumour growth is influenced by the IGF-1 physiology of the host. A translational research 
approach showed that a pattern of gene expression induced by IGF-1 could predict poor outcome in 
patients with breast cancer (Creighton et al, 2008). More recently, several drug candidates that target 
IGF signalling were found to have anti-neoplastic activity in vivo, both as single agents and in 
combination with currently approved drugs, and are currently undergoing clinical trials (Gao et al, 
2012). The influence of host hyperinsulinaemia on cancer behaviour has been the subject of recent 
investigations: in general, these results provide strong (but circumstantial) evidence that 
hyperinsulinaemia may be a mediator of the adverse effect of obesity on cancer prognosis. 
Population studies. Different studies have been undertaken to examine influences of IGF-1 excess 
and deficiency on cancer in humans. Although they provide limited evidence in favour of a 
relationship between higher levels of IGF-1 and malignancy, they are not definitive. In both cases, 
treatment of the endocrine disorder may complicate interpretations, and both conditions are rare 
enough that assembly of large cohorts is challenging. Epidemiologic research provides direct and 
circumstantial evidence for the relevance of insulin and IGFs to neoplasia. Examples of circumstantial 
evidence include observations concerning somatic growth patterns and mammographic density 
(Pollak, 2009). Given that IGF-1 is known to influence growth patterns, it is of interest that well-
controlled studies provide evidence that height and weight at birth (which is related to the 
concentration of IGF-1 in the umbilical cord) are related to risk of some cancers, and that breast 
cancer in particular is related to patterns of peripubertal growth (Alhgren et al, 2004). Mammographic 
breast density, a strong risk factor for breast cancer, has been related both to the level of circulating 
IGF-1 and to polymorphisms in IGF-related genes. Rigorous prospective studies provided evidence 
for a relationship between the levels of circulating IGF-1 and the risk of developing prostate, breast, 
colorectal or other cancers, such that individuals at the high end of the normal range of serum IGF-1 
concentration had more than double the risk of a subsequent cancer diagnosis of those at the low end 
of the normal range (Pollak, 2009). Some of these early reports also described the finding that higher 
circulating levels of IGFBP3 were associated with reduced cancer risk, which was interpreted as 
reflecting an influence of IGFBP3 in reducing IGF-1 bioactivity, in keeping with laboratory studies 
(Giovannucci et al, 2000). However, follow-up studies have failed to confirm these reports, or have 
revealed more complicated relationships. The basis for these inconsistencies is under investigation by 
several research groups.  
Genetic studies. They provide evidence, methodologically unrelated to serum assays, that 
implicates IGF-1 physiology in cancer risk. A study suggests that, in some individuals, high levels of 
IGF-1 are in fact associated with reduced IGF-1R activation owing to subtle variants of IGF-1R that 
are deficient in signalling activity. In this situation, homeostatic control mechanisms raise the ligand 
levels in the serum in an attempt to compensate. In such cases, the assumption that higher amounts 
of ligand in the serum can be used as a surrogate for higher levels of signaling may be false, and this 
would attenuate any association between IGF-1 serum levels and cancer risk. More work needs to be 
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done to investigate this issue and to clarify the frequency of thesereceptor variants in different 
populations (Pollak, 2009). 
 
Aberrant autocrine and paracrine IGF-2 signalling, leading to the enhancement of cell proliferation 
and resistance to apoptosis, has long been implicated in the initiation and progression of tumour 
growth (Toretsky and Helman 1996). Epigenetic alterations, such as the loss of DNA imprinting, occur 
in cancer at least as commonly as genetic mutations. The majority of imprinted genes exist in 
clusters, and their expression is regulated by the methylation status of CpG-rich cis-elements, known 
as differently methylated regions (DMRs). The DMRs are differentially methylated on CpG sites by 
DNA methyltransferases, depending on the parental origin of the allele (Mann et al. 2000). Igf2 is an 
example of an imprinted gene; the loss of imprinting (LOI) of the normally silent maternal allele of Igf2 
leads to overexpression of IGF-2 protein and an increased risk of malignancy. Ligation of IR-A by 
IGF-2 initiates a proliferative response comparable to that of IGF-1R, and aberrant IR-A signalling has 
been implicated in a number of diseases, including cancer (Belfiore et al, 2009). IGF-2 signalling 
through IR-A has also been shown to induce differential expression of genes involved in signal 
transduction, cell cycle, metabolism, angiogenesis and adhesion, when compared with insulin 
signalling (Harris and Westwood, 2012). 
IR-A has long been recognized as the predominant IR isoform expressed by carcinomas of the 
breast, colon and lung (Frasca et al. 1999). Activation of IR by IGF-2 in human breast cancer cell 
lines stimulates proliferation, with IGF-2 exhibiting 63% of the potency of insulin. In contrast, IGF-2 
signalling through IR in non-malignant human breast cells is less than 1% as potent as insulin 
(Sciacca et al. 1999). 
The tumour suppressor function of the IGF-2R was first demonstrated in 1999, when it was 
showed that down-regulation of IGF2R expression in JEG-3 choriocarcinoma cells enhanced 
proliferation in vitro, and increased tumour growth rate in vivo (O’Gorman et al. 1999). Conversely, 
IGF-2R overexpression reduced JEG-3 cell proliferation in vitro, and decreased tumour growth in 
nude mice. IGF-2R overexpression did not alter endogenous IGF-2 production, or secretion of the 
IGF-2R ligands procathepsin D and L, but did promote secretion and activation of latent TGF-β1. 
Overexpression of a soluble form of the receptor dramatically reduced tumour cell growth in vitro and 
in vivo, but did not alter the level of TGF-β1 (O’Gorman et al. 2002). These data suggest that 
increased levels of soluble IGF-2R inhibit cell proliferation. Unlike its murine homologue, human Igf2r 
exhibits biallelic expression, although a few individuals exclusively express the maternal allele. 
Mutations in Igf2r, or loss of heterozygosity at the 6q26–27 locus where Igf2r resides, lead to reduced 
IGF-2R expression and increased circulating concentrations of IGF-2. Loss of biallelic Igf2r 
expression has been reported in cancers of the breast, liver, prostate, lung, adrenal gland, head, neck 
and endometrium (Martin-Kleiner and Gall 2010). Loss of heterozygosity proximal to the Igf2r locus is 
also predictive of the presence of disseminated tumour cells in the bone marrow of ovarian cancer 
patients, before and after chemotherapy (Kuhlmann et al. 2011). 
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The Insulin/IGF system in breast cancer 
Numerous evidences have shown that the IGF pathway is strongly implicated in breast cancer.  
IGF-1R is over-expressed in about 90% of breast cancer cases and IGF-1R levels are higher in 
cancer cells than in normal breast tissue or in benign mammary tumors. Furthermore, breast cancer 
cells over-express both IGF-1R and IR-A and that leads potentially to formation of hybrid IGF-1R–IR-
A receptors (HRs) as well (Yang and Yee, 2012).  IGF-1R has been associated with the cell’s 
metastasizing potential: more than one decade ago it was demonstrated that inhibition of IGF-1R 
resulted in suppression of adhesion, invasion and metastasis of breast cancer cells, while that 
inhibition did not significantly suppress the growth of the primary tumor (Dunn et al, 1999). The 
IGF/IGF-1R downstream signaling pathways have recently been shown to be directly  involved in the 
metastatic cascade in breast cancer cells and over-expression of IGF-1R has been associated with 
poor prognosis in patients with early breast cancer (Taunk et al, 2010). Despite data from human 
breast tumors that demonstrated IGF-1R over-expression and hyper-phosphorylation, the prognostic 
utility of IGF-1R expression in breast carcinomas is still debated, also due to technical issues (e.g. 
optimal cut-off point value defining receptor over-expression) (Law et al, 2008). Interestingly enough, 
it has been shown that IGF-1R expression varies among breast cancer subtypes and is correlated 
with either good (e.g. luminal cancers) or bad prognosis (e.g. HER2-enriched tumors) (Yerushalmi et 
al, 2012). More interestingly, IGF-dependent enhanced cellular proliferation has been documented in 
triple negative breast carcinomas, which can provide new targets for the so far limited therapeutic 
options (Davidson et al, 2011). Although receptor activation has been observed, neither mutations nor 
amplification of the gene that encodes IGF-1R have been described. However, it has been shown that 
certain IGF-1R single nucleotide polymorphisms (SNPs) might be useful predictive factors regarding 
recurrence of estrogen receptor positive breast cancer patients treated with endocrine agents (Winder 
et al, 2011). 
Several studies indicate a role for IGF-1 in the development of breast cancer. High levels of total 
IGF-1 in plasma have been reported to be a risk factor for breast cancer in premenopausal women: 
these findings are supported by a small study reporting that a combination of low plasma IGFBP-3 
and high IGF-1 increases the risk of ductal carcinoma in situ in pre-menopausal women (Helle, 2004). 
Significantly higher serum IGF-1 levels have been found in breast cancer patients compared to 
healthy controls. However, these results are not consistent, and a small recent study did not detect 
any differences regarding serum IGF-1, while IGBP-3 was decreased in cancer patients. Another 
report has shown that the IGF-1/IGFBP-3 ratio, which is used as an index of IGF-1 bioavailability, is 
elevated in pre-menopausal breast cancer patients compared to controls. While plasma IGF-1 levels 
may be important for the development of breast cancer, the presence of manifest breast cancer 
disease also influences the IGF system. A number of patients with advanced breast cancer have 
increased plasma IGFBP-3 protease activity which correlates with clinical stage and alterations in 
tumour burden due to therapy. Increased IGFBP-3 protease activity is also observed in other cancers 
and other serious conditions. The occurrence of elevated IGFBP-3 protease activity in a variety of 
pathological conditions probably reflects a non-specific phenomenon: anyway, elevated IGFBP-3 
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protease activity may theoretically increase the delivery of IGF-1 to the tumour, but this condition is 
also associated with lower plasma levels of IGF-1 and -2 (Martin and Baxter, 2011). 
To assess the role played by IGF-2 in breast cancer, female transgenic mice were engineered to 
exhibit enhanced IGF-2 expression in the mammary gland and as a result they displayed an 
increased incidence of aggressive, metastatic, mammary tumours, implicating chronic IGF-2 signaling 
as a tumorigenic stimulus (Pravtcheva and Wise 1998). As predicted, when these animals were 
crossed with transgenic mice overexpressing IGF-2R, their offspring exhibited a significant delay in 
the onset of mammary tumour formation and reduced tumour burden (Wise and Pravtcheva 2006). 
Biallelic IGF-2 expression has been observed in human breast cancer samples: one study reported 
LOI in 67% of benign lesions and 60% of malignant lesions, whereas all control samples displayed 
normal IGF-2 imprinting (McCann et al. 1996). However, only three benign and five malignant tissue 
samples were analyzed, so these data must be interpreted with caution. ProIGF-2 has been shown to 
promote the survival of the MCF7 breast cancer cell line by activating PI3K/Akt signalling and 
upregulating the expression of the antiapoptotic proteins Bcl-2 and Bcl-XL (Singh et al. 2008). Mature 
IGF-2 can also promote breast cancer progression by activating ER-α and ER-β in the absence of 
estrogen. In breast cancer cells, IGF-2 binding to IGF-1R and IR-A was found to induce translocation 
of ERα and ERβ to the mitochondria, facilitating activation of cell survival pathways (Richardson et al. 
2011). 
 
The Insulin/IGF system as prognostic factor 
A topic of increasing interest concerns the influence of IGFs and insulin on cancer prognosis, as 
distinct from cancer risk. Available evidence suggests that hyperinsulinaemia is associated with worse 
cancer outcome, whereas IGF-1 levels are less important as prognostic factors (Goodwin et al, 2002; 
Giovannucci et al, 2000). The biological basis for the apparently stronger relationship between insulin 
levels, as opposed to IGF-1 levels, and cancer is under investigation. One possibility is that the level 
of IR may be higher than that of IGF-1R in established cancers, whereas the reverse may be the case 
in at-risk but untransformed epithelial cells. It is also plausible that the levels of circulating IGF-1 or 
IGF-2 fail to reflect significant local effects of autocrine or paracrine production of these ligands by 
aggressive cancers (Pollak, 2009). Studies are not consistent regarding this issue. One study 
reported that expression of IGF-1R is associated with a better relapse-free survival compared to lack 
of expression. However, others found that expression of IGF-1R was associated with a poor 
prognosis in the subgroup of ER-negative cancers, or to be without prognostic importance. Increased 
level of IGF-1R expression in breast cancer specimens was found to inhibit apoptosis, and was 
associated with an increased risk of relapse after radiation therapy (Helle, 2004). IRS-1 levels, which 
is phosphorylated after IGF-1R activation, was found to predict worse disease-free survival in small 
tumours. However, there are also data which indicate that expression of IGF-1R and IRS-1 is 
decreased in poorly differentiated tumours. Moreover, high levels of immunoreactive IGFBP-3 were 
found in tumours with poor prognostic features (ER and PR negativity, high S phase, and aneuploidy). 
Other investigators found that high levels of immunoreactive IGFBP-3 in tumours were associated 
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with an increased risk of death (Helle, 2004). 
 
 
The Insulin/IGF system as therapeutic target 
 
The fact that insulin is mitogenic for neoplastic cells in culture was known before the development 
of the paradigm that targeting peptide growth factor receptors represents a useful strategy for cancer 
drug development. These provocative results, however, were not pursued with regards to their 
potential clinical relevance. To understand why, it is necessary to recognize that the general notion of 
targeting peptide growth factor receptors was not developed at the time. Even if it had existed as a 
theoretical concept, there were no practical pharmacological strategies available, as there were no 
examples of drugs that inhibited receptor tyrosine kinase activity, and the use of anti-receptor 
antibodies as drugs had not been demonstrated yet (Pollak, 2008). However, by the late 1990s, the 
general interest in these receptors in the context of neoplasia increased, due to increasing 
epidemiologic evidence for a relationship between circulating levels of IGF-1 and cancer risk, and 
also because of increasing laboratory evidence for a role for IGF-1 receptors in neoplastic growth. In 
addition, attention was given to the considerable amount of circumstantial evidence linking insulin and 
IGF physiology to neoplasia (Toretsky and Helman, 1996; Belfiore et al, 2009). At the same time, the 
progresses in drug development lead to the introduction of those new classes of compounds (like the 
mentioned anti-receptor antibodies and RTKi) nowadays used in targeted therapies. 
The IGF axis has thus become an increasingly attractive target for cancer research. Progress has 
been substantial in recent years, and the field has moved to more sophisticated models and clinical 
trials. Targeted strategies include, on one hand, a reduction of ligand levels or bioactivity, and, on the 
other hand, inhibition of receptor function using receptor-specific antibodies or small-molecule 
tyrosine kinase inhibitors. In contrast to the history of early drug development for molecular targets 
such as ERBB2, many different drug candidates that target the IGF-1R are being evaluated 
simultaneously in dozens of ongoing clinical trials (Pollak, 2009). Nine mAbs and six small molecules 
have been tested across approximately 150 phase I to III trials in 16 solid tumor types and certain 
hematologic malignancies (i.e. multiple myeloma and leukemia). Objective response to IGF-1R–
targeting mAb monotherapy is rare, with notable occurrences in approximately 10% of patients with 
various sarcomas, in particular the Ewing subset. Objective, and in some cases durable, responses 
have been reported in phase I and phase II studies of mAbs that target IGF-1R (i.e. Figitumumab and 
Ganitumumab) in adults and children with heavily pretreated sarcomas. Nevertheless, disease 
stabilization, defined as lack of objective response or progressive disease at 12 weeks, remains the 
major efficacy signal (Olmos et al, 2011). IGF-targeting agents are generally expected to show their 
full potential by augmenting the efficacy of endocrine, cytotoxic, or other targeted therapies, possibly 
by mitigating the development of resistance to otherwise effective interventions. Although 
combinations of large or small IGF-targeting molecules with various standard-of-care therapies have 
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generally shown a reasonable toxicity profile, this strategy has yet to translate preclinical promise into 
therapeutic efficacy. Few of the IGF-1R targeting antibodies under investigation have progressed to 
or completed phase III testing, facing various problems (Gao et al, 2012). For examples, as recently 
as 2010, 2 phase III clinical trials were testing Figitumumab (CP-751871) globally, one in conjunction 
with paclitaxel plus carboplatin and another with Erlotinib. Both of these pivotal trials were 
discontinued after data showed an increase in serious adverse events (Jassem et al, 2010). 
Activators of AMP-activated protein kinase (AMPK), such as metformin, are also being studied not 
only because they lower the amounts of circulating insulin, but also because there is evidence that 
they act as anti-proliferative agents by reducing signalling downstream of IR and IGF1R (Pollak, 
2009).  
 
Classes of inhibitors 
Ligand-targeting approaches 
First-generation strategies that included the use of somatostatin analogues to reduce circulating 
IGF-1 levels were unsuccessful. One of the largest clinical trials using this approach fortunately 
included a translational science component that showed that the desired suppression of ligand levels 
was not achieved, so the negative results represent a failure of a particular strategy, rather than 
evidence that the target is unimportant. Other approaches, such as ligand specific antibodies or 
growth-hormone antagonists show interesting preclinical potential (Pollak, 2009). MEDI-573 is 
currently the only mAb in clinical testing that exerts its effects by neutralizing both IGF-1 and IGF-2. 
Distinct from all the IGF-1R–targeting mAbs under development, MEDI-573 specifically inhibits IGF 
signaling through IGF-1R and IR-A, as well as through their hybrid receptors. The ongoing phase I 
clinical trial has shown stabilization of disease in 7 of 16 patients, most of whom had chemoresistant 
cancers. Importantly, preliminary data strongly suggest that MEDI-573 might achieve this result 
without inducing hyperglycemia (Menefee et al, 2010). If confirmed, this observation would be 
consistent with expectations about ligand- versus receptor- based targeting of the IGF axis, 
specifically with respect to the clinical consequences of sparing IR-B and its various hybrid receptors, 
each of which has potential to alter glucose metabolism via interactions with insulin (Gao et al, 2012). 
Receptor-specific antibodies 
Many receptor-specific antibodies have been studied preclinically, and several are being evaluated 
in clinical trials. To date, the largest clinical experience has been with the Pfizer antibody CP-751871 
(Figitumumab). In general, toxicity has been acceptable, and early clinical results have not only 
revealed activity in terms of pharmacodynamic endpoints, but have also suggested that administration 
of the antibody together with chemotherapy significantly improves the response rate in patients with 
non-small-cell lung cancer. The most recent available update showed the largest improvement was in 
squamous cancers (response rate to chemotherapy alone 41%; with antibody 72%), but squamous 
lung cancers were noted to express higher levels of IGF-1R than other histological types (Gualberto 
et al, 2008); ongoing research will reveal whether this early result is confirmed in phase III clinical trial 
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studies, and if it affects survival endpoints. 
Additional IGF-1R specific antibodies have been developed. Those for which early clinical trial 
data have been reported include AMG-479 (Ganitumumab, Amgen), AVE-1642 (Sanofi-Aventis), 
IMC-A12 (Cixutumumab, Imclone), MK-0646 (Dalotuzumab, Merck) and R1507 (Roche) (Pollak, 
2009). Although these antibodies differ with respect to IgG subclass and serum half-life, they share 
many similarities. These include a generally favourable toxicity profile without dose-limiting toxicity 
and disease stabilization or objective response in a minority of patients in phase I single-agent clinical 
trials. Several of the antibodies have induced objective responses in metastatic, chemotherapy-
refractory Ewing sarcoma, although it is clear that not all patients with this disease respond in a 
similar manner. Initial evaluation of Dalotuzumab included pharmacodynamic studies on neoplastic 
tissue, which revealed reduction of phospho-Akt and phospho-s6 kinase, both of which function 
downstream of the receptor, as well as downregulation of receptor levels and reduction in 
proliferation. Different IGF-1R specific antibodies are now being evaluated in phase II clinical trials for 
many oncological indications in various combinations with approved agents. As already reported, 2 
phase III clinical trials were testing Figitumumab (CP-751871) globally, one in conjunction with 
paclitaxel plus carboplatin and another with Erlotinib. Both of these pivotal ADVancing IGF-IR in 
Oncology (ADVIGO) trials were discontinued after data showed an increase in serious adverse 
events, including mortality, and a low likelihood of meeting the primary endpoint of improved overall 
survival (Jassem et al, 2010). A compensatory increase in the circulating concentrations of growth 
hormone and IGF-1 occurs on administration of IGF1R-specific antibodies. This was predicted and is 
reminiscent of the rise in estrogen levels that results from treatment with estrogen-targeting drugs in 
premenopausal patients with breast cancer. The hyperglycaemia encountered occasionally with IGF-
1R specific antibody treatment probably reflects the insulin resistance that is induced by the high 
levels of growth hormone (rather than any interaction between the antibody and IR). This possibility is 
supported by the modest treatment-induced hyperinsulinaemia that has been observed in patients, as 
well as by correction of hyperglycaemia by the use of metformin. There is no evidence to date that the 
increase in IGF-1 level can overcome the blocking effect of IGF-1R specific antibodies (Pollak, 2009).  
Receptor kinase inhibitors 
Several tyrosine kinase inhibitors that inhibit IGF-1R and IR have been developed and found to be 
active in preclinical models, and some are currently being evaluated in phase I clinical trials: BMS-
754807 (Selleckbio), NVP-AEW541 (Novartis) and OSI-906 (Linsitinib, Selleckbio) are promising 
examples of small molecule inhibitors. Details of relative in vivo inhibitory activity for the IR and IGF-
1R in different tissues remain unclear. As these compounds were initially expected to also inhibit the 
function of IR, the possibility of more serious metabolic toxicity than that seen with the IGF-1R specific 
antibodies required careful investigation. If these small molecules penetrate the blood–brain barrier 
there is also a theoretical possibility of neurotoxicity (especially with long-term exposure), as IGF-1 
signalling has neuroprotective activity in the brain. However, it is possible that these agents will be 
more potent antineoplastics, if indeed IR present on malignant cells has an important role in 
neoplastic behaviour. In agreement with this possibility, a model of IR-A mediated resistance to IGF-
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1R targeting has been described (Buck et al, 2010). Even if most TKIs show limited selectivity of IGF-
1R over IR in vitro or in vivo, due to the high degree of homology of the intracellular β subunits of the 
two receptors, new and more selective compounds have been developed and are being tested. 
Ongoing clinical trials are trying to clarify the relative advantages and disadvantages of receptor-
specific antibody and tyrosine kinase inhibitor approaches in terms of both efficacy and adverse 
effects.  
NVP-AEW541 
NVP-AEW541 is an optimized IGF-1R kinase inhibitor that selectively distinguishes between the 
native IGF-1R and the closely related IR (Garcia-Echeverria, 2004). Small molecules belonging to the 
pyrrolo[2,3-d]pyrimidine class were identified in Novartis in a high-throughput screening of a 
compound archive as inhibitors of the IGF-1R in vitro kinase activity. This compound class was 
subjected to a medicinal chemistry program aimed at optimizing the potency and selectivity toward 
the IGF-1R kinase, as well as their drug-like properties. NVP-AEW541 is a representative example of 
such an optimization process, whose potency and selectivity was first assessed in a series of in vitro 
kinase assays using different recombinant kinase domains or purified kinases and synthetic peptide 
substrates. The compound was found to inhibit the in vitro kinase activity of the recombinant IGF-1R 
kinase with an IC50 value of 0.15 µM and to be equipotent against the recombinant IR kinase domain. 
NVP-AEW541 was confirmed to be active toward the IGF-1R kinase (IC 0.086 µM) and to be 27-fold 
more potent toward the native IGF-1R, as compared to the structurally related native IR. The 
selectivity observed at the cellular level indicates that, despite the 84% identity of the two receptors 
kinase domains, there are conformational differences between the native forms of these receptor 
tyrosine kinases that are not recapitulated by the recombinant kinase domains used in the in vitro 
kinase assay. Thus, at the cellular level, NVP-AEW541 is highly selective against the IGF-1R, as 
compared to both the IR and other tyrosine kinases. The compound was found to fulfill all the key 
characteristics expected from an IGF-1R inhibitor. It effectively inhibits the survival function ascribed 
to IGF signaling and prevents the ability of transformed cells to grow in an anchorage-independent 
manner, both events occurring at concentrations that are consistent with its capacity to inhibit IGF-1R 
autophosphorylation. Despite the cellular selectivity achieved toward the IGF-1R, as compared to the 
IR, there remains a potential risk of such a compound interfering with glucose metabolism. In fact, the 
two receptors can form heterodimers, a situation where a selective IGF-1R inhibitor would prevent 
cross-phosphorylation and activation of the associated IR heterodimeric partner. Alternatively, the 
compound could in principle accumulate at concentrations high enough to also inhibit the IR. To 
assess this potential risk, plasma glucose and plasma insulin were monitored in mice treated with 
efficacious doses (50 mg/kg, bid, p.o.) of NVP-AEW541. No significant differences were observed 
when the plasma glucose and insulin levels of vehicle and compound treated animals were compared 
after 10 days of treatment. Thus, NVP-AEW541 specifically targets the IGF-1R and represents a 
novel, potential therapeutic strategy for the treatment of tumor types for which IGF-1R-mediated 
signaling is a required driving/survival function (Garcia-Echeverria, 2004). 
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Metformin and AMPK activators 
The biguanide metformin is commonly prescribed in the treatment of type II diabetes because it 
lowers both glucose and insulin levels. Population studies provided preliminary evidence that it might 
have anti-neoplastic or chemopreventive activity, thereby motivating further laboratory investigations. 
Although often referred to as an insulin sensitizer because it lowers insulin levels, recent evidence 
suggests that the key mechanism of action of metformin is as an activator of the AMPK–LKB1 
pathway (Evans et al, 2005). In the liver, this results in inhibition of gluconeogenesis and hepatic 
glucose output, which in turn reduces circulating glucose level, resulting in a secondary decrease in 
insulin level. In transformed epithelial cells, metformin, similarly to other AMPK activators, inhibits 
rather than increases insulin-stimulated proliferation (Zakikhani et al, 2006). Therefore, metformin has 
two properties of potential oncological relevance: it reduces systemic insulin levels and has direct 
AMPK–LKB1-dependent growth-inhibitory action. Reduction of systematic insulin levels would be 
predicted to be of greatest benefit in the important subset of cancer patients who are 
hyperinsulinaemic and, hence, whose tumours may be growth-stimulated by insulin. The anti-
neoplastic actions of metformin (and other AMPK activators) have been modelled in laboratory 
studies, and found to be more complex than would be expected if they acted only as insulin-lowering 
agents (Pollak, 2009). Although most models using AMPK activators show anti-proliferative effects, 
AMPK activation could in certain contexts also enhance cellular survival under stress, a topic which 
requires further study before large-scale clinical trials can be launched. Further research is required to 
clarify the extent to which clinically relevant doses of metformin act to activate AMPK in neoplastic 
tissue as compared with liver tissue, since at the moment there are important knowledge gaps in its 
pharmacokinetics. However, this remains an important area of investigation, given preliminary 
evidence regarding metformin from population and clinical studies together with datasets linking 
hyperinsulinaemia to adverse cancer outcome (Pollak, 2009). 
Figure 4 IGF-1R specific-antiboby targeted therapy, IGF ligand-neutralizing antibody targeted therapy and IGF-1R 
kinase activity inhibition. (Cancer Res, 2012) 
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Combinations 
Although there have been multiple documented examples of single-agent activity of IGF-1R 
specific antibodies in Ewing sarcoma and other solid tumours in phase I clinical trial studies, it is 
commonly assumed, based on the experience with other receptor kinase inhibitors, that combination 
therapies will have an important role in treatment. This view is consistent with evidence that IGF-1R 
activation tends to reduce responsiveness to many approved antineoplastic therapies. A few 
combinations represent obvious priorities (Pollak, 2012). Many targeted therapies are routinely used 
in combination with other agents, and most trials with agents that target the IGF system have involved 
combinations selected not on the basis of a specific synergy demonstrated preclinically, but rather on 
a pragmatic approach involving the addition of a drug candidate to a current standard regiment that 
has some existing activity but needs to improve its efficacy. Early experience suggests that combining 
cytotoxics with IGF-1R blockade might be useful. In addition, there is evidence that IR and IGF-1R 
can have a role in conferring resistance to rapamycin and its analogues; therefore there is interest in 
combining these with IGF-1R targeting agents. Similarly, there is considerable evidence that IGF-1R 
mediated signalling confers resistance to therapies that target EGF receptor family members, so 
simultaneous inhibition of these receptor families is of interest. Combined inhibition of steroid signal 
transduction and IGF-1R is also proposed for breast and prostate cancer, based on preclinical 
models. The combinations of a growth-hormone receptor antagonist or metformin with IGF-1R 
specific antibody would be of interest as this might reduce the GH-induced insulin resistance, 
hyperglycaemia and hyperinsulinaemia that are associated with IGF-1R targeting, thereby improving 
tolerability and/or efficacy. Finally, the possibility that IGF-1R inhibition might enhance radiotherapy 
outcomes is being examined (Pollak, 2009). 
 
IGFs as Predictive Biomarkers 
A growing clinical database suggests that efficacy and toxicity of all the compounds targeting the 
IGF system may be predicted by quantifiable factors such as tumor IGF-1R or circulating IGF ligand 
levels. Target expression levels such as these, if validated, would serve as relatively straightforward 
predictive biomarkers for identifying patient subpopulations likely to respond to IGF targeted therapies 
(Gao et al, 2012). For IGF-1R antibodies, elevated tumor IGF-1R expression and circulating IGF-1 
have both been shown to correlate to some degree with responses in early clinical trials. As stated 
before, data from the phase II study testing the IGF-1R specific mAb Figitumumab in combination with 
paclitaxel plus carboplatin in NSCLC showed a higher objective response rate in the subset of 
patients with squamous cell carcinoma histology. Despite the limited sample size, these data are 
particularly compelling in light of biomarker analysis showing the highest IGF-1R expression in the 
squamous subtype. In addition, a higher response rate to the combination of paclitaxel plus 
carboplatin and Figitumumab was observed in epithelial-to-mesenchymal transitional tumors (71%), 
defined by intermediate E-cadherin and high IRS-1 expression, compared with those in the 
mesenchymal- like subset (32%), defined by low expression of both E-cadherin and IRS-1. By 
contrast, sample analysis showed high plasma levels of free IGF-1 and vimentin as predictive of 
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clinical benefit in the adenocarcinoma subtype. Ancillary data from the NSCLC study of Figitumumab 
showed improved PFS among patients with high pretreatment-free IGF-1 levels compared with 
patients with low pretreatment-free IGF-1 levels, pointing to the potential role of this ligand as a 
predictive marker (Gualberto et al, 2011). These intriguing data are indirectly supported by interim 
results from a phase I to II study of Figitumumab in 31 patients with relapsed sarcoma, which 
suggested that pretreatment plasma levels of IGF-1>110 ng/mL conferred a significant treatment 
advantage compared with lower levels. Overall, these data suggest the value of evaluating circulating 
IGF-1 as a possible predictive marker in studies of IGF-targeting agents and opportunities for 
enriching future study populations (Olmos et al, 2011). A growing body of nonclinical and clinical data 
provide valuable lessons for the development of ligand-based approaches (such as MEDI-573) in 
terms of patient selection. In particular, they provide a compelling rationale for a priori identification of 
patients with tumors that overexpress IR-A and IGF-2 in addition to IGF-1R, which may prove a 
critical determinant of clinical response to monotherapy or combination regimens in molecularly 
defined subpopulations. This hypothesis has been supported by preclinical studies in which high 
levels of IR expression and elevated mRNA levels of IR-A compared with IR-B have been found in 
most of the cancer cell lines tested (Garofalo et al, 2011; Gao et al, 2011). Other molecular markers 
may also predict tumor response to IGF-targeting compounds. IRS-1 expression levels have been 
positively correlated with sensitivity of preclinical models to IGF-1R targeting (Kurmasheva et al, 
2009). Increased VEGF production by cancer cells following rapamycin treatment has been shown to 
correlate with synergistic responses to rapamycin and IGF-1R antibody combined therapy in certain 
sarcoma tumor models . Among the cancers associated with dysregulation of the IGF axis, increased 
IGF-2/IR-A signaling has been best documented in breast cancer, in which conventional criteria (e.g., 
ER and/or PR and/or HER2 status, stage, grade, luminal type A vs. type B) together with IR-A 
signatures may enable identification of and enrichment for subpopulations likely to respond to dual 
targeting of IGF-1R and IR-A (Belfiore and Frasca, 2008). MEDI-573 has been shown to inhibit IGF-
induced proliferation of cells expressing IGF-1R or IR-A, either together or alone, pointing to a distinct 
theoretical advantage over IGF-1R–targeting antibodies in selected populations. A global clinical trial 
is currently testing whether MEDI-573 in conjunction with an aromatase inhibitor enhances 
therapeutic outcomes in patients with advanced ER-positive, HER2-negative breast cancer. Whether 
these markers achieve the level of validation required to predict for sensitivity to different types of 
IGF-targeted agents has yet to be confirmed by clinical testing (Gao et al, 2012). 
 
Insulin/IGF system and chemoresistance 
The observation that a range of RTKs can function to drive tumorigenesis has revolutionized 
anticancer drug discovery and development efforts in recent decades. However, tumor cells exhibit a 
high degree of signaling plasticity, which can contribute to adaptive survival in the presence of RTK 
inhibitors, and identifying the mechanisms of acquired resistance to these agents is a major goal 
toward individualizing their use in the clinic. Multiple RTKs can be activated simultaneously within a 
single cell, and cross talk can exist between them. Cross talk between EGFR and either IGF-1R or 
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MET can provide adaptive survival for tumor cells when EGFR is targeted individually. Preclinical data 
highlighting reciprocity for these receptor pairs have spurred the evaluation of combinatorial RTK 
targeting in the clinic for EGFR inhibitors (Buck et al, 2010). As already reported, there is growing 
support for IR as a mitogenic driver for tumor cells, and there are several examples in which IGF-1R 
or IR can compensate for the inhibition of the other in nontransformed cells: indeed, the activity of 
IGF-2 on IR was first discovered in studying mouse development, where it was found that IR, 
activated by IGF-2, can compensate for IGF-1R disruption to rescue embryonic growth: other studies 
have later described enhanced signaling by insulin when IGF-1R is disrupted in tumor cells (Zhang et 
al, 2007). Of particular significance is the observation that elevated phosphorylation of both IGF-1R 
and IR has been observed in many human tumor cell lines, thus showing that IGF-1R/IR cross talk is 
another means exploited by tumor cells to maintain activation of cell survival pathways when IGF-1R 
is specifically targeted. It is demonstrated that treatment with either insulin or IGF-2 can maintain 
activation of the AKT pathway when IGF-1R is selectively targeted: insulin concentrations 
corresponding to mild hyperinsulinemia can promote an increase in phosphorylation of IR and AKT, 
independent of IGF-1R. Collectively, these data support the approach of cotargeting IGF-1R and IR to 
deliver enhanced and sustained antitumor activity for cancers that rely on signaling through both of 
these receptors. Moreover, because resistance to IGF-1R–specific antibodies may emerge via 
increased IR signaling, dual targeting of IGF-1R and IR by TKIs may be effective following failure of 
an anti IGF-1R antibody. Identifying biomarkers associated with the activation of IGF-1R and IR will 
be important for optimally evaluating emerging therapeutic agents (Buck et al, 2010). 
 
Insulin, IGFs and their role in the resistance to breast cancer therapy 
Although significant improvement has been achieved and more effective agents are currently 
available in the treatment arsenal against breast cancer, the vast majority of patients will develop 
resistance. The IGF pathway has been reported to play an important role in the development of 
resistance against several DNA-damaging agents, as IGFs protect cancer cells from apoptotic cell 
death via IGF-1R-mediated activation of the PI-3K/AKT pathway, as well as rescue from drug-induced 
cytostasis through activation of MAPK pathway signals. The IGF system transduces signals that may 
also confer a multidrug resistance (MDR) phenotype to cancer cells, by the induction of MDR-related 
genes such as Mdr-1 (with increased expression of its product, the p-glycoprotein drug efflux pump) 
and the manganese superoxide dismutase (MnSOD) (Guo et al, 2003). Indeed, IGF-1R signaling has 
been associated with resistance and increased survival of breast cancer cells treated with 5-
fluorouracil, methotrexate, or camptothecin via IGF-1R inhibition of apoptosis (Karamouzis and 
Papavassiliou, 2012). Inhibition of IGF-dependent signaling with mAbs or TKIs results in 
enhancement of the cytotoxic effect of several chemotherapeutics, including gemcitabine, irinotecan, 
etoposide, carboplatin, adriamycin, ifosfamide, navelbine, 5-fluorouracil and vincristine, both in vitro 
and in vivo (Tao et al, 2007). Moreover, resistance to hormonal therapy against breast cancer may be 
partially explained by cross-talk between ER and IGF pathways as well as through the modulation of 
downstream pathways. One possible mechanism by which breast cancer cells escape tamoxifen-
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induced apoptosis may be the activation of the AKT pathway via IGF-mediated signaling, which leads 
to phosphorylation of ER at Ser-167 and subsequent ligand-independent activation of ER (Campbell, 
2001). IRS-1 is the major adaptor protein of IGF-1R/IR but also the mediator of cross-reaction with 
other membrane associated molecular networks that are responsible for the development of 
hormone-resistance in breast carcinomas. Additionally, expression levels of IGFBPs were found to be 
predictive factors for response to hormonal agents. For example, IGFBP-2 mRNA and protein levels 
have been reported to be over-expressed in cell lines resistant to the anti-estrogens fulvestrant and 
tamoxifen (Juncker-Jensen, 2006). 
The IGF-1R pathway has also been implicated in resistance to radiotherapy (RT). It is believed 
that it exerts its activity, in part, by modulating ataxia telangiectasia mutated (ATM) function, which 
controls the response of the cell to DNA damage induced by RT via triggering cell-cycle arrest and 
apoptosis, as well as DNA repair, and it has been documented that inhibition of IGF-1R signaling 
enhances sensitivity of breast cancer to RT, thus representing a way to enhance the efficacy of RT in 
cases of radioresistant tumors (Karamouzis and Papavassiliou, 2012). 
 
Crosstalk and combination therapy in breast cancer 
IGF-1R Monoclonal Antibodies and mTOR Inhibitors  
mTOR inhibitors affect the S6K1-IRS1 negative feedback loop and result in enhanced PI3K- AKT 
activation through IGF-1R signaling: if this pathway represents a resistance mechanism for the mTOR 
inhibitors, then co-targeting IGF-1R and mTOR might result in enhanced clinical benefit over mTOR 
inhibitor monotherapy. Studies showed that dual inhibition of IGF-1R and mTOR improved antitumor 
activity in vitro and in breast cancer and other cancer patient tumor samples (Wan et al, 2007). 
Currently, Merck is determining the benefits of IGF-1R monoclonal antibody (Dalotuzumab) and 
mTOR inhibitor (Ridaforolimus) combination therapy in breast cancer patients with ER-positive tumors 
(NCT01220570, NCT01234857). Amgen is evaluating the clinical benefits of combining Ganitumumab 
with Everolimus in patients having advanced cancers (NCT01061788, NCT01122199). The results of 
these clinical trials are expected to reveal the benefits of co-targeting IGF-1R and mTOR. It is worth 
noting that drugs acting as dual inhibitors of PI3K and mTOR, such as NVP-BEZ235, also 
demonstrated improved antitumor efficacy compared to mTOR inhibitors alone (Yang and Yee, 2012).  
Targeting IGF-1R/IR and Estrogen Receptor-α (ERα)  
Cross talk between IGF/insulin system and ER signaling pathway is well established. IGF/insulin 
signaling activates ERα via PI3K/AKT and/or MAPK pathways respectively by phosphorylating ERα 
Ser167 and/or ERα Ser118. Estrogen increases expression of several key genes in the IGF signaling 
pathway including IGF-2, IGF-1R, and IRS-1, while decreasing expression of other genes, such as 
IGFBP-3 and IGF-2R. Thus, the overall effect of estrogen on the IGF/insulin system is to positively 
regulate signaling. Acquired resistance to anti-estrogen therapies is an important clinical problem. 
Since ERα may function together with IGF-1R signaling to enhance cell survival, targeting both 
pathways may have value (Yang and Yee, 2012). More recently, microarray data suggest that a gene 
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signature (co-regulated by IGF-1 and estrogen) correlated with poor prognosis in human breast 
cancer, which also implies dual inhibition of IGF-1R and ER pathway may be necessary in certain 
breast cancer subtypes (Casa et al, 2012). However, the clinical trials using the combination therapy 
for patients with endocrine-resistant breast cancer have been disappointing. In these trials, most 
women had already developed resistance to anti-ER therapies. In most of the reported trials, the anti 
IGF-1R strategies were tested as the second or third line endocrine therapies (Kaufman et al, 2010). 
It has been recently shown that tamoxifen-resistant (TamR) cells and tumors lose expression of 
IGF-1R while maintaining IR expression. These findings suggest IGF-1R is a poor target in TamR 
tumors and IR might be an alternative option in treating TamR breast cancer (Fagan et al, 2012). 
Patients with TamR tumors also show loss of IGF-1R at the time of progression on tamoxifen. Thus, 
endocrine resistant patients might not be the best candidates for anti IGF-1R therapies. However, 
there are other ways to target IGF-1R and IR with small molecule TKIs, ligand neutralizing antibodies, 
or even growth hormone receptor antagonists, so the final word about the clinical relevance of these 
cross talk pathways is not yet settled (Yang and Yee, 2012). 
Targeting IGF-1R and Human Epidermal Growth Factor Receptor (EGFR) 
About 30 % of the patients with invasive breast cancers have amplification or overexpression of 
HER2, which is associated with poor prognosis breast cancer. Trastuzumab is a recombinant 
humanized monoclonal antibody that targets the extracellular domain of HER2: initially it showed 
outstanding anti-tumor efficacy in patients with HER2 positive breast cancer in combination with 
cytotoxic chemotherapy. However, not all patients benefit from this regimen and in advanced breast 
cancer, resistance develops in about one year (Esteva, 2002). IGF-1R and HER2 are reported to form 
heterodimers in Trastuzumab-resistant breast cells. Furthermore, IGF-1 was shown to activate HER2 
signaling in Trastuzumab-resistant breast cancer cells but not parental cells. Inhibition of IGF 
signaling resulted in restoration of Trastuzumab sensitivity to resistant cells (Browne et al, 2011). 
These preclinical findings led to several clinical trials aimed at evaluating the benefits of co-targeting 
IGF-1R and HER2 in Trastuzumab-resistant breast cancer patients (NCT01479179, NCT00788333, 
NCT00684983, and NCT01111825) (Yang and Yee, 2012). 
Targeting IGF/Insulin Signaling and Chemotherapy 
Combining either IGF-1R monoclonal antibodies or IGF-1R TKI could enhance doxorubicin drug 
efficacy (Zeng, 2012). It is demonstrated that giving cytotoxic chemotherapy prior to or concurrently 
with IGF-1R inhibitors resulted in a better tumor response. In contrast, IGF-1R inhibition prior to 
cytotoxic chemotherapy did not improve the benefits of doxorubicin and may represent an 
interference pathway between cytotoxic chemotherapy and IGF-1R inhibitors. These results suggest 
a combination of IGF-1R blockade and chemotherapy works in a sequence-dependent fashion (Yang 
and Yee, 2012). 
IGF/Insulin System Therapy and Metformin 
As noted above, IGF-1R inhibition is predicted and proven to result in compensatory upregulation 
of circulating IGFs and insulin. These effects may cause hyperinsulinemia and be clinically manifest 
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as metabolic syndrome or type-2 diabetes. Therefore, combining insulin sensitizing drugs to decrease 
serum levels of insulin with metformin might be necessary to attenuate the metabolic effects of the 
anti IGF-1R/IR drugs. The I-SPY2 trial of neoadjuvant breast cancer therapy is testing the therapeutic 
value of combining Ganitumumab, metformin and paclitaxel. The metformin will help to manage any 
acquired insulin resistance induced by Ganitumumab (Barker et al, 2009). Metformin also reduces 
reactive oxygen species in mitochondria, which potentially would be important to inhibit tumorigenesis 
independent of the effects on glucose metabolism. Thus metformin combined with IGF-1R blockades 
may not only attenuate the drug-induced hyperglycemia and hyperinsulinemia, but may also exhibit 
antitumor efficacy (Yang and Yee, 2012). 
 
 
Hypoxia 
 
Oxygen is essential for eukaryotic life and is inextricably linked to the evolution of multicellular 
organisms. Proper cellular response to changes in oxygen tension during normal development or 
pathological processes, such as cardiovascular disease and cancer, is ultimately regulated by the 
transcription factor, hypoxia-inducible factor (HIF). Over the past decade, unprecedented molecular 
insight has been gained into the mammalian oxygen-sensing pathway involving the canonical oxygen-
dependent prolyl-hydroxylase domain-containing enzyme (PHD)–von Hippel-Lindau tumour 
suppressor protein (pVHL) axis and its connection to cellular metabolism (Greer et al, 2012). 
Hypoxia is a state of reduced oxygen pressure below a critical threshold, which restricts the 
function of organs, tissues and cells (Hockel M and Vaupel, 2001). Normal oxygen partial pressure 
(pO2) levels range from 150 mm Hg in the upper airway to 5 mm Hg in the retina, and a pO2 <40 mm 
Hg in arterial blood constitutes hypoxia. Hypoxia can be caused by a reduction in oxygen supply, for 
example at increased altitude or by localized ischemia caused by the disruption of blood flow to a 
given area. Many solid tumors also contain hypoxic regions (pO2 <5 mm Hg), owing to the inability of 
the local vasculature to supply sufficient oxygen to the rapidly growing tumor because of the rate of 
growth of the tumour itself and the severe structural abnormality of tumor microvessels (Semenza, 
2012). However, hypoxia also has an important and beneficial role in mammalian physiology; indeed, 
its presence is crucial for proper embryogenesis. At the cellular level, the response to hypoxia 
includes a switch from aerobic metabolism to anaerobic glycolysis and the expression of a variety of 
stress proteins regulating cell death or survival. Further adaptations that occur at the tissue level to 
increase oxygen delivery include the induction of erythropoiesis and angiogenesis (Koh et al, 2008). 
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Hypoxia Inducible Factors (HIFs) 
 
Human cells require adequate supplies of O2 on a continuous basis to use as the terminal electron 
acceptor in the process of mitochondrial respiration that generates ATP, which is used to power most 
biochemical reactions. Both the delivery and consumption of O2 are  regulated through the activity of 
hypoxia-inducible factors (HIFs) (Semenza, 2011). As cells proliferate, increased oxygen 
consumption results in hypoxia, which activates HIFs, leading to transcription of the VEGF gene, 
which encodes vascular endothelial growth factor, a secreted protein that stimulates angiogenesis 
and thereby increases oxygen delivery (Semenza, 2012). 
Hypoxia-inducible factors are DNA-binding transcription factors that associate with specific nuclear 
cofactors under hypoxia to transactivate a myriad of genes to trigger various adaptive responses to 
compromised oxygen tension, mediating the primary transcriptional responses to hypoxic stress in 
normal and transformed cells (Greer et al, 2012). HIFs are basic helix-loop-helix–PER–ARNT–SIM 
(bHLH–PAS) proteins that form heterodimeric complexes that are composed of an O2 -labile α-
subunit (HIF-1α, HIF-2α or HIF-3α) and a stable β-subunit (HIF-1β; also known as ARNT). Together, 
these subunits bind hypoxia-responsive elements (HREs) that contain a conserved 5’-RCGTG-3’ core 
sequence, thereby eliciting transactivation of downstream genes and the adaptive hypoxic response 
(Keith et al, 2012). Based on genome-wide chromatin immunoprecipitation combined with DNA 
sequencing or mRNA microarrays (ChIP-seq and ChIP-chip, respectively), the number of direct HIF 
target genes is currently greater than 800 (i.e. at least one in 30 of all human genes) (Semenza et al, 
2012). HIFs also indirectly regulate gene expression by transactivating genes encoding microRNAs 
and chromatin-modifying enzymes (Schödel et al, 2011). Hypoxic HIF activity is controlled primarily 
through post-translational modification and stabilization of HIF-1α and HIF-2α subunits, so that HIFα 
protein levels and overall HIF transcriptional activity increase as cells become more hypoxic (Keith et 
al, 2012). 
HIF-1α was first described by Semenza and colleagues in 1995, when it was shown to have a 
central role in mediating hypoxia-dependent transcriptional responses (Wang et al, 1995). In 1997, 
the identification by independent groups of HIF-2α - which was initially called endothelial PAS protein 
1 (EPAS1), HIF-related factor (HRF), HIF1α-like factor (HLF) or member of PAS family 2 (MOP2)11 - 
indicated that HIF regulation was more complex than initially fathomed (Keith et al, 2012). Whereas 
HIF-1α seems to be expressed in nearly all cell types, RNA in situ hybridization of mouse embryos 
revealed that the expression of Epas1 is more restricted and is particularly abundant in blood vessels. 
This observation led to the hypothesis that the primary role of HIF-2α is to modulate vascular 
endothelial cell function, an idea that is supported in part by the close correlation of the mRNA 
expression patterns of EPAS1 and vascular endothelial growth factor A (VEGF-A). A more complex 
view emerged as HIF-2α protein expression was identified in multiple cell types in hypoxic rat kidney, 
lung and colonic epithelia, as well as in hepatocytes, macrophages, muscle cells and astrocytes, 
indicating that both HIF-1α and HIF-2α are co-expressed in many cell types.  
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Most HIF transcriptional responses have been attributed to HIF-1α and HIF-2α; however, a third 
HIFα subunit (HIF-3α) has also been described. HIF3A mRNA is differentially spliced to produce 
multiple HIF-3α isoforms that either promote or inhibit the activity of other HIF complexes, although 
little is currently known about the impact of HIF-3α on tumour progression under hypoxic conditions 
(Heikkila et al, 2011). Similarly, ARNT2 (HIF-2β) has been identified and shown to regulate neuronal 
development and to exhibit overlapping activity with HIF-1β; however, its activity in human cancer 
cells has not been studied in depth (Hirose et al, 1996; Keith et al, 2011). Although it will be important 
to determine whether (and how) HIF-3α and ARNT2 affect HIF-mediated responses in cancers, the 
available evidence suggests that HIF-1α and HIF-2α (together referred to as HIFα hereafter) account 
for the vast majority of HIF-dependent effects on tumour growth and progression that have been 
described to date (Keith et al, 2012).  
 
 
 
The role of HIFα as transcription factors in the context of oxygen sensing and tumourigenesis has 
been extensively characterized. While the aforementioned role of HIFα in cell signaling regulation is 
considered the most important, emerging evidence has implicated a larger role for HIFα in cell 
biology. 
Role of HIF in embryonic development 
HIF1α has previously been shown to promote a metabolic switch to glycolysis in response to 
chronic hypoxia through the transcriptional regulation of key metabolic enzymes such as pyruvate 
dehydrogenase kinase-1 (PDK1) and lactate dehydrogenase A (LDHA) (Kim et al, 2006). HIF-1α 
drives a metabolic shift to glycolysis during transition of pluripotent embryonic stem cells (ESCs) to 
epiblast stem cells (EpiSCs) and maintains pluripotency in ESCs and HSCs (hematopoietic stem 
cells) through TGFb/Activin/Nodal signalling. These findings suggest that the high expression of HIF-
1α and shift to glycolytic metabolism is not just a result of the hypoxic environment of the bone 
marrow, but is tightly regulated by haematopoietic stem-cell–associated transcription factors. Whether 
or not unique ESC-associated transcription factors regulate HIFα in ESC remains to be determined 
(Greer et al, 2012). 
Figure 5 structure of HIF subunits (Nature, 2012) 
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Role of HIF in immunity  
Inflamed tissues are often hypoxic as a result of decreased perfusion, edema, vascular insult 
and/or influx of oxygen-consuming immune cells or pathogens (Nizet and Johnson, 2009). Thus, the 
role of HIFα in host immune responses and inflammation has become of particular interest: one 
example is its role in promoting differentiation of TH17 cells by several distinct mechanisms. 
Role of HIF in Notch-dependent developmental pathways 
HIFα can modulate human leukocyte differentiation via canonical and non-canonical pathways. 
However, HIFα can induce or suppress the differentiation of a multitude of cell types, including but not 
limited to adipocytes, medulloblastoma precursor cells, neuroblastoma cells, glioblastoma stem cells, 
and neural crest progenitors. A number of these reports have implicated Notch, a well-established 
mediator of cellular differentiation processes, as an important effector: an example of the interaction 
between HIFα and Notch in crystal cell development, which requires direct stabilization of endosomal 
Notch by HIFα (Greer et al, 2012). 
 
HIF regulation 
The induction of HIF-1 activity during hypoxia can be attributed to a variety of factors. HIF-1α is 
continuously transcribed and translated in hypoxia despite an overall decrease in global protein 
translation. Additionally, several mechanisms regulate the stability and activity of HIF-1α protein in an 
oxygen-dependent manner. Recent years have seen great advances in the field of HIF-1α regulation, 
providing a clearer understanding of established pathways and also introducing new and sometimes 
controversial findings involving novel regulators and mechanisms controlling HIF-1α levels. The most 
recent informations involving HIF-1 protein regulation revolve around different important aspects 
governing the availability of the HIF-1α subunit: its proteasomal degradation, a well-characterized field 
that has recently seen a wealth of new information, and its transcription as well as translation, two still 
developing and, at times, controversial fields (Koh et a, 2008). 
 
Degradation 
pVHL dependent pathway: ubiquitylation 
To enable the rapid response to changes in oxygen levels, cells have evolved a highly 
sophisticated mechanism for both sensing and adapting to hypoxia. The oxygen-dependent regulation 
of the HIF-α subunit through its ubiquitin-proteasomal degradation von Hippel Lindau protein (pVHL) 
pathway has been well studied: under aerobic conditions, HIF-1α is hydroxylated by specific prolyl 
hydroxylases (PHD1, PHD2 and PHD3) at two conserved proline residues (Pro402 and Pro564) 
situated within its oxygen-dependent degradation (ODD) domain. This reaction requires oxygen, 2-
oxoglutarate and ascorbate as cofactors. Under hypoxic conditions (<5% O2), PHD activity is 
inhibited, resulting in HIF-1α stabilization. In addition to the enzymatic inhibition of the PHDs, hypoxia 
causes perturbations in the mitochondrial electron-transport chain, thus increasing the levels of 
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cytoplasmic reactive-oxygen species (ROS), which alters the oxidation state of Fe2+ (a cofactor for 
PHD activity) to Fe3+, which cannot be utilized. This alteration inhibits PHD activity and promotes HIF-
1α stabilization (Koh et al, 2008). Thus, disruption of mitochondrial function using either 
pharmacological or genetic inhibition or knockout of the mitochondrial electron-transport chain 
convincingly prevents HIF-1α stabilization during hypoxia (Simon, 2006). In addition, the essential role 
of mitochondria in HIF-1α regulation is highlighted by the exclusive enrichment of mitochondrial 
inhibitors from a library of >600000 diverse compounds by using a HIF-1 reporter assay (Lin et al, 
2008). However, the role of ROS in hypoxia and HIF-1 regulation remains controversial, owing to 
discrepancies in different model systems, a lack of tools for accurate detection of ROS and variability 
in the severity and length of hypoxia applied. It is believed that future studies will provide a clearer 
role for the mitochondria in HIF-1α regulation. In addition to mitochondrial-dependent mechanisms, 
the PHDs are subject to regulation by other factors, including intracellular calcium concentrations and 
the seven in absentia homologs 1 and 2 (Siah1 and Siah2) E3 ubiquitin ligases (Simon, 2006). HIF-1α 
hydroxylation facilitates binding of pVHL to the HIF-1α ODD. pVHL forms the substrate-recognition 
module of an E3 ubiquitin ligase complex comprising elongin C, elongin B, cullin-2 and ring-box 1, 
which directs HIF-1α poly-ubiquitylation and proteasomal degradation. Recognition of HIF-1α by 
pVHL is further facilitated by HIF-1α acetylation at Lys532 by arrest-defective-1 (ARD1) N-
acetyltransferase, which functions mainly under normoxic conditions. It should be noted, however, 
that the acetylation of HIF-1α by ARD1 and its importance have been disputed (Koh et al, 2008). The 
central role of pVHL in HIF-1α regulation is manifest in von Hippel Lindau (VHL) disease, where the 
inactivation of the VHL gene results in the development of highly vascularized tumors of the kidney, 
retina and central nervous system (Kaelin, 2007). In addition to pVHL, human double minute 2 
(Hdm2), the E3 ligase that binds to and degrades the p53 tumor-suppressor protein, can also induce 
HIF-1α proteasomal degradation in an oxygen-independent manner via p53–HIF-1α binding (Ravi et 
al, 2000). 
pVHL itself is subject to tight regulation by mechanisms that modulate its stability or its affinity for 
HIF-1α and other components of the pVHL E3 ubiquitin ligase complex. One such regulator is E2-
endemic pemphigus foliaceus (EPF) ubiquitin carrier protein (UCP), a member of the E2 enzyme 
family: it can specifically ubiquitylate pVHL leading to its degradation. Hence, UCP overexpression 
causes the proteasomal-dependent degradation of pVHL, resulting in the accumulation of HIF-1α in 
normoxia (Jung et al, 2006). Other novel regulators of HIF-1α include osteosarcoma-9 (OS-9) and 
spermidine/spermine-N1-acetyltransferase (SSAT)2, which were both identified as HIF-1α binding 
partners in a yeast two-hybrid screen. OS-9 overexpression results in the marked reduction of HIF-1α 
protein levels under both normoxia and hypoxia by promoting pVHL-dependent degradation. OS-9 
forms a ternary complex with HIF-1α and PHD2 or PHD3, thereby promoting HIF-1α proline 
hydroxylation and directing pVHL binding and subsequent proteasomal degradation. SSAT2 
simultaneously binds to pVHL and elongin C, thereby stabilizing their interaction and promoting HIF-
1α ubiquitylation. Accordingly, SSAT2 overexpression decreases HIF-1α levels, whereas SSAT2 
knockdown increases HIF-1α levels under both normoxia and hypoxia. SSAT2 might be a necessary 
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component of the pVHL E3 ligase complex because it is required for the decrease in HIF-1α levels 
mediated by overexpression of either PHD2 or pVHL (Koh et al, 2008). 
pVHL dependent pathway: de-ubiqitylation 
The pVHL-interacting de-ubiquitylating enzyme (VDU2; also called USP20) is the sole HIF-1α de-
ubiquitylating enzyme (DUB) identified to date. VDU2 itself can be ubiquitylated and degraded by the 
pVHL E3 ligase complex. VDU2 binds and de-ubiquitylates HIF-1α in a pVHL-dependent manner, 
hence salvaging it from proteasomal degradation. The region of pVHL, which is commonly altered in 
VHL disease, harbors the binding sites for both VDU2 and HIF-1α (Koh et al, 2008). 
pVHL dependent pathway: SUMOylation 
Hypoxia induces small ubiquitin-like modifier (SUMO)-1 expression and increases HIF-1α 
SUMOylation, a process that has been shown to lead to its stabilization. However, new evidence 
indicates that HIF-1a SUMOylation can also lead to HIF-1a degradation. Hypoxia-induced HIF-1α 
SUMOylation can promote hydroxyproline-independent HIF-1α–pVHL E3 ligase complex binding, 
thus leading to ubiquitylation and proteasomal degradation. These findings provide evidence for an 
alternative signal for pVHL binding in the absence of proline hydroxylation. Hence, hypoxia-induced 
HIF-1α SUMOylation can promote either its stabilization or pVHL-dependent degradation. Further 
characterization of the type (SUMO 1–3) or nature of HIF-1α SUMO conjugation during hypoxia 
should shed light on this newly identified mechanism for HIF-1α regulation (Koh et al, 2008). 
 
pVHL independent pathways 
Increasing evidence indicates that mechanisms other than pVHL-dependent HIF-1α degradation 
have an important role in controlling its levels. Compared with pVHL, the regulation of these new 
pathways seems to be less dependent on oxygen availability and more on specific cellular conditions 
such as calcium or the presence of growth factors. HIF-1α protein stability is regulated through an 
oxygen- independent pathway involving the molecular chaperone 90 kDa heat-shock protein (HSP90) 
and receptor of activated protein kinase (PK)C (RACK1), which compete for binding to HIF-1α. 
RACK1 homodimerizes and recruits elongin C and other components of the E3 ligase complex to 
HIF-1α, leading to its ubiquitylation and degradation in a manner mechanistically similar to the pVHL 
pathway. RACK1–HIF-1α binding is dependent upon the presence of SSAT1, which stabilizes the 
interaction (Liu et al, 2007.1). It is intriguing that both SSAT1 and SSAT2 bind to and promote HIF-1α 
ubiquitylation by completely different mechanisms: SSAT2 promotes oxygen and pVHL-dependent 
HIF-1α degradation, whereas SSAT1 promotes oxygen-independent, RACK1- dependent HIF-1α 
degradation. The RACK1 pathway can also be regulated by calcium through the activity of 
calcineurin, a calcium- and calmodulin- dependent and serine/threonine-specific protein phosphatase. 
Calcineurin A dephosphorylates RACK1 in a calcium-dependent manner, thus blocking RACK1 
dimerization and inhibiting RACK1-mediated HIF-1a degradation (Liu et al, 2007.2). 
PI3K–Akt signaling activates a variety of signaling cascades with diverse outcomes, including cell 
survival and death, and is also intricately linked to HIF-1 regulation, not only by inducing HIF-1α 
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translation in response to growth factors but also through the regulation of HIF-1α protein 
degradation. However, the modulation of the PI3K–Akt pathway and its role in HIF-1α regulation 
during hypoxia remains controversial and is highly context dependent. It has been suggested that the 
PI3K pathway might be activated by short-term hypoxia but inhibited by prolonged hypoxia (Mottet et 
al, 2003) . Glycogen synthase kinase 3 (GSK3) is phosphorylated and inactivated by Akt: its 
overexpression results in prolyl-hydroxylation- and pVHL-independent HIF-1α ubiquitylation and 
proteasomal degradation. Similarly, overexpression of forkhead box (FOX)O4 or of constitutively 
active FOXO3a, both of which are also negatively regulated by Akt, also represses HIF-1α, the former 
by inducing pVHL-independent HIF-1α ubiquitylation and degradation and the latter by inhibiting HIF-
1α transactivation in a p300-dependent manner. Hence, it is possible that prolonged hypoxia might 
inhibit the PI3K pathway, resulting in increased GSK3b activity and perhaps also FOXO4 and 
FOXO3a, which then results in decreased HIF-1α levels and activity (Koh et al, 2008; Mottet et al, 
2003).  
In summary, the regulation of HIF-1α protein levels through degradation is complex, involving 
multiple pathways and regulatory factors, some yet to be fully characterized. 
 
Transcription 
Surprisingly, relatively little is known about the transcriptional regulation of the HIF1A and EPAS1 
genes. Nuclear factor-κB (NF-κB) regulates the transcription of HIF1A. Moreover, helper T cell (TH)1 
cytokines stimulate this NF-κB–HIF1α pathway to activate a range of HIF1α target genes, whereas 
the TH2 cytokines interleukin-4 (IL-4) and IL-10 differentially activate EPAS1 expression, although the 
precise mechanisms involved are not clear. Expression at the HIF1A locus, in contrast to the EPAS1 
locus, is also regulated by the SWI/SNF chromatin remodelling protein BRG1-associated factor 57 
(BAF57; also known as SMARCE1). Additional investigation into differential HIF1A and EPAS1 
transcription is certainly warranted (Keith et al, 2012). 
 
Translation 
Under normoxia 
A variety of oncoproteins, growth factors and cytokines regulate HIF-1α protein translation in 
normoxic conditions (Semenza, 2011). In certain contexts, HIF-1α protein induction is dependent on 
activation of the PI3K/Akt/mTOR and the MAPK pathways (Zhou and Brune, 2006). These pathways 
phosphorylate the translational repressors (eIF)4E binding proteins (4E-BP1, 4E-BP2 and 4E-BP3) 
and the ribosomal kinase S6K. eIF4E is an mRNA cap-binding protein that mediates the binding of 
the eIF4F complex to the 50 cap structures of mRNA. Hypophosphorylated 4E-BP1 binds to eIF4E 
with high affinity, thereby preventing eIF4F-complex formation and translation initiation. Activation of 
mTOR and ERK promotes protein synthesis by phosphorylating 4E-BP1 on several sites, hence 
decreasing its affinity for eIF4E and enabling the formation of the eIF4F complex and subsequent 
cap-dependent translation. Phosphorylation of S6K by mTOR and ERK controls translation by 
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phosphorylating components of the translational machinery including the ribosomal protein S6, eIF4B 
and eEF2K (Sonenberg and Hinnebusch, 2007). It was originally believed that phosphorylation of S6 
by S6K stimulates translation by increasing the affinity of ribosomes for the 50-terminal 
oligopyrimidine tract (50 TOP) motif in certain mRNAs. The putative presence of a 50 TOP motif 
downstream of nucleotide +32 in the 50 untranslated region (UTR) of HIF-1α that was initially found 
was proposed to be the mechanism by which mTOR and S6K drive HIF1-α translation (Van den 
Beucken, 2006). However, it is now believed that the 50 TOP motif is not present in HIF1A mRNA, 
and both S6K and S6 are dispensable for the translational activation (Sonenberg and Hinnebusch, 
2007). Hence, the mechanism for S6K-mediated translational regulation of HIF-1α remains unclear. 
 
Under hypoxia 
Hypoxia leads to an almost immediate shutdown of general protein translation as a means of 
decreasing energy consumption during stress. Translation inhibition during hypoxia is regulated by at 
least two separate pathways. The first pathway, the unfolded protein response (UPR), is activated 
rapidly (1–2 h) at oxygen concentrations of <1% and stimulates the endoplasmic reticulum (ER) 
kinase PKR-like ER kinase (PERK), which phosphorylates a crucial regulator of translation initiation, 
eIF2a. The second pathway, controlled by mTOR, is activated by prolonged hypoxia and inhibits 
translation by disrupting the eIF4F complex . Thus, the level and length of oxygen deprivation seems 
to determine the specific mechanism(s) for translation inhibition, each driving distinct gene-expression 
patterns (Koh et al, 2008). Despite a decrease in global protein translation during hypoxia, a small 
group of proteins crucial for survival, including HIF-1α, continue to be translated. The evidence 
supporting the continued translation of HIF-1α was determined using several independent 
approaches including reporter assays (Young et al, 2008). However, how HIF-1α is selectively 
translated during periods of global translation inhibition remains incompletely understood. One 
suggested mechanism is through IRES (internal ribosome entry site) elements. Several studies in the 
past have reported that the 50 UTR of HIF-1α contains an IRES capable of promoting translation of a 
downstream reporter in bicistronic reporter assays. However, more recent work convincingly disputes 
the role of IRES in HIF1-α translation. Moreover, whether an IRES-dependent mechanism contributes 
substantially to protein translation during hypoxia remains a subject of debate, and observations of 
protein translation in hypoxia owing to cryptic promoter activity rather than IRES-mediated translation 
have been reported (Koh et al, 2008). Recent work indicates that, in breast cancer, overexpressed 
4E-BP1 and eIF4G function are a hypoxia-activated switch that facilitates cap-independent translation 
over cap-dependent translation of HIF-1α and other key pro-angiogenic and pro-survival mRNAs 
(Braunstein et al, 2007). Thus, although translation of HIF-1α and a subset of other stress-survival 
proteins is maintained or even increased during hypoxia, despite the global decrease in cap-mediated 
protein translation, the exact mechanism remains unclear. A role for calcium in the regulation of HIF-
1α translation during hypoxia is receiving increasing attention. Most cells in fact respond to hypoxia 
with a sustained increase in cytoplasmic free calcium, but studies addressing the role of calcium in 
the regulation of HIF-1α levels have been inconsistent with regards to the effect or the mechanism: 
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this controversy reflects the complexity of calcium-dependent signaling (Koh et al, 2008). Intriguingly, 
it has been demonstrated that HIF-1α expression in RCC cell lines seems to be regulated by both 
mTOR-containing kinase complexes mTORC1 and mTORC2, whereas HIF-2α expression is 
mTORC2-dependent and mTORC1- (Toschi et al, 2008). Other forms of differential translation control 
have been reported for HIFα proteins. For example, the iron response element (IRE) binding protein 1 
(IREBP1; also known as aconitase) was shown to bind a canonical IRE in the 5′ untranslated region 
(UTR) of EPAS1, thereby inhibiting its translation. This effect seems to be specific for HIF-2α, as 
IREBP1 fails to bind the HIF1A transcript or regulate its translation, despite the presence of a near-
consensus IRE in the 5′ UTR of HIF-1A. This regulation is also consistent with the identification of 
HIF-2α as the primary regulator of erythropoiesis and cellular iron metabolism in vivo (Keith et al, 
2012). 
 
 
HIFs in cancer progression 
 
HIFs play key roles in cancer progression, as several specific HIF-regulated genes are involved in 
many aspects of tumour biology including angiogenesis, stem cell maintenance, metabolic 
reprogramming, autocrine growth factor signaling, epithelial-mesenchymal transition, invasion, 
metastasis, and resistance to radiation therapy and chemotherapy. An extensive body of 
experimental and clinical data has validated HIFs role in cancer: first, in addition to intratumoral 
hypoxia, loss-of-function for tumor suppressor genes (most notably, VHL), and gain-of-function for 
oncogenes and viral transforming genes, increase HIF activity; second, levels of HIF-1α or HIF-2α 
correlate with tumor growth, vascularization, and metastasis both in animal models and in clinical 
studies. In different cancers, the HIF-dependent expression of these genes may be increased either 
by genetic alterations or by intratumoral hypoxia (Semenza, 2012).  
(a) Increased cell proliferation and survival  
Among the first changes that distinguish neoplastic from normal cells are an increased rate of cell 
proliferation and a decreased rate of cell death as a result of increased expression of secreted 
growth/survival factors. Often, the same cells express the cognate membrane receptors for these 
factors, resulting in autocrine signaling. Among the growth/survival factors that are encoded by HIF-
regulated genes and participate in autocrine signaling we find: transforming growth factor-α (TGF-α) 
in clear-cell renal carcinoma; insulin-like growth factor-2 (IGF-2) in colorectal carcinoma; vascular 
endothelial growth factor (VEGF) in colorectal, gastric, and pancreatic cancer; endothelin 1 (EDN1) in 
breast, prostate, and ovarian cancer and erythropoietin (EPO) in breast, prostate, and renal cancer 
and melanoma. Immortalization of cancer stem cells also requires the expression of telomerase 
(TERT), as well as pluripotency factors and factors that block cellular senescence (Semenza, 2012). 
(b) Metabolic reprogramming 
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The uptake of glucose by metastatic cancer cells is so reliably and markedly increased compared 
to normal cells that it serves as the basis for the clinical test used to screen cancer patients for occult 
metastases in which 18F-fluorodeoxyglucose is imaged by positron emission tomography (FDG-
PET). HIF-1 mediates the expression of genes encoding glucose transporters (GLUT1, GLUT3) and 
glycolytic enzymes (ALDOA, ENO1, GAPDH, HK1, HK2, PFKL, PGK1, PKM2, LDHA) that convert 
glucose to lactate. HIF-1 also actively suppresses mitochondrial oxidative metabolism by increasing 
the expression of pyruvate dehydrogenase kinase 1 (PDK1), which phosphorylates and inactivates 
pyruvate dehydrogenase, the enzyme that converts pyruvate to acetyl-CoA thereby fuelling the TCA 
cycle (Semenza, 2011.2). HIF-1 also downregulates oxidative metabolism by activating the 
expression of the genes encoding BNIP3 and BNIP3L, which mediate mitochondrial-selective 
autophagy (Bellot et al, 2009). Recent data suggest that in some cell types HIF-1 may also mediate 
expression of transketolase enzymes (TKT, TKTL2) of the pentose phosphate pathway (PPP), which 
non-oxidatively catalyze the production of ribose required for nucleic acid synthesis (Zhao, 2010). 
(c) Angiogenesis 
HIF-1 controls the expression of multiple genes encoding angiogenic growth factors, including 
vascular endothelial growth factor (VEGF), stromal-derived factor 1 (SDF1), placental growth factor 
(PlGF), platelet-derived growth factor B (PDGFB), and angiopoietin (ANGPT) 1 and 2 (Rey and 
Semenza, 2010). In mouse models, inhibition of HIF-1 activity dramatically inhibits tumor 
vascularization (Liao D and Johnson, 2007). 
(d) Epithelial–mesenchymal transition 
HIF-1 activates the transcription of genes encoding repressors (i.e. ID2, SNAI1, SNAI2, TCF3) that 
block the expression of E-cadherin and other proteins that contribute to the rigid cytoskeleton, cell-cell 
adhesion, and other differentiated characteristics of epithelial cells (Esteban et al, 2006). HIF-1 also 
mediates expression of genes (TGFA, VIM) that promote flexibility in the cytoskeleton and other 
characteristics of the mesenchymal phenotype (Gunaratnam et al, 2003). 
(e) Invasion and metastasis.  
HIF-1 activates transcription of genes encoding proteases that degrade (i.e. CTSC, MMP2, MMP9) 
or remodel (LOX, LOXL2, LOXL4) the extracellular matrix within the primary tissue and at distant sites 
of metastasis (Wong et al, 2011) as well as motility (AMF, MET) and permeability factors (VEGF, 
ANGPT2) that promote the intravasation of cancer cells into blood vessels and cell surface (L1CAM) 
and secreted (ANGPTL4) proteins that promote extravasation of cancer cells into the parenchyma at 
metastatic sites such as the lung (Zhang et al, 2012). 
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Although HIF-1α and HIF-2α clearly influence tumour progression by directly regulating the 
expression of unique and shared target genes, recent evidence indicates that these HIFα proteins 
also affect tumour progression by exerting distinct, often opposing, effects on crucial oncoproteins 
and tumour suppressors, including MYC, p53 and mTOR. Interestingly, multiple recent studies have 
also revealed unexpected tumour-suppressive activities of HIF-1α and HIF-2α in specific contexts 
(Maranchie et al, 2002; Acker et al, 2005). Although initially viewed as having largely overlapping 
functions, there is now mounting evidence that the two can promote highly divergent, even opposing, 
outcomes when expressed in the same cell type. It seems that HIF-1α and HIF-2α mediate these 
disparate responses partly through independent regulation of distinct target genes, but also through 
direct and indirect interactions with complexes that contain important oncoproteins and tumour 
suppressors (Keith et al, 2012). 
 
HIFs in breast cancer 
As mentioned earlier, hypoxic areas can often be observed in breast cancer samples. Besides the 
tumours with an obvious hypoxic and necrotic manifestation, some type of hypoxic response is 
Figure 6 HIF regulation of genes encoding for proteins involved in crucial aspects of cancer progression. 
(Trends in Pharmacological Sciences, 2012) 
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commonly detected in a large fraction of invasive breast cancer samples. By using HIF-1α as a 
marker for hypoxia, approximately 25-40% of all invasive breast cancer samples are hypoxic (Vleugel 
et al, 2005). In general, HIF-1α positivity is linked to large tumour size, high grade, high proliferation, 
lack of lymph-node metastases and hormone-receptor negativity. It should be noted that it is not 
obligate with necrotic areas in large tumours and there could accordingly be marked HIF-1α positivity 
even in small tumours despite the link between hypoxia and tumour size. The large variation of HIF-
1α positive tumours in the different studies probably depends on the cutoff used for scoring positive 
tumours (Lundgren et al, 2007). Although hypoxia is the major factor regulating HIF-1α, it can also be 
triggered by growth factor stimulation and/or genetic alterations in oncogenes and suppressor genes, 
and a fraction of the breast cancer samples expressing HIF-1α are probably not hypoxic. It has been 
shown that out of 44% HIF-1α positive samples, 13.5% expressed HIF-1α in a perinecrotic fashion, 
whereas 30.5% had a more diffuse HIF-1α staining indicative of an alternative activation of the factor 
(Vleugel et al, 2005). The HIF-1α downstream target CAIX was further coexpressed with HIF-1α only 
in the perinecrotic and scattered HIF-1α expressing tumours. The lack of association between HIF-1α 
and downstream targets in certain high expressing breast cancers also supports differing cellular 
response depending on the mechanism underlying HIF-1α expression and on the context in which the 
hypoxia marker appears. On the other hand, when analyzing CAIX in large breast cancer cohorts, 
there was a strong link to HIF-1α expression as well as to large tumour size, grade, proliferation, and 
hormone receptor negativity (Brennan et al, 2006). It has been shown also that the presence of 
hypoxia in a primary breast cancer corresponds to hypoxia markers in lymph-node metastasis, 
strengthening the hypothesis that besides effects from the microenvironment, the intrinsic angiogenic 
hypoxia potential of a tumour is maintained during tumour progression. An association between HIF-
1α and MET overexpression has also been demonstrated in breast cancer, suggesting that HIF-1α 
promotes aggressive breast cancer disease by induction of MET. Other reports have shown a strong 
correlation between HIF-1α and VEGF-C as well as lymphatic microvessel density in human breast 
cancer. This suggests that HIF-1α could affect tumour-associated lymphangiogenesis, which is a 
critical parameter in the spreading of breast cancer cells. Hypoxia can further stimulate breast 
carcinoma cell invasion through general effects on a multitude of invasion/migration-associated gene 
products, exemplified by matrix metalloproteinase MT1-MMP and MMP2 activation as well as 
stabilisation of microtubules, and promoting the trafficking of integrins (Lundgren et al, 2007). 
 
Relationship between HIF-1α and ERα 
The presence of ERα is an important marker for endocrine treatment response in breast cancer 
and constitutes a key molecule in targeted treatment of the disease. ERα is also implied in the 
development and progression of breast cancer and is altogether intimately linked to several important 
breast cancer features. Interestingly, hypoxia has been shown to decrease ERα protein content in 
breast cancer cell lines, and several groups have reported specific downregulation of ERα and PR 
under various hypoxic conditions (1% and 0.1% oxygen). The mechanisms of ERα downregulation 
during hypoxia are probably dependent on both increased proteasomal degradation and decreased 
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transcriptional activation (Cho et al, 2005). The transcriptional inhibition of ERα during hypoxia seems 
to be mediated by the ERK pathway, since downregulation could be inhibited by MEK and ERK 
inhibitors (Lundgren et al, 2007). 
 
Hypoxia and HIF-1α as prognostic markers in breast cancer 
In general there is a rather strong link between the expression of hypoxia markers in breast cancer 
and aggressive disease, and consequently impaired patient prognosis. Several large studies have 
observed that HIF-1α protein expression is linked to a worse prognosis, though with some variations 
in the specific subgroup of breast cancer where HIF-1α was an independent prognostic marker 
(Lundgren et al, 2007). It should be noted that the majority of the studies analyzing HIF-1α in breast 
cancer in relation to prognosis have been conducted using immunohistochemistry, thus the evaluation 
of HIF-1α is in fact troublesome: it is therefore important to include tissues with defined hypoxic areas 
when analyzing HIF-1α in clinical materials, increasing the validity of the results obtained. The use of 
CAIX as well as HIF-1α antibodies can serve as positive controls in tissue-based analyses. Studies 
on HIF-1α in an unselected material of 745 invasive breast cancer samples observed that high HIF-1α 
expression significantly correlated to poor overall survival and high metastatic risk (Dales et al, 2005). 
Multivariate statistical analysis further showed that the prognostic value of HIF-1α was independent of 
other current prognostic markers. The prognostic features of HIF-1α were also significant for the 
subgroup of lymph node-negative patients. Other studies have shown that HIF-1α is linked to poor 
survival also in lymph node-positive disease: the true prognostic information of HIF-1α has been 
assessed also by analyzing a control group of patients who did not receive any adjuvant treatment 
after surgery. This ensures that the specific link between HIF-1α and tumour aggressiveness was 
studied without interference of potential associations between HIF-1α and treatment effects. Also, in 
this study there was a correlation between HIF-1α and prognosis, but specifically in the subgroups of 
lymph node-positive disease or in grade 1-2 tumours. Rather striking and contrasting results between 
diffuse and scattered HIF-1α staining have been observed: tumours with scattered staining, indicative 
of hypoxia-driven HIF-1α expression, were in general more aggressive compared to tumours with 
diffuse staining (Vleugel et al, 2005). Larger studies of whole sections of breast cancer samples are 
probably needed in order to fully clarify the different roles for scattered and diffuse HIF-1α in breast 
cancer. Another problem is the use of slightly different end-points between studies: this should be 
considered when comparing results from larger studies, and a future aim would be to use the same 
criteria for tumour aggressiveness.  
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HIFs as therapeutic targets 
 
HIF inhibitors 
The discovery of HIF-1 in the early ‘90s provided a molecular target associated with intratumor 
hypoxia that could be used for the development of novel cancer therapeutics. Despite the intrinsic 
challenges associated with the discovery and development of pharmacological inhibitors of 
transcription factors, more so in the absence of structural information that could facilitate drug design, 
many academic groups and pharmaceutical companies have attempted to identify HIF-1 inhibitors. 
For the most part, efforts have been based on high throughput screening assays aimed at 
identification of inhibitors of HIF-1 expression and/or transcriptional activity (Melillo, 2007). After 
several years of attempts and many HIF-1 inhibitors described in the literature, there are several 
conclusions that can be drawn and considerations that can be made. The common denominator of 
most, if not all, HIF-1 inhibitors described so far is the lack of specificity, which indicates that they 
inhibit multiple targets and that HIF-1 inhibition cannot be easily separated from other activities 
exerted by these agents. This feature of HIF-1 inhibitors may have hampered efforts in validating HIF-
1 as a target using pharmacological approaches; nevertheless HIF-1 inhibitors may still have potential 
applications for therapeutic purposes (Semenza, 2007). A challenge that HIF-1 inhibitors must face to 
be “validated” as potential therapeutic tools is the evidence that they inhibit the intended target in 
relevant in vivo models and more so in patients with cancer. Indeed, inhibition of HIF-1 expression 
and/or activity in cell culture is hardly predictive of their potential usefulness as therapeutic agents. 
However, validation of HIF-1 inhibitors in preclinical models is hindered by the lack of established 
biomarkers that can be consistently associated with HIF-1 inhibition in tumor tissue. Different 
endpoints have been measured to assess HIF-1 inhibition in published studies, including but not 
limited to IHC and/or western blot analysis of HIF-1α protein expression, mRNA expression of HIF-1 
target genes and more indirect, surrogate endpoints of HIF inhibition, e.g., angiogenesis and micro-
vessels density. Despite these challenges, efforts to validate HIF-1 inhibitors in appropriate in vivo 
models are essential to move these potential therapeutic agents to the clinical setting. This is even 
more relevant in light of the potential lack of antitumor activity of HIF-1 inhibitors used as single 
agents. In fact, antitumor activity cannot be and should not be used as a surrogate endpoint for the 
validation of HIF-1 inhibition, as it is conceptually difficult to envision how HIF-1 inhibition alone may 
be associated with dramatic tumor shrinkage in xenograft models in which HIF-1 expression in tumor 
tissue is heterogeneous and focal in nature. Even more challenging is, of course, to generate 
evidence of HIF-1 inhibition in the clinical setting (Onnis et al, 2009). However, this is a necessary 
path for the validation of HIF-1 inhibitors in early clinical trials and for the development of this strategy 
in combination approaches, which appears to be a more promising avenue for the application of HIF-
1 inhibitors. 
It should be noted that the reports published so far relate for the most part to HIF-1α, although 
many of these agents may also affect HIF-2α. Both subunits are potential targets of small molecule 
inhibitors and no clear selectivity, capable of discriminating between inhibition of HIF-1α or HIF-2α, 
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has been so far convincingly demonstrated (Onnis et al, 2009). According to their putative mechanism 
of action and although this is an obviously simplified classification, HIF inhibitors could be tentatively 
divided in agents that modulate: 
HIF-1α mRNA expression 
Aminoflavone, the active component of the prodrug AFP-464, which is currently in Phase I cancer 
trials, partially inhibits HIF-1α mRNA expression but almost completely blocks HIF-1α protein 
expression, suggesting that it decreases both the stability and translation of HIF-1a mRNA (Terzuoli 
et al, 2010).  
HIF-1α synthesis 
Drugs that inhibit the translation of HIF-1α mRNA into protein include: mTOR inhibitors, such as 
rapamycin, temsirolimus (CCI-779), and everolimus (RAD-001); cardiac glycosides, such as digoxin, 
which have been used for decades to treat heart disease; microtubule targeting agents, such as 2-
methoxyestradiol and taxotere; topoisomerase I and II inhibitors, such as topotecan and NSC-
644221, respectively; and synthetic oligonucleotides, such as EZN-2968, a locked nucleic acid 
oligonucleotide that binds to HIF-1α mRNA and blocks its translation, which is currently in Phase I 
clinical trials. This category also includes anticancer drugs that inhibit receptor tyrosine kinases, such 
as BCR/ABL, EGFR, and HER2, and thereby indirectly inhibit mTOR activity. YC-1 [3-(50-hydroxy 
methyl-20-furyl)-1-benzylindazole] may also block HIF-1α protein expression by inhibiting mTOR. PX-
478 (S-2- amino-3-[40-N,N,-bis(2-chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride) 
inhibits HIF-1α translation by an undetermined mechanism and sensitizes tumor xenografts to 
radiation therapy: indeed, three different mechanisms have been proposed. Many of the drugs in this 
category show preferential activity against HIF-1α, seemingly with less effect on HIF-2α (Semenza, 
2012). 
Topotecan 
One of the first agents described to affect HIF-1α protein translation was topotecan (TPT), an FDA 
approved chemotherapeutic agent currently used as second line therapy for patients with small cell 
lung cancer or ovarian cancer. Topotecan was originally identified at the National Cancer Institute in a 
high throughput screen using a cell-based assay of HIF-1 transcriptional activity (Rapisarda et al, 
2002). Topotecan is a camptothecin analog that poisons topoisomerase I by inducing the formation of 
stable Top1-DNA cleavage complexes, which in the presence of DNA replication generate double 
strand DNA breaks and cytotoxicity. Interestingly, topotecan inhibited HIF-1α translation by a Top1-
dependent but DNA damage-independent mechanism, suggesting that cytotoxicity and HIF-1α 
inhibition could be mechanistically distinguished. Indeed, daily low dose administration of topotecan in 
a mouse xenograft glioma model caused inhibition of HIF-1α protein expression, angiogenesis and 
tumor growth (Rapisarda et al, 2004). More recently, it has been shown that administration of daily 
topotecan in combination with the anti-VEGF antibody bevacizumab exerts synergistic antitumor 
activity in xenograft models, providing a rationale for clinical development of this combination strategy 
(Rapisarda et al, 2009). The ability to inhibit HIF-1α protein translation appears to be shared by all the 
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agents that inhibit Top1. Because topotecan has a short half-life when administered to patients, it is 
conceivable that other topoisomerase 1 inhibitors with more favorable pharmacokinetics may be more 
suitable for chronic suppression of the HIF-1 pathway. In this regard an interesting agent is EZN-
2208, a PEGylated form of SN38, the active metabolite of CPT-11 (Irinotecan), characterized by 
improved pharmacokinetics and by remarkable antitumor activity in preclinical models of solid tumors 
and lymphomas, including CPT-11-resistant tumors (Onnis et al, 2009). One of the criticisms of 
proposed trials involving compounds such as topotecan is that these are drugs that have already 
failed to show significant anticancer effects in clinical trials. However, the key distinction that must be 
made between prior and current trials is that these drugs have previously been administered 
episodically at maximum tolerated dose as cytotoxic agents, whereas their current utilization as HIF 
inhibitors involves frequent administration at lower doses in an effort to maintain continuous inhibition 
of HIF activity. In a recently completed pilot pharmacodynamics study involving 16 patients with 
advanced cancer and biopsy-proven HIF-1α overexpression, the administration of topotecan orally at 
1.6 mg/m2/day _ 5 days/week _ 2 weeks/28-day cycle resulted in decreased tumor blood flow in 
seven of 10 patients and loss of HIF-1α expression on repeat biopsy in four of seven patients, 
suggesting that the drug hit the target in vivo (Kummar et al, 2011). During the trial, the topotecan 
dose was reduced to 1.2 mg/m2/day due to myelosuppression, although it is not known whether this 
side effect reflected cytotoxicity due to DNA damage or was a direct consequence of HIF inhibition, 
independent of DNA damage. In either case, it remains to be determined whether two-week-on/two-
week-off inhibition of HIF will be an effective anticancer strategy and whether there is a therapeutic 
window that will allow chronic use of topotecan as a HIF inhibitor (Semenza, 2012). 
HIF-1α stability 
Drugs that induce the degradation of HIF-1α protein include HSP90 inhibitors, such as 17- 
allylamino-17-demethoxygeldanamycin, which cause VHL-independent, RACK1-dependent 
ubiquitylation and proteasomal degradation of HIF-1α; antioxidants, such as ascorbate (vitamin C) 
and N-acetyl cysteine, which block tumor xenograft growth by promoting HIF-1α degradation through 
the PHD2–VHL–proteasome pathway; the thioredoxin inhibitor PX-12, which induces HIF-1α 
degradation that may be due in part to increased expression of SSAT1, a protein that binds to HIF-1α 
and promotes RACK1-dependent ubiquitylation and proteasomal degradation; Class II histone 
deacetylase (HDAC) inhibitors, such as LAQ824, which stimulate ubiquitylation of HIF-1α by an 
undetermined mechanism; Grich oligonucleotides, which represent another nucleic acid-based 
strategy but in this case the target is HIF-1α protein rather than mRNA; berberine, a natural product 
that induces HIF-1α degradation and has antiangiogenic effects both in cancer cells and in endothelial 
cells; Se-methylselenocysteine, which induces HIF-1α degradation and sensitizes hypoxic cancer 
cells to the effects of the chemotherapy drug irinotecan; and YC-1, a guanylate cyclase activator that 
induces HIF-1α degradation by an unknown mechanism. YC-1 and deguelin, an HSP90 inhibitor, 
sensitize tumor xenografts to radiation therapy. Most of the drugs in this category show similar activity 
against HIF-1α and HIF-2α (Semenza et al, 2012). 
HIF heterodimerization 
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Acriflavine, a drug that was used clinically as an antibacterial agent before the discovery of 
penicillin, binds directly to the PAS-B subdomain of HIF-1α and HIF-2α and blocks their interaction 
with HIF-1β, thereby blocking HIF-dependent gene transcription, leading to impaired tumor growth 
and vascularization (Lee et al, 2009).  
HIF DNA-binding activity 
Anthracyclines, such as doxorubicin (Adriamycin) and daunorubicin, bind to DNA and block the 
binding of HIF-1 and HIF-2 in cultured cells and block HIF-1-dependent expression of angiogenic 
growth factors, leading to impaired tumor growth and vascularization. Echinomycin, another DNA 
intercalating agent that inhibits HIF-1 activity, has been shown to block lymphoma and acute 
myelogenous leukemia growth by eradicating cancer stem cells (Semenza, 2012). 
HIF-1α-dependent transactivation 
The proteasome inhibitor bortezomib, which is approved by the FDA for treatment of mantle cell 
lymphoma and multiple myeloma, inhibits HIF-1 transcriptional activity by targeting the C-terminal 
transactivation domain of HIF-1a that interacts with the coactivator p300, although drug treatment 
does not disrupt the interaction. In prostate cancer cells, bortezomib blocks HIF-1α protein expression 
by inhibiting phosphatidylinositol-3-kinase/AKT/mTOR and ERK signaling (Molineaux, 2012). 
Chetomin, a dithiodiketopiperazine metabolite of the fungus Chaetomium species, previously 
characterized as having antimicrobial activity, was also found to be able to block the interaction of 
HIF-1α and HIF-2α with p300 by disrupting the HIF-interacting domain of p300 (Kung et al, 2004). 
Nanobodies 
An interesting new class of inhibitors is composed by a new kind of antibodies, llama heavy-chain 
antibodies, which are also referred to VHH or nanobodies, are stable at high temperatures and can 
bind antigen in high salt concentrations. The characteristic of small molecular can make nanobidies 
go through the membrane structure, cripple intracellular viral replication, block enzymatic activity, 
pass the blood–brain barrier and can be used for various immunological applications like classical 
antibodies (Hu et al, 2012). Nanobodies against HIF-1 protein are screened based on their activity on 
essential domain of HIF-1 pathways, e.g. the ODD domain and PAS domain, that are necessary for 
synthesis, translation, transcription and oxygen-dependent regulation. Nanobodies recognize the 
domain and specially bind with it, in order to block the synthesis, speed the degradation of HIF-1 
protein or affect transcriptional activities of targeted genes. Many researchers have focused their 
attention on the field. A set of VHH against both human and mouse HIF-1α has been identified (Groot 
et al, 2006). These VHH were mapped to epitopes within the oxygen-dependent degradation domain 
(ODDD), and when combined they can also prevent HIF-1α/β dimerization. These anti-HIF-1α VHH 
were engineered into higher affinity bivalent VHH (Groot et al, 2008). Others nanobodies specific to 
HIF-1α of pancreatic cancer were isolated from a naive camelidae VHH library. Anti-HIF-1α VHH 
nanobodies (AHPC) are able to recognize HIF-1α within the Per-Arnt-Sim-B (PAS-B) domain 
responsible for the dimerization of HIF-1α and HIF-1β and combine with it specifically in order to 
prevent the dimerization, reduces the level of HIF-1 and blocks tumor proliferation and metastasis (To 
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et al, 2006).  Ablynx (Nanobody®, Ghent, Belgium) is the first company that focused on the discovery 
and development of nanobodies, for a range of serious human diseases including inflammation, 
haematology, oncology and pulmonary disease. 
 
Cross talk and combination therapy 
In addition to extensive data indicating that HIFs mediate resistance to radiation therapy and 
chemotherapy (Moeller et al, 2007; Rohwer and Cramer, 2011), there is mounting evidence that HIF-
1 activity may contribute to the development of resistance to novel targeted therapies, such as 
imatinib treatment of chronic myeloid leukemia. HIF-1 appears to mediate resistance to imatinib 
through metabolic reprogramming, by activating expression of transketolase and thereby increasing 
glucose flux through the non-oxidative arm of the pentose phosphate pathway (Zhao, 2010). The 
switch from oxidative to reductive metabolism that is mediated by HIF-1 has the effect of reducing 
cellular ROS levels, and this may increase resistance to cytotoxic chemotherapy (Santamaria et al, 
2006). In the case of VEGF receptor inhibitors, data from several mouse models indicate that 
treatment, either with the anti-VEGFR2 antibody DC-101 or the small molecule tyrosine kinase 
inhibitor sunitinib, reduced primary tumor growth and vascularization but increased metastasis, 
probably because impaired angiogenesis led to increased intratumoral hypoxia and increased HIF 
activity (Loges et al, 2009). The failure of the anti-VEGF antibody bevacizumab to affect breast 
cancer progression, which led to revocation of approval by the FDA, may involve HIF-1-dependent 
expression of other angiogenic growth factors (Tanne, 2011). By contrast, HIF inhibitors dramatically 
decreased the spontaneous metastasis of human breast cancer cells to the lungs in mouse orthotopic 
transplantation models by affecting multiple steps in the metastatic process [26,27]. Taken together, 
these results suggest that combination treatment with HIF inhibitors may improve the efficacy of 
antiangiogenic agents, a conclusion that is supported by data from mouse models (Wong et al, 2011; 
Zhang et al, 2011). Traditional chemotherapy may also be more effective when administered with a 
HIF inhibitor, and many different molecular mechanisms underlie this effect in a cell-type and 
chemotherapy-specific manner. First, HIFs have been shown to regulate the expression of genes 
encoding ATP-binding cassette multidrug transporters, including MDR1 (ABCB1) and BCRP 
(ABCG2), which efflux chemotherapy drugs from cancer cells. Second, HIF-1 inhibits chemotherapy-
induced cancer cell senescence. Third, HIF-1 inhibits expression of proapoptotic mitochondrial 
proteins (BAX, BID) and caspases (CASP3, CASP8, CASP10) and induces expression of 
antiapoptotic proteins (BCL2, BIRC5). Fourth, HIF-1 prevents chemotherapy-induced DNA damage 
by inhibiting the expression of topoisomerase IIa protein or the DNA-dependent protein kinase 
complex. Last but not least, HIF-1-dependent metabolic reprogramming may decrease ROS levels 
and thereby inhibit chemotherapy-induced cell death (Semenza, 2012). 
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Flavonoids and cancer 
 
The flavonoids are polyphenolic compounds found as integral components of the human diet. 
They are universally present as constituents of flowering plants, particularly of food plants. The 
flavonoids are phenyl substituted chromones (benzopyran derivatives) consisting of a 15-carbon 
basic skeleton (C6-C3-C6), composed of a chroman (C6-C3) nucleus (the benzo ring A and the 
heterocyclic ring C), also shared by the tocopherols, with a phenyl (the aromatic ring B) substitution 
usually at the 2-position. Different substitutions can typically occur in the rings, A and B 
(Kanadaswami et al, 2005). Several plants and spices containing flavonoid derivatives have found 
application as disease preventive and therapeutic agents in traditional medicine in Asia for thousands 
of years: they display a wide range of pharmacologic properties, including anti-inflammatory, 
anticarcinogenic, and anticancer effects (Ross and Casum, 2002). The much lower risk of colon, 
prostate and breast cancers in Asians raises the question of whether flavonoid components mediate 
the protective effects of diets that contain them at high levels by acting as natural chemopreventive 
and anticancer agents. An impressive body of information exists on the antitumor action of plant 
flavonoids. In vitro research has concentrated on the direct and indirect actions of flavonoids on tumor 
cells, and has found a variety of anticancer effects, such as cell growth and kinase activity inhibition, 
apoptosis induction, suppression of the secretion of matrix metalloproteinases and of tumor invasive 
behavior. Furthermore, some studies have reported the impairment of in vivo angiogenesis by dietary 
flavonoids. Experimental animal studies indicate that certain dietary flavonoids possess antitumor 
activity. The hydroxylation pattern of the B ring of the flavones and flavonols, such as luteolin and 
quercetin, seems to critically influence their activities, especially the inhibition of protein kinase activity 
and antiproliferation. The different mechanisms underlying the potential anticancer action of plant 
flavonoids await further elucidation. Certain dietary flavonols and flavones targeting cell surface signal 
transduction enzymes, such as protein tyrosine and focal adhesion kinases, and angiogenesis-
inducing processes appear to be promising candidates as anticancer agents. Further in vivo studies 
of these bioactive constituents is deemed necessary in order to develop flavonoid-based anticancer 
strategies. In view of the increasing interest in the association between dietary flavonoids and cancer 
initiation and progression, this important field is likely to witness expanded effort and to attract and 
stimulate further in depth investigations (Kanadaswami et al, 2005). 
 
Luteolin 
Luteolin, belonging to the flavone subclass of flavonoids, usually occurs in its glycosylated form in 
celery, green pepper, perilla leaf, and camomile tea, etc., and as an aglycone in perilla seeds. 
Recently, a potent anticancer effect of luteolin has been shown in several experiments in vitro; 
however, the bioavailability of luteolin has not yet been fully tested. Only one study on mouse skin 
cancer development has shown an anticancer effect of the luteolin-containing perilla leaf extract in 
vivo (Ueda et al, 2003), suggesting a potential anticancer effect of any form of luteolin in vivo. 
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Apoptosis is supposed to be the main mechanism of the anticancer effects of luteolin, although other 
mechanisms, such as cell cycle inhibition by inactivating cyclin-dependent kinase 2 (CDK2), and 
antiangiogenesis by inhibiting vascular endothelial growth factor (VEGF)–induced phosphatidylinositol 
3V-kinase activity, have been shown (Casagrande and Darbon, 2001; Hasebe et al, 2003). The 
suggested mechanisms for the luteolin-induced apoptosis include activation of wild-type p53, 
inactivation of receptor tyrosine kinase, inactivation of topoisomerases, sensitization to tumor necrosis 
factor-α (TNF-α), imbalance in Bcl-2 family of proteins and inhibition of fatty acid synthase activity 
(Kanadaswami et al, 2005). 
As already stated, Luteolin exerts it activity as antiangiogenic agent by inhibiting VEGF, a HIF-1 
target gene: surprisingly, it has been demonstrated that HIF-1α levels are in fact increased rather than 
decreased after treatment with luteolin (Hasebe et al, 2003). The two results, in apparent contrast, 
can be explained by the fact that while HIF-1α levels are increased, HIF-1 nuclear activity is in fact 
inhibited, as we could see also in our laboratory in HCT116, a colon cancer cell line (data not 
published). Another explanation indicate flavonoids to impair VEGF transcription by an alternative 
mechanism that did not depend on nuclear HIF levels, for example that flavonoids suppressed 
hypoxia-induced STAT3 tyrosine phosphorylation and that this activity correlated with their potency as 
VEGF inhibitors, suggesting that inhibition of STAT3 function may play a role in this process (Ansò et 
al, 2010). Another study on gastric cancer cells, on the other hand, showed how luteolin significantly 
enhanced the radioresponse of human tumors transplanted into nude mice: this radiosensitizer effect 
was accompanied by a a decreased expression levels of both VEGF and HIF-1α (Zhang et al, 2009). 
The mechanism under luteolin control of HIF-1α remains nowadays unclear. 
 
 
Cellular metabolism 
 
Metabolism is broadly defined as the sum of biochemical processes in living organisms that either 
produce or consume energy. It is a dauntingly large sum: more than 8,700 reactions and 16,000 
metabolites are now annotated in the Kyoto Encyclopedia of Genes and Genomes. Core metabolism 
can be simplified to those pathways involving abundant nutrients like carbohydrates, fatty acids, and 
amino acids, essential for energy homeostasis and macromolecular synthesis in humans. Pathways 
of core metabolism can then be separated conveniently into three classes: those that synthesize 
simple molecules or polymerize them into more complex macromolecules (anabolism); those that 
degrade molecules to release energy (catabolism); and those that help to eliminate the toxic waste 
produced by the other classes (waste disposal). These pathways are profoundly important. Stated 
bluntly, they are the sole source of energy that allows life to resist the urge to degrade into entropy. 
Defining these pathways and understanding their physiological roles have been among the most 
fruitful pursuits in biological research (De Berardinis and Thompson, 2012). The ‘‘golden age of 
biochemistry’’ (roughly the 1920s to 1960s) defined most of the metabolic network responsible for 
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nutrient utilization and energy production in humans and other organisms. These included core 
activities like glycolysis (Embden, Meyerhof, and Parnas), respiration (Warburg), the tricarboxylic acid 
(TCA) and urea cycles (Krebs), glycogen catabolism (Cori and Cori), oxidative phosphorylation 
(Mitchell), and the supremacy of ATP in energy transfer reactions (Lipmann). Biochemistry and the 
analysis of metabolic pathways dominated basic and medically oriented research during these 
decades, with some 15 Nobel Prizes in either Physiology/Medicine or Chemistry awarded for work 
related to energy balance or core metabolic pathways. By the end of this period, it was possible to 
understand at the level of enzymatic control such complex matters as the temporal and organ-specific 
regulation of fuel preferences. Research in metabolism has been propelled by the realization that 
metabolic perturbations accompany common human diseases.  
 
Ongoing exploration of cell biology and disease has recently stimulated a renaissance of interest 
in small-molecule metabolism (McKnight, 2010). The last 10 years have revealed a host of functions 
for metabolites and metabolic pathways that could not have been predicted from a conventional 
understanding of biochemistry. As a result, it is no longer possible to view metabolism merely as a 
self-regulating network operating independently of other biological systems. Rather, metabolism 
impacts or is impacted by virtually every other cellular process. Recent work has identified numerous 
regulatory mechanisms that either link cell signaling to the orchestration of metabolic pathways or 
enable cells to sense fuel availability and transmit the information through signaling networks. The 
integration of biochemical pathways in the cellular response to growth factors is a good example. In 
most mammalian cells, growth occurs only when promoted by extracellular ligands. These growth 
factors stimulate signal transduction pathways such as the PI3K/Akt/mTOR pathway. Activation of this 
and other pathways alter the phosphorylation states of numerous targets, which together coordinate 
the cellular activities that culminate in cell division. But a successful transition from a resting state to 
growth can only occur if metabolism is reprogrammed to meet the rising demands of proliferation. 
Growth factor-induced signaling coordinates these functions, including maintaining a bioenergetic 
state permissive for growth (Lum et al, 2005). In particular, the PI3K/Akt/mTOR pathway stimulates 
both a rapid increase in essential nutrient uptake and the proper allocation of these nutrients into 
catabolic and anabolic pathways to produce energy and macromolecules, respectively (Gibbons et al, 
Figure 7 An simplified overview  of core metabolism, focusing on the use of major nutrients 
(glucose, amino acids, and fatty acids) to produce or store energy and to grow. (Cell, 2012) 
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2009). Disruption of any of these metabolic effects renders the growth factor ineffective. Dynamic 
mechanisms also sense cellular energy status and regulate the balance between anabolism and 
catabolism. Whereas the PI3K/Akt/mTOR pathway promotes anabolism and suppresses catabolism, 
AMP-activated protein kinase (AMPK) does the reverse. This serine-threonine kinase is a ‘‘fuel 
sensor’’ activated during compromised bioenergetic states such as acute nutrient deprivation and 
hypoxia (Hardie, 2011). By phosphorylating a number of key targets, AMPK inactivates energy-
consuming, growth-promoting pathways like protein and lipid synthesis and activates catabolism of 
fatty acids and other fuels. This enables the cell to reset the balance between energy supply and 
demand. Interestingly, AMPK also regulates a p53- dependent cell-cycle checkpoint activated by 
glucose deprivation in cultured cells, thereby limiting growth in energetically unfavorable states (Jones 
et al, 2005). 
 
Metabolism and cancer 
Cancer is a prime example of a common human disease with genetically defined, pathological 
metabolic perturbations. Altered cellular metabolism is a hallmark of cancer, contributing to malignant 
transformation and to the initiation, growth, and maintenance of tumors (Hanahan and Weinberg, 
2011). Although the recent renaissance in metabolism research, in particular work in basic regulation 
of core metabolic pathways, owes much to cancer cell biology (Bensaad et al, 2006; Gao et al, 2009; 
Vander Heiden et al, 2010), the principle of perturbed metabolism in tumors is very old, dating almost 
to the era of early work in chemical carcinogens and viruses as cancer-promoting agents. Otto 
Warburg performed the first rigorous work in cancer metabolism in the early 1920s: in 1924 he found 
that carcinoma slices from rats and humans consumed much more glucose and secreted much more 
lactate than normal tissue, even when presented with enough oxygen to metabolize glucose 
completely to CO2 (De Berardinis and Thompson, 2012). As already stated, in most mammalian cells 
glycolysis is inhibited by the presence of oxygen, which allows mitochondria to oxidize pyruvate to 
CO2 and H2O. This inhibition is termed the ‘Pasteur effect’, after Louis Pasteur, who first 
demonstrated that glucose flux was reduced by the presence of oxygen (Racker, 1974). This 
metabolic versatility of mammalian cells is essential for maintenance of energy production throughout 
a range of oxygen concentrations. The shift towards glycolisys was interpreted as a fundamental 
change in the way glucose metabolism is regulated in cancer cells and was termed the ‘‘Warburg 
effect’’ (Warburg, 1956): still it is a critical feature of solid tumors and the basis of diagnostic cancer 
imaging techniques, such as fluorodeoxyglucose positron emission tomography (FDG-PET) 
(Shanmugam et at, 2009). After Warburg, generations of cancer biologists and biochemists refined 
his hypothesis and attempted to provide mechanistic explanations for it. Basically, these studies have 
confirmed the central observation that many tumors can outcompete surrounding tissue for glucose, 
but the molecular basis of the Warburg effect and rationale behind cancer cells undergoing aerobic 
glycolysis have not been completely elucidated (Mucaj et al, 2012). 
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In contrast to Warburg’s original hypothesis, damaged mitochondria are not at the root of the 
aerobic glycolysis exhibited by most tumor cells. Most tumor mitochondria are not defective in their 
ability to carry out oxidative phosphorylation. Instead, in proliferating cells, mitochondrial metabolism 
is reprogrammed to meet the challenges of macromolecular synthesis. This possibility was never 
considered by Warburg and his contemporaries. Advances in cancer metabolism research over the 
last decade have enhanced our understanding of how aerobic glycolysis and other metabolic 
alterations observed in cancer cells support the anabolic requirements associated with cell growth 
and proliferation. It has become clear that anabolic metabolism is under complex regulatory control 
directed by growth-factor signal transduction in nontransformed cells (Ward and Thompson, 2012). 
Yet despite these advances, the repeated refrain from traditional biochemists is that altered 
metabolism is merely an indirect phenomenon in cancer, a secondary effect that pales in importance 
to the activation of primary proliferation and survival signals (Hanahan and Weinberg, 2011). One 
common hypothesis to unify these metabolic pathways is that aggressive tumor growth requires a 
restructuring of metabolism to meet the bioenergetic and biosynthetic demands of rapid cell growth 
and to protect the cells against stresses induced by a harsh microenvironment (Semenza, 2010). 
Metabolic flux studies in cancer cells have validated this model, emphasizing the integration of these 
three core pathways (DeBerardinis et al. 2007). Thus, cancer is a paradigm for how perturbed 
metabolism at the cellular level contributes to disease. What drives metabolic reprogramming in 
tumour cells is, as in IEMs (Inborn Errors of Metabolism diseases), the fact that metabolic 
idiosyncrasies of are genetically defined, resulting from the same mutations that promote malignancy. 
However, in IEMs, germline mutations elicit wholesale changes in metabolism that tend to reduce 
overall fitness. Cancer mutations are, in general, acquired somatically and are associated with 
metabolic effects that appear to increase fitness and growth at the cellular level. Two different classes 
of mutations can reprogram metabolism in tumours. First, many human oncogenes and tumor 
suppressors regulate glucose metabolism: tumour-promoting mutations in these genes tend to 
converge on a metabolic phenotype of enhanced glycolysis and energy production, thereby 
contributing to self sufficiency of growth and evasion of growth-suppressive signals. Second, 
Figure 8 Pasteur and Warburg effects in non-invasive (MCF-7) and 
metastatic (MDA-MB-231) breast cancer cell lines. (Nature, 2004) 
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metabolic reprogramming can occur as the direct effect of enzyme mutations: this was first observed 
in a subset of patients with IEMs who displayed an increased risk of cancer (DeBerardinis and 
Thompson, 2012). Recently, it has become apparent that cancer is also associated with metabolic 
mutations confined to the tumor. In these diseases, the metabolic enzymes behave genetically as 
oncogenes or tumour suppressors (Frezza et al, 2011; Thompson, 2009). These forms of cancer are 
a unique opportunity to determine the cell-intrinsic consequences of metabolic perturbations. The first 
such examples were mutations in TCAcycle enzymes in familial cancer syndromes. Mutations in 
succinate dehydrogenase (SDH), an oxidoreductase complex that functions in both the ETC and TCA 
cycle, were identified in dominantly inherited familial paraganglioma. Mutations in the TCA-cycle 
enzyme fumarate hydratase (FH) have been identified in familial syndromes characterized by 
susceptibility to renal cell cancer and leiomyomatosis (smooth muscle tumors of the uterus and skin). 
In families with SDH- or FH-deficient tumors, affected individuals inherit one mutation, and their 
tumors display loss of the wild-type allele. Thus, both SDH and FH are tumor suppressors. Other 
enzyme mutations may function as oncogenes. Genomic sequencing of gliomas and acute 
myelogenous leukemia identified mutations in two isoforms of NADP+-dependent isocitrate 
dehydrogenase (IDH1 and IDH2). These enzymes normally oxidize isocitrate to α-ketoglutarate, with 
NADP+ reduced to NADPH in the process. IDH1 and IDH2 mutations in cancer are somatically 
acquired, present on only one allele, and confined to the enzyme’s active site. Thus, unlike FH and 
SDH, it was difficult to make a case for IDH1 and IDH2 as tumor suppressors. The surprising 
involvement of IDH1, IDH2, SDH, and FH in cancer has prompted efforts to identify other metabolic 
genes whose alteration at the genomic level causes or facilitates tumorigenesis. This work recently 
uncovered phosphoglycerate dehydrogenase (PHGDH), an enzyme required to produce the amino 
acids serine and glycine from glucose. Serine and glycine are crucial intermediates in a variety of 
biosynthetic processes, including the production of nucleotides, proteins, glutathione, creatine, and 
methylated DNA. High levels of PHGDH protein expression relative to normal tissue correlate with 
disease severity in breast cancer patients (DeBerardinis and Thompson, 2012). 
 
HIFs and cancer metabolism 
Cancer cells are characterized by rapid proliferation and require adaptive metabolic responses to 
allow continued biosynthesis and cell growth in the setting of decreased oxygen (O2) and nutrient 
availability. The hypoxia-inducible factors (HIFs) are a common link between adaptation to low O2, 
changes in cancer metabolism, and malignant progression. The HIF-α subunits differentially regulate 
metabolic enzymes and other key factors involved in glycolysis, changes in redox status, and 
oxidative phosphorylation. Importantly, metabolic changes can, in turn, regulate HIF activity. Finally, 
changes in metabolism under hypoxia lead to important crosstalk between cancer cells and the 
stromal compartment of the microenvironment (Mucaj et al, 2012). The placement of HIF-1 both 
upstream and downstream of cancer metabolism results in a feed-forward mechanism that may play 
a major role in the development of the invasive, metastatic, and lethal cancer phenotype (Semenza, 
2010.2). 
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Glycolysis allows for continued ATP production without the need for O2-dependent oxidative 
phosphorylation, and is thus an important pathway under hypoxic conditions. Metabolic intermediates 
from the glycolytic pathway can also be funneled into macromolecular biosynthesis for continued 
growth. HIF-1α activates transcription of genes encoding glucose transporters and other glycolytic 
enzymes such as LDHA, PGK-1, and HK1 and thus plays an important role in the glycolytic switch. 
The HIFs prevent entry into the TCA cycle in part by preventing acetyl coenzyme A (acetyl-CoA) 
production from pyruvate, and thus redirect glucose away from the oxidative phosphorylation 
pathway. Pyruvate dehydrogenase (PDH), the enzyme responsible for conversion of pyruvate to 
acetyl-CoA, is indirectly regulated by HIF activity through the modifying enzyme pyruvate 
dehydrogenase kinase (PDK). PDK1 is upregulated by HIF-1α expression and in turn deactivates 
PDH. Hypoxia and HIF increase glucose/carbon flux through the glycolytic pathway while minimizing 
input into the TCA cycle and oxidative phosphorylation (Semenza, 2010.2). Hypoxia and HIFs have 
been implicated in promoting reverse flux through the TCA cycle and lipogenesis through activity of 
IDH1 (Metallo et al, 2011): in fact renal cell lines lacking VHL exhibit constitutive reductive 
carboxylation of glutamine to α-ketoglutarate even at normal O2 tensions. An obvious role exists for 
HIF-mediated control of mammalian cell metabolism and acetyl-CoA production for lipogenesis under 
hypoxia. Cells may adjust to low O2 tensions through changes in metabolism and methods of ATP 
production, but are also known to adaptively alter strategies for macromolecular biosynthesis, using 
metabolic intermediates to fuel nucleotide and lipid synthesis. Hypoxic cells have unique metabolic 
needs and respond through HIF-regulated changes in metabolism and protein synthesis. 
A recent study has established a novel connection between PKM2 and HIF-1α that is independent 
of its enzymatic properties. PKM2, which has been previously established to be a transcriptional 
target of HIF-1α, has also been demonstrated to physically interact with HIF-1α in the nucleus, 
positively modulating HIF-1α transcriptional activity (Luo et al, 2011). Taken together, these findings 
suggest that PKM2 plays an important role in malignant metabolic reprogramming under low O2 
conditions, by enhancing the pro-glycolytic signals controlled by HIF-1α. 
In addition to HIF-1α, the PHD2-VHL pathway also regulates HIF-2α, which can dimerize with HIF-
1β and activates target gene expression: increased levels of both HIF-1α and HIF-2α are observed in 
many human cancers and associated with increased patient mortality (Semenza, 2010.2). Studies in 
mice suggest that HIF-2α may regulate SOD2 and other genes encoding antioxidant proteins. Thus, 
whereas HIF-1α inhibits oxidant generation, HIF-2α promotes antioxidant generation. It is therefore of 
interest that the NAD+-dependent deacetylase sirtuin 1 (SIRT1) was found to bind to, deacetylate, 
and increase transcriptional activation by HIF-2α but not HIF-1α. Another NAD+-dependent enzyme is 
poly(ADPribose) polymerase 1 (PARP1), which was recently shown to bind to HIF-1α and promote 
transactivation through a mechanism that required the enzymatic activity of PARP1. Thus, 
transactivation mediated by both HIF-1α and HIF-2α can be modulated according to NAD+ levels 
(Semenza et al, 2010.2). Further studies are required to understand the significance of these novel 
findings in the context of cancer cell metabolism. 
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Cell lines 
During this study a panel of 4 human breast cancer cell lines was analyzed: T47D and MCF-7 
(ERα+, PR+, HER2-), MDA-231 (ERα-, PR-, HER2-) and SK-BR3 (ERα-, PR-, HER2+) were obtained 
from the American Type Culture Collection (ATCC, Rockville, MD) through the Tumour 
Microenvironment Laboratory (TML, SAIC-NCI Frederick, MD). Cells were routinely cultured as 
monolayer at 37°C and 5% CO2 in RPMI medium supplemented with 5% fetal bovine serum (FBS, 
Euroclone) and 1% antibiotics (penicillin/streptomycin, Sigma Aldrich) for T47D, MCF-7 and MDA-231 
or in McCoy’s medium supplemented with 10% FBS and 1% antibiotics for SK-BR3. 
 
Drugs 
NVP-AEW541 was kindly provided by Novartis Pharma (Basel, Switzerland): stock solution of this 
drug was prepared in DMSO and stored at -20°C. MAB292, rhIGF-1 and rhIGF-2 were purchased 
from R&D Systems: stock solutions were prepared following the manufacturer instructions and stored 
at -20°C. Topotecan (NSC 609699) was kindly provided by the TML (SAIC-NCI Frederick, MD). 
Luteolin was purchased from Sigma Aldrich: stock solution was prepared in EtOH and stored at -
20°C. Working dilutions of all drugs were prepared in culture media immediately before use. 
 
RT- and real time-PCR 
To analyze the constitutive levels of the various components of the IGF and HIF systems, as well 
as the effect of the different compounds on cellular transcription levels, cells were seeded in dishes 
and let to grow for 24 hours before being put in different conditions of oxygenation (pO2 21% or 1%) 
and/or treated with the different compounds (NVP-AEW541 1 µM, Topotecan 250 nM, Luteolin 25 µM, 
MAB292 5 µg/mL) for 24 or 48 hours. Cells treated with rhIGF-1 or rhIGF-2 (50 ng/mL for 15 minutes) 
were starved for 4 hour previous the exposure. Total RNA was then extracted following the 
manufacturer instructions (RNeasy kit, Quiagen) and quantitated (ND-1000, NanoDrop, 
ThermoScientific): 250 ng (in 10 µL) mRNA were added to 15 µL of RT solution (High Capacity cDNA 
Reverse Transcription Kit, Applied Biosystem) and retrotranscribed following the optimized protocol: 
25°C for 10’, 37°C for 120’, 85°C for 5’ and 4°C ∞ . The cDNA thus obtained was used in a real time-
PCR reaction: 2.5 ng (3.75 µL) of cDNA were added with 21.25 µL of a solution containing 2X Master 
Mix (TaqMan or SYBR, Applied Biosystems), 3 µM reverse and forward primers (final concentration 
300 nM, custom made, IDT), 20X eukaryotic 18S rRNA endogenous control (VIC/TAMRA probe, 
Applied Biosystems) and H2O. The run was performed in a thermocycler following the protocol: 95°C 
for 10’, 95° for 15’’ and 60°C for 60’’ (the last two steps were repeated 45 times) and the results 
analyzed by the ABI7300 software (Applied Biosystems). Reverse and forward primer sequences are 
reported in table 2. 
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Gene Forward primer Reverse primer 
IGF-1 (NM_000618) 5’-TCTCTTCTACCTGGCGCTGT-3’ 5’-AAGCAGCACTCATCCACGAT-3’ 
IGF-2 (NM_000612) 5’-CTTCCAGACACCAATGGGAAT-3’ 5’-GTCCCCACAGACGAACTGGA-3’ 
IGF-1R (NM_000875) 5’-CTAAACCCGGGGAACTACACAG-3’ 5’-TTCACAGAGGCATACAGCAC-3’ 
IGF-2R (NM_000876.2) 5’-TACAACTTCCGGTGGTACACC-3’ 5’-CATGGCATACCAGTTTCCTCCA-3’ 
IR-A (NM_001079817) 5’-TGAGGATTACCTGCACAACG-3’ 5’-ACCGTCACATTCCCAACATC-3’ 
IR-B (NM_000208) 5’-CGTCCCCAGAAAAACCTCTTC-3’ 5’-GGACCTGCGTTTCCGAGAT-3’ 
IGFBP-3 (NM_000598.4) 5’-CAGAGACTCGAGCACAGCAC-3’ 5’-GATGACCGGGGTTTAAAGGT-3’ 
HIF-1α (NM_001243084.1) 5’-TTTGAGGACTTGCGCTTTCA-3’ 5’-TTTGAGGACTTGCGCTTTCA-3’ 
HIF-2α (NM_001430.4) 5’-AGCAGATGGACAACTTGTACCTGA-3’ 5’- TGTCGCCATCTTGGGTCAC-3’ 
VEGF-A (NM_001025366.2) 5’-GGAGGCGCAGCGGTTAG-3’ 5’-AACCCGGATCAATGAATATCAAA-3’ 
PDK-1 (NM_002610.3) 5’-CAAGAATGCAATGAGAGCCACTA-3’ 5’-CCAGCGTGACATGAACTTGAA-3’ 
Actin (NM_001100.3) 5’-CATTCGCGACAGGATGCA-3’ 5’-CTCAGGAGGAGCAATGATCTTGA-3’ 
B2M (NM_004048.2) 5’-GACTTGTCTTTCAGCAAGGA-3’ 5’-ACAAAGTCACATGGTTCACA-3’ 
Table 2 Reverse and forward primer sequences used for real time‐PCR 
 
SDS page e Western Blot 
Constitutive levels of IGF-1R, IGF-2R, IR and HIF-1α as well as activation of IGF-1R and IR were 
evaluated on 3 of the 4 cell lines in our panel (T47D, MCF-7 and MDA-231). To analyze the effects of 
NVP-AEW541 compound on IR/IGF-1R signaling pathway starved cells were treated for 24 hours 
with NVP-AEW541 (1µM) and then exposed to rhIGF-1 or rhIGF-2 (50 ng/mL, 15 minutes). In a 
second set of experiments, we followed MAB-292 (5 µg/mL) inhibitory effects on IR/IGF-1R-related 
signaling pathways by exposing the three cell lines to the compound for 24 hours in standard medium 
and after exposure to rhIGF-2. Finally, after having assessed the effects of hypoxia on the insulin/IGF 
system, we evaluated the effect of the combination of the two compounds on both IGF-1R and IR 
phosphorylation, as well as the effect of the combination NVP-AEW541/Topotecan (1 µM/250 nM) 
and NVP-AEW541/Luteolin (1 µM/25 µM) in hypoxic conditions. Cell lysates were prepared in RIPA 
buffer containing protease inhibitor cocktail (Sigma Aldrich). To determine phosphorylation status the 
lysis buffer was added with phenylmethylsulfonylfluoride (PMSF, 1 mmol/L) and sodium 
orthovanadate (Na3VO4, 1 mmol/L). Protein concentration was determined by Bradford Method 
(BioRad) or BCA Method (Pierce) and equivalent amounts of total cell lysate (100µg) were added with 
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sample buffer 2X (Laemmli, Sigma Aldrich), separated by 7% or 10% acrylamide SDSpage under 
denaturating conditions and transferred onto PVDF membrane. Membranes were incubated overnight 
with primary antibodies: anti-phospho-IGF-1Rβ(Tyr1316), dilution 1:1000 (Cell Signaling); anti-
phospho-IRβ (Tyr1361), dilution 1:1000 (Cell Signaling); anti-IGF-1R, dilution 1:1000 (Cell Signaling); 
anti-IR, dilution 1:1000 (Cell Signaling); anti-IGF-2R, dilution 1:1000 (Acam), and anti HIF-1α, dilution 
1:300 (Novus Biological). As a control of the correct loading membranes were also incubated with 
anti-actin antibody, dilution 1:5000 (Sigma Aldrich). Then they were incubated with secondary anti-
rabbit or anti-mouse antibody conjugated to horseradish peroxidase, dilution 1:10000 (Amersham). 
Membranes were revealed by enhanced chemiluminescence Western blotting detection reagents 
(Amersham and Pierce) and detected on films (Hyperfilm ECL, Amersham). 
 
ELISA assay   
Constitutive levels of IGF-2 and IGFBP-3 were evaluated in 3 of the 4 cell lines in our panel. Cells 
were seeded in 6 well plates and let to grow for 48 hours before being starved and put in different 
conditions of oxygenation (pO2 21% or 1%). 24 hours later supernatants were collected and stored at 
-80°C or immediately quantitated through ELISA kit specific for IGF-2 or IGFBP-3 (Insight Genomics 
and R&D Systems) following the manufacturer protocols. 
 
Flow Cytometry 
Constitutive levels of IGF-1R, IGF-2R and IR were evaluated on all 4 cell lines in our panel. Cells 
were seeded in 6 well plates and let to grow for 48 hours before being put in different conditions of 
oxygenation (pO2 21% or 1%). 24 hours later cells were collected, counted and incubated for 1 hour 
at 4°C with specific conjugated antibodies (IGF-1R/PE, IGF-2R/FSC and IR/PE, R&D Systems) as 
well as IgG isotype control antibodies (R&D Systems). Red and green fluorescence was then read at 
a flow cytometer (Guava easyCyte, Millipore). Percentage of fluorescent cells present in IgG isotype 
controls was subtracted to the corresponding samples during analysis. 
 
SRB 
To evaluate the IC50 of luteolin in all cell lines we performed SRB assay. Cells were seeded in 96 
well/plates, let to grow for 24 hour and then treated with crescent concentration of luteolin (0.5-50 
µM). Then they were fixed with TCA 50% for 1 hour at 4°C at different times (T0, 6h, 24h and 48h). 
They were stained with SRB for 15 minutes, rinsed in Acetic acid 0.1%, air-dried and the staining was 
dissolved in Tris. The absorbance was then read at a spectrophotometer (490 nm) and the values 
thus obtained used to draw proliferation curves and calculate the IC50. The IC50 of NVP-AEW541 
was already known from previous experiments in our laboratory. The IC50 of Topotecan was kindly 
provided from the TML. 
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Scratch Wound Healing Assay   
To evaluate the effect of the different compounds on the migration potential of the most aggressive 
cell line among our panel, MDA-231, cells were seeded at high density in specific supports (µ-dish 
Culture Inserts, Idibi) and let to grow for 24 hour. Cells were then exposed to the different 
compounds, put in different conditions of oxygenation (pO2 21% or 1%) and the inserts were 
removed: pictures of the wound scratch were taken at the time of removal (T0) and at regular times 
for a total of 48 hours. The experiment has been repeated two times; all the treatments and condition 
were tested at the same time. 
 
Boyden Chamber assay 
To further asses the migration potential of MDA-231, the effects of the different compounds in 
study were determined also by Boyden Chamber Assay. Boyden chambers (CellBiolabs Inc.) were 
pre-incubated for 30 minutes at 37°C in 24 well plates containing on the bottom 600 µL of medium 
and FBS (1:1): cells were then added on top of the chambers and let to grow and migrate for 24 or 48 
hours. At the end-points, the chambers were removed from the plate, fixed and stained in two steps 
(Eosin + AzurA/AzurB, 2 minutes each) to colour the cell that migrated in the chamber and finally 
photographed. Analysis didn’t involve counting the number of migrating cells but only the visible 
differences between the treatments. 
 
Phospho arrays (Kinase and RTK) 
To investigate the overall effects of the treatment with Luteolin at the protein level, we performed 
two phospho arrays on MDA-231 cells, the first one investigating the activation of the different protein-
kinases and the second one on a panel of tyr-kinase receptors. Cells were seeded in dishes and let to 
grow for 24 hours before being put in different conditions of oxygenation (pO2 21% or 1%) and/or 
treated with Luteolin 25 µM for 24 hours. Cells lysates were prepared using the specific lysis buffers 
included in the two different kits and used to perform the array following the manufacturer protocol 
(R&D Systems). 
 
Seahorse XF24 
The Seahorse XF24  (Seahorse Bioscience) instrument measures the rate of change of analytes 
(currently dissolved oxygen and pH) in the media immediately surrounding living cells cultured in a 
microplate (24 well/plate). Changes in the extracellular media are caused by the consumption or 
production of analytes by the cells. Therefore, a sensitive measurement of the media flux can be used 
to determine rates of cellular metabolism with great precision and in a totally non-invasive, label-free 
manner. A unique feature of the XF technology is its ability to make accurate and repeatable 
measurements in as little as five minutes. This is accomplished by isolating an extremely small 
volume (less than 10 µL) of media above the cell monolayer. Cellular metabolism causes rapid, easily 
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measured changes to the “microenvironment” in this small volume. Typically, a measurement cycle is 
performed for 2-5 minutes. During this time, the media is gently mixed and is followed by a short 
temperature recovery period. The analyte levels are then measured until the oxygen concentration 
drops approximately 20-30% and media pH declines approximately 0.1-0.2 pH units. The 
measurement is performed using 24 optical fluorescent biosensors embedded in a sterile disposable 
cartridge that is placed into the Seahorse 24 well tissue culture microplate. Baseline metabolic rates 
are typically measured 3-4 times, and are reported in pmol/min for OCR (and PPR) and in mpH/min 
for ECAR. Compound is then added to the media and mixed for 5 minutes, and then the post-
treatment OCR and ECAR measurements are made and repeated. As cells shift metabolic pathways, 
the relationship between OCR and ECAR (PPR) changes. Because XF measurements are non-
destructive, cells can be profiled over a period of minutes, hours or days. Shifts in substrate utilization 
and metabolism, characteristic of cancer cells, can be detected conveniently and simultaneously with 
this instrument through detection of the oxygen consumption rate (OCR), to quantify mitochondrial 
respiration, and the extracellular acidification rate (ECAR), an indicator of glycolysis (together with the 
proton production rate or PPR). Measuring the ECAR  (or PPR) provides a method for detection and 
quantitation of glycolytic flux in cancer cells in response to genetic changes, or to drugs. The XF 
Analyzer simultaneously measures OCR and ECAR, providing a more comprehensive assessment of 
cellular bioenergetics, and analysis of the dynamic interplay between the two major energy-yielding 
pathways in cancer cells and other cell types. These parameters are determined by measuring OCR 
after the sequential injection of oligomycin to inhibit the ATP synthase and preventing phopshorylating 
respiration, carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) to uncouple the 
mitochondrial  inner membrane and allow for maximum electron flux through the ETC, therefore 
causing a rapid energy consumption without ATP generation (this causes an increase in OCR due to 
the uncoupling activity but also an increase in ECAR due to the attempt to create ATP using 
glycolysis), and rotenone (to inhibit complex I and block mitochondrial function) or antimycin (to inhibit 
complex III). To better evaluate the glycolisis process it is also possible to perform a run that 
contemplates the sequential injection of glucose, oligomycin and 2-DG (2-deoxyglucose). 
The XF24 system include a bench top analyzer and touch screen controller, disposable 
measurement/compound delivery cartridges, microplates for cell culture, calibration media and XF24 
software, as well as a plate preparation station (PS) for exchanging media in the tissue culture plate. 
Cells are seeded 24 hour prior the run in the specific microplate and let to grow overnight: at the 
same time the sensors are put in the PS to hydrate in 1 mL of a specific solution. The following day 
the medium is removed from the cells and a specific DMEM (without glucose, it can be added with the 
desired concentration) is added: the plate is then placed in the PS (at 37°C without CO2) for about 60 
minutes. In the meanwhile working solutions of the different compounds are prepared and put in the 
different ports of the cartridge. The plate with the cells is placed in the instrument, let to calibrate and 
then the cartridge is added for the run. 
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Analysis of the constitutive levels of insulin/IGF and HIF systems 
components 
 
mRNA expression 
The first step in our study contemplated the characterization of the panel of breast cancer cell lines 
regarding the insulin/IGF and HIF systems: we started with the analysis of the constitutive levels of 
expression of the different genes of the two systems, preformed by real time-PCR. 
Concerning the IGF system, first of all it is interesting to notice the difference between the two 
ligands: while IGF-1 mRNA levels result undetectable in all cell lines in both conditions (pO2 21% and 
pO2 1%), IGF-2 is on the contrary detectable in all of them, with a noticeable level of variability among 
cell lines. As expected, in three of the four cell lines we observed an increase in the mRNA 
expression in hypoxia, in agreement with the fact that IGF-2 is one of HIF-target geneg: interestingly, 
we could not detect any increase in the MCF-7 cell line, that we used as a term of comparison to 
investigate the differences in basal expression of all the components of the systems (figure 10). IGF-
1R and IGF-2R are both detectable: type-1 receptor shows higher levels of expression compared with 
type-2 receptor. IGF-1R results decreased in hypoxia in all cell lines, with MDA-231 showing the 
smallest decrease (70% of mRNA left compared to normoxia), while IGF-2R results slightly decreased 
in hypoxia in all cell lines, with MDA-231 showing the biggest decrease (70% of mRNA left compared 
to normoxia). When comparing the four cell lines, contrary to our expectations, MDA-231 were 
observed to posses the lowest levels of IGF-1R and the highest of IGF-2R: this profile of expression 
would be more expected in a non-aggressive cell line, like for example MCF-7, which in fact showed 
basically the opposite profile (figure 11). Anyway, these data cannot be discussed without the 
analysis of the levels in proteins effectively present at the cellular level: proteins analysis was 
performed and will be presented later in this chapter. Other components of the IGF system that were 
investigated were IGFBP-3 and IR. IGFBP-3, the most abundant regulator of IGF tissue delivery was 
expressed at low levels in all cell lines with the exception of MDA-231, and its levels were increased 
in hypoxia especially in MDA-231 but again with the exception of MCF-7, where we observed the 
opposite behavior. Analysis of IR contemplated the use of two different primers specific for the two 
variants, IR-A and IR-B: as reported in literature, all cell lines showed the presence on high levels of 
the variant A, predominant on variant B (figure 12). MDA-231 in particular possessed the highest 
levels of IR-A which remained unchanged in hypoxia (even after starvation). 
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Figure 10 Fold change in the expression of the insulin/IGF system genes in MDA-231 (a), T47D (b) and SK-BR3 (c) 
compared to MCF-7, used as a term of comparison for the other three cell lines. 
 
Figure 11 Fold change in the expression of the insulin/IGF system genes in MCF-7 (a), MDA-231 (b), T47D (c) and 
SK-BR3 (d) in hypoxic condition (pO2 1%) compared to normoxic expression (pO2 21%). 
Figure 12 Comparison between IR-A and IR-B expression in all cell lines, in the presence (a) or absence (b) of 
FBS in the culture media. 
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Concerning the HIF system, we analyzed the expression of the α subunit, both 1 and 2. HIF-1α 
mRNA levels were comparable in the four cell lines in our panel, with MDA-231 showing the highest 
levels, and a slight decrease in hypoxia, due to the general cellular shut down in stress conditions. 
Considering HIF-2α, its levels were very high in SK-BR3 and MDA-231, high in T47D and very low in 
MCF-7 (figure 13): these levels were maintained in hypoxia in all cell lines. We analyzed also two HIF-
target genes, VEGF-A and PDK-1. VEGF-A was expressed in all cell lines: T47D exhibited the lowest 
expression, while MDA-231 showed the highest. In all cell lines we could observe an increment in 
mRNA in hypoxia. PDK-1 mRNA followed a similar pattern, with MCF-7 expressing the lowest levels 
but also the largest increase in hypoxia (figure 14). 
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Figure 13 Fold change in the expression of the HIF system genes in MDA-231 (a), T47D (b) and SK-BR3 (c) 
compared to MCF-7, used as a term of comparison for the other three cell lines. 
Figure 14 Fold change in the expression of the HIF system genes in MCF-7 (a), MDA-231 (b), T47D (c) 
and SK-BR3 (d) in hypoxic condition (pO2 1%) compared to normoxic expression (pO2 21%). 
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Protein expression 
Together with mRNA expression we also investigated the constitutive levels of proteins actually 
present in the cells. We performed ELISA assays to verify the concentration of IGF-2 and IGFBP-3 
secreted in the medium (we decided not to perform ELISA of IGF-1 considering the absence of the 
transcript of said protein) and we could observe an interesting pattern which includes both proteins. In 
fact while the levels of both resulted comparable in the three cell lines analyzed (MCF-7, MDA-231 
and T47D) in normoxic condition, when subjected to hypoxic conditions the three cell lines behaved in 
two opposite ways.  MCF-7 and T47D showed a substantial decrease in IGF-2 protein levels and 
stable levels of IGFBP-3: on the contrary, MDA-231 displayed a remarkable raise in both proteins 
(figure 15).  
 
 
At the same time we also performed flow cytometric evaluation of the four cell lines to assess the 
presence of the receptors (IGF-1R, IGF-2R and IR) in cell membranes. Flow analysis confirmed the 
PCR data about IGF-1R, showing the highest presence in MCF-7 and T47D; IGF-2R expression was 
comparable in all cell lines and showed no significant differences between normoxia and hypoxia 
(similarly to IGF-1R). The same situation was observed also in IR levels with the exception of MCF-7, 
where a decrease was detected under hypoxic conditions (figure 16). 
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Figure 15 Quantification of the concentration in supernatant of IGF-2 (a) and IGFBP-3 (b) 
through ELISA assay in normoxic and hypoxic conditions. 
Figure 16 Quantification of the membrane expression of IGF-1R (a), IGF-2R (b) and IR (c) through flow 
cytometry in normoxic and hypoxic conditions. 
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Overcoming the resistance to NVP
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proliferation (investigated through SRB assay) 
with NVP (figure 26). 
 
 
 
Figure 25 Levels of IGF-1R 
with topotecan and luteolin, alone or in combination with NVP
 
Figure 26 Analysis of the ability to migrate of MDA
with Topotecan or Luteolin, alone or in combination with NVP
 
and migration with both assays, in com
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-AEW541, through Western Blot. As a control 
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Assay (a) and Boyden Chamber Assay (b). 
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Analysis of Lutein effects on the different cell lines 
 
Based on the activity profile described in the literature for luteolin, we also performed a screening 
of the biological activity of this compound, including cytotoxicity assays and  phosphoarray analysis 
under normoxic or hypoxic conditions. 
 
Cytotoxicity 
 The survival curves obtained for the four h cell lines indicate that the antiproliferative effect of 
Luteolin was not significantly affected underhypoxic conditions (figure 27). When comparing its 
efficacy in the different cell lines, MCF-7 cells appeared to be more sensitive, than the other three cell 
lines, displaying a similar behavior. Based on the  the IC50 values estimated from the survival 
curves,: for the subsequent experiments we decided to use  the subtoxic concentration of 25 µM. 
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Figure 27 Fraction of survival of the four cell lines after treatment with different concentration of Luteolin, 
in both normoxic and hypoxic conditions. 
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Analysis of the profile of activation of PK and RTK 
To investigate the overall effects of 
the treatment with Luteolin at the protein 
level, we performed two phospho arrays 
on MDA-231 cells, the first one 
investigating the activation of the 
different protein-kinases and the second 
one on a panel of receptors tyr-kinase. 
We opted to evaluate the modulation of 
the different proteins after treatment in 
both normoxic and hypoxic conditions. 
The two maps in figure 28 represent 
variations in the activation of the two 
class of proteins: the resulting profile is 
complex, showing both increase and 
decrease in the phosphorylation in 
different sets of PK and RTK. We mainly 
focused on VEGF receptors, particularly 
R1, as well as on the STAT (Signal 
Transducer and Activator of 
Transcription) proteins, and Akt, whose 
phosphorylation was significantly, if not 
altogether completely inhibited after 
treatment. Other proteins of interest that 
warranting further investigation were: 
Paxillin, a protein involved in cell 
anchorage and consequently in the 
migration process, that was inhibited; 
Chk-2 (activated); AMPKα -1 and -2 
(both inhibited); and Axl (strongly 
activated). Activation of EGFR and ERK 
was also observed, but was less clear-
cut than the results obtained for the 
other genes. As a last consideration, IR 
activation also seemed increased by 
phosphoarray analysis, but this result is 
contradicted by the total inhbition 
observed by western blot analysis. 
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Figure 28 Profile of activation of PK and RTK of MDA-231 cell line in 
normoxic and hypoxic condition, with and without treatment with 
Luteolin 25 µM. 
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Analysis of the  metabolic profile (Seahorse XF24) 
 
Constitutive levels 
 Given the implication of the insulin receptor in the present study, and its role in the metabolic 
activity of the cells, we finally assessed the metabolic profile of three of the cell lines in our panel. This 
part of the project was made possible by the collaboration with the TML in Frederick. Figure 29 shows 
the efficiency of oxidative respiration and glycolysis under basal conditions The three cell lines 
possess almost overlapping oxidative profiles (a), the glycolytic capacity under normoxic conditions 
was significantly lower for MCF7 cells than for the other two cell lines (b); in this regard, the metabolic 
profile of MCF7 cells more closely resembles that observed in normal cells rather than that of tumor 
cells, notoriously characterized by an increase in aerobic glycolysis (the so-called "Warburg effect").  
 
Modification on the metabolic profile following inhibition of the IGF system or 
treatment with  Luteolin 
Further preliminary experiments were performed following combined exposure to NVP-AEW541 
and MAB292 or Luteolin (Figure 30): interestingly,  inhibition of the IGF system, as well as exposure 
to Luteolin) seems to affect the efficiency of both metabolic processes, albeit with different behavior in 
the different cell lines.  
Further experiments are required to assess the full impact of these compounds on cellular 
metabolism, as well as the metabolic processes and responses in hypoxia: this last part was not 
practicable at the moment due to the absence of an hypoxic chamber in which to put the Seahorse 
XF24 and perform the experiments. The TML is actually still waiting for approval of said hypoxic 
chamber.
Figure 29 Metabolic profile of the three cell lines under consideration displayed by parameters such as oxygen consumption 
(OCR, an indicator of oxidative phosphorylation, a) and acidification of the culture medium (ECAR, an indicator of glycolysis, 
b) detected after sequential injections of oligomycin (1 µM, A), FCCP (0.5 or 0.125 µM, B) and rotenone (0.1 µM, C). 
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(a) 
Figure 30 Changes in the metabolic profile of the three cell lines after treatment with Luteolin or NVP-AEW541 + MAB292, 
viewed through parameters such as oxygen consumption (OCR indicator oxidative phosphorylation, a) and acidification of 
the culture medium (ECAR, an indicator of glycolysis, b) detected after sequential injections of oligomycin (1 µM, A), FCCP 
(0.5 or 0.125 µM, B) and rotenone (0.1 µM, C ). 
(b) 
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The observation in the last decade that several receptor tyrosine kinase can act as promoters of 
tumour development and growth has led to a revolution in the study of new pharmacological targets, 
in the hope of being able to develop more specific anti-cancer drugs: examples of pathways targeted 
with success are the HER2/neu family (i.e. the humanized antibody Trastuzumab or the small 
molecule Lapatinib) or EGFR (i.e. the chimeric monoclonal antibody Cetuximab or the small-molecule 
Tyr-kinase inhibitor Gefitinib). These compounds have been developed in the last fifteen years and 
are now being used as part of clinical routine in a number of countries worldwide (Conte and 
Guarnieri, 2012). 
One of the most studied systems in this field appears to be that of the Insulin-like Growth Factors 
(IGF): in this case, however, the development of targeted agents is still in clinical trials of different 
phases. In fact, many different  
The insulin/IGF pathway holds crucial role in metabolism, cell growth, differentiation and 
proliferation. Aberrant regulation of the IGF system has been attributed to the pathogenesis of 
different tumour types, in particular in breast cancer, where it has been shown to contribute to various 
stages of breast carcinogenesis. Therefore, the IGF axis has emerged as a meaningful therapeutic 
target for oncology drug development that is strongly supported by preclinical studies and drug 
candidates that target IGF-1R are being evaluated simultaneously in dozens of ongoing clinical trials 
(Pollak, 2009). However, this complex system presents distinct developmental challenges, and 
demonstration of meaningful clinical benefit remains elusive (Karamouzis and Papavassiliou, 2012). 
While reduction of IGF levels can be achieved through several different approaches, including 
inhibition of the GH-releasing hormone (GHRH)–GH axis or the neutralization of the ligands, IGF-1R 
inhibition is by far the most extensively explored. Two different strategies have been developed for 
the inhibition of IGF-1R, using either monoclonal antibodies (mAbs) against the receptor (i.e. 
Figitumumab, Ganitumumab, Cixutumumab) or small molecules that inhibit the TK activity of IGF-1R 
(i.e. Linsitinib, NVP-AEW541, BMS-754807). IGF-targeting agents are generally expected to show 
their full potential by augmenting the efficacy of endocrine, cytotoxic, or other targeted therapies, 
possibly by mitigating the development of resistance to otherwise effective interventions. Although 
combinations of large or small IGF-targeting molecules with various standard-of-care therapies have 
generally shown a reasonable toxicity profile, this strategy has yet to translate preclinical promise into 
therapeutic efficacy. 
Unfortunately, indeed, tumour cells show a high degree of plasticity and redundancy in proliferative 
and anti-apoptotic pathways, which may contribute to the development of resistance to specific 
inhibitors: the identification of these mechanisms of resistance, and their overcoming, are two 
fundamental goals in the development of these targeted drugs, to identify their effectiveness and their 
possible actual use in the clinic. An example of signal redundancy is given by EGFR, whose cross-
talk with IGF-1R or MET may determine an adaptive response following inhibition of EGFR itself. 
Another example is the cross-talk between IGF-1R and ERα in breast cancer. In cases like these, the 
most effective solution lies in the combined inhibition of the different players in the maintaining of the 
signal. 
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Within this study we encountered a similar problem: the experiments conducted have in fact 
shown how the drug in use, NVP-AEW541, a specific, low molecular weight inhibitor of the catalytic 
activity of IGF-1R (Garcia-Echeverria, 2004), is perfectly able to inhibit the signal transduced by the 
receptor following stimulation with IGF-1, but in fact seems to lose effectiveness following stimulation 
with IGF-2, which was especially evident for one of the cell lines under study (MDA-231, featuring a 
TNBC phenotype and the most aggressive characteristics) to migrate even in the presence of the 
drug, even though Western blot analysis showed how the compound exerted its inhibitory function on 
IGF-1R regardless of the type of ligand used for its stimulation. 
Starting from the hypotesis that IGF-2 acts as a key factor in the observed resistance, a search of 
the literature has yielded an increasing number of experimental evidence in support of the role of the 
insulin receptor (IR), in particular of its splicing variant A upon binding IGF-2, in the maintenance of a 
proliferative signal similar to that classically attributed to activation of IGF-1R (Buck et al, 2010). For 
this reason early inhibitors that had been abandoned because of their lack of selectivity for IGF-1R 
versus IR could be considered again of interest. 
Indeed the results of our study are in line with those reported in literature concerning the presence 
of the variant A of the insulin receptor in breast carcinomas (Frasca et al, 1999; Pollack, 2012). In 
contrast with IR-B, this variant is capable of binding IGF-2 with higher affinity over insulin itself, and to 
maintain a proliferative signal even after inhibition of IGF-1R. our results show that IR was especially 
activated after stimulation with rhIGF-2, but even rhIGF-1 elicited some degree of activation, despite 
the lower affinity of the receptor for this ligand, probably due to the particularly high concentration of 
exogenous IGF-1. This activation could (at least partially) justify the dramatic loss of effectiveness of 
NVP-AEW541 following stimulation with rhIGF-2 in regard of migration of MDA-231 cells. Further 
evidence confirming that IGF-1R inhibition can be bypassed in this cell line comes from partial 
activation of Akt despite NVP-AEW541 treatment. 
While dual IGF-1R/IR inhibition could prevail over this signal redundancy, the role played by IR in 
cellular metabolism raises serious concerns regarding the safety of this approach. Actually, variant A 
of the receptor differs from the classical variant B only in the absence of a single exon (exon 11, 
coding for a fragment of 12 aa in the C-terminal portion of the α subunit of the receptor) and this 
makes it particularly difficult to create compounds able to discern between the two variants. Evidence 
from a number of clinical trials of both antibodies directed against the IGF-1R and inhibitors of 
tyrosine kinase activity indicates that administration of currently available compounds able to inhibit 
one or both receptors lead to a transient hyperglycemia (Pollak, 2008; Gao et al, 2012; Karamouzis 
and Papavassiliou, 2012). In this regard, we performed preliminary study of the metabolic profile of 
the cell lines in basal conditions and after inhibition of the IGF system (through the use of different 
strategies that do not involve the direct targeting of IR): the results obtained confirmed that this 
modulation actually affects the levels of cellular metabolism (data will be further discussed later in this 
section).  
A different and probably more feasible strategy would be to hit IGF-2, i.e. the ligand responsible of 
the combined IGF-1R/IR activation. The Igf2 gene is an example of imprinted gene and loss of 
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imprinting (LOI) in the maternal gene (normally silenced) leads to increased protein expression and a 
consequent increase in the risk of developing cancers (Harris and Westwood, 2012). The strategy 
proposed in the present study closely mimics the physiological mechanism controlling IGF-2 levels: in 
fact normal cells control the levels of circulating IGF-2 by binding the ligand to IGF-2R, followed by 
internalization and lysosomal degradation. The tumour suppressor function of IGF-2R was first 
demonstrated 15 years ago, and later it was shown that overexpression of a soluble form of the 
receptor dramatically reduced tumour cell growth in vitro and in vivo, suggesting the ability of IGF-2R 
to inhibit cell proliferation. Mutations in Igf2r, or loss of heterozygosity (LOH) at the 6q26–27 locus 
where Igf2r resides, lead to reduced IGF-2R expression and increased circulating concentrations of 
IGF-2. Loss of biallelic Igf2r expression has been reported in cancers of the breast, liver, prostate, 
lung, adrenal gland, head, neck and endometrium (Martin-Kleiner and Gall 2010). The different cell 
lines used in the present study exhibited similar levels of IGF2R expression, as assessed by PCR, 
western blot and flow cytometry. 
MEDI-573 is the only mAb currently in clinical testing that exerts its effects by neutralizing not only 
IGF-2 but also IGF-1. Distinct from all the IGF-1R–targeting compounds under development, MEDI-
573 can thus inhibit IGF signaling through both IGF-1R and IR-A, as well as through their hybrid 
receptors. The ongoing phase I clinical trial has shown promising results and strongly suggested that 
MEDI-573 might achieve this result without inducing hyperglycemia (Menefee et al, 2010). If 
confirmed, this observation would be consistent with expectations about ligand- versus receptor- 
based targeting of the IGF axis, specifically with respect to the clinical consequences of sparing IR-B 
and its various hybrid receptors, each of which has the potential to alter glucose metabolism via 
interactions with insulin (Gao et al, 2012). 
To confirm the validity of this strategy in breast cancer, we used a neutralizing antibody specific for 
IGF-2 (MAB292) thus making impossible for the ligand to bind and activate both IGF-1R and IR-A. 
MAB292 was effective as single agent and even more in combination with NVP-AEW541: following 
exposure to this antibody, IR-A was predominantly unphosphorylated, in contrast to the effect of NVP-
AEW541 alone ; particularly, MDA-231 cells were totally unable to respond to stimulation with rhIGF-2 
and, more interestingly, they totally lost the ability to migrate. 
IGF2 neutralization could be a particularly winning strategy,  especially considering the fact that, at 
the low oxygen levels that are frequently encountered within the tumor mass (pO2 1%), the activation 
of pathways  as a result of HIF-1α stabilization of and subsequent dimerization with HIF-1β leads to 
increased  IGF2 levels of the same IGF-2, as reported in the literature and observed in our 
experiments both at transcript and protein  levels of especially in the case of MDA-231 cells 
(Semenza, 2012). This increase is possibly implicated in hypoxia-dependent resistance of MDA-231 
cells to the administration of NVP-AEW541, similarly  to what has been observed following 
administration of exogenous IGF-2, although obviously to a lesser extent, considering the different 
(lower) concentrations of IGF-2 present in hypoxic conditions compared to those administered. As 
confirmation of the key role of IGF-2 in the resistance to NVP-AEW541 in the presence of low oxygen 
concentrations, treatment with MAB292 under hypoxic conditions was able to inhibit the migration of 
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MDA-231 with the same efficacy shown in normoxia following exposure to  rhIGF-2, and  combined 
treatment NVP-AEW541/MAB292 again determined the total loss of the migratory capacity, 
seemingly as a result of the loss of IR phosphorilation. Considering the close relationship between the 
IGF and HIF system, we decided to further investigate IGF-2R presence in the cell lines, and in 
particular its regulation under hypoxic conditions: the modulation of this receptor in the presence of 
low pO2 in fact has not been extensively studied. Actually our experiments could not detect a direct 
and defined relationship between HIF-1α and IGF-2R levels: we observed a reduction in mRNA levels 
in hypoxia in all cell lines, but this decrease could not be detected at the protein level (either in 
membrane expression, evaluated by flow cytometry, or in total protein levels assessed by western 
blot). Further and more detailed studies are needed to assess the possible correlation between the 
two proteins. However, it should be emphasized that the use of soluble forms of the receptor, in 
theory a possible strategy to lower IGF-2 concentration, is actually of difficult practicability. Analysis of 
IGF-2R levels is probably more interesting and useful as a marker of tumour aggressiveness and/or 
worse prognosis. 
Based on this observation it is therefore evident that a further strategy to overcome the resistance 
to NVP-AEW541 (and to IGF-1R inhibitors in general) given by IGF-2 overexpression may be the 
simultaneous inhibition of HIF-1α. The discovery of HIF-1 (and later HIF-2) and its role in activating 
mechanisms of proliferation and survival in conditions of oxygen concentrations lower than the 
physiological (pO2 <2.5%) has led to a great interest in the development of compounds capable of 
inhibiting the major actors, mainly HIF-1α and HIF-2α. At present, the major problem in targeting HIFs 
is the lack of specific inhibitors: many chemotherapic drugs, in fact, have a complete or partial 
inhibitory activity on HIF-1α, but this is often accompanied by a number of off-target effects. 
Information published so far relates for the most part to HIF-1α, although many of these agents may 
also affect HIF-2α. Specific inhibitors of HIF-1α and/or HIF-2α are currently under validation 
(Semenza, 2007; Onnis et al, 2010). 
In the present study, HIF-1α inhibition was obtained through the use of Topotecan, a 
chemotherapeutic in use in the management of ovarian and small cell lung cancer. Topotecan it is a 
Top-1 poison that inhibits HIF-1α translation by a Top1-dependent but DNA damage-independent 
mechanism, suggesting that its effect as HIF-1α inhibitor could be mechanistically distinguished from 
those characterizing its cytotoxic activity. One of the criticisms involving compounds such as 
Topotecan is that these are drugs that have already failed, as single citotoxic agents, to show 
significant anticancer effects in clinical trials: however, the key distinction that must be made is that 
their current utilization as HIF inhibitors involves frequent administration at lower doses in an effort to 
maintain continuous inhibition of HIF activity (Semenza, 2012). As evidenced by our experiments, the 
presence of Topotecan (administrated at subtoxic concentrations, so that it could exert its role as HIF-
1 inhibitor to a greater extent compared to its activity as a cytotoxic drug) determined a restore in the 
effectiveness of NVP-AEW541 in hypoxia following the reduction in the levels of IGF-2 (both mRNA 
and protein) as a consequence of HIF-1α inhibition, demonstrated not only in the levels of HIF-1α 
protein but also in the levels of HIF-1 target genes (the already mentioned IGF-2 but also VEGF-A 
and PDK1). IR, as well as IGF-1R, were un-phosphorylated after treatment and the efficacy on 
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migration was especially noticeable. 
A similar effect on migration, if not even more prominent, was also observed following the use of 
Luteolin, a natural compound belonging to the flavonoid class that can be found as integral 
components of the human diet and possess anti-proliferative and anti-migratory activity: in this case, 
despite the inhibition of HIF-1α investigated by Western Blot resulted not significant at the cellular 
level, we could observe a reduction in the levels of IGF-2 (both at mRNA and protein level) and a 
synergistic effect with NVP-AEW541. 
The case of Luteolin is more complex in regard to its effect on HIF-1. Literature data report how 
this compound seems in fact to be able to inhibit HIF-1 nuclear activity more rather than affect α 
subunit levels, that were reported to be increased or decreased in different studies (Hasebe et al, 
2003; Zhang et al, 2009). Anyway, starting from our data the most interesting feature of this 
compound, more than its activity on HIFs, resulted to be its anti-migratory potential: the use of 
Luteolin, as already stated, completely inhibited migration in MDA-231. However, the use of Luteolin 
in chemotherapy is far from being near: apart from the need to test its effective bioavailability, the 
need to use high concentration of the compound even in in vitro experiments and the observation 
after treatment of a general inhibition in mRNA transcription may be incompatible with its use in 
therapy. 
As a last point in our study, we focused our attention on the metabolic alteration determined by the 
modulation of insulin/IGF system. Since deregulation of cellular energy metabolism is considered an 
increasingly important hallmark of cancer, IR and its related metabolic syndromes have become 
another major focus in the breast cancer research and treatment field. Both obesity and type 2 
diabetes mellitus could lead to hyperinsulinemia, which has been reported to activate insulin 
receptors in normal breast epithelial cells and in neoplastic tissues, increase the risk of developing 
breast cancer in patients with metabolic syndromes, promote metastatic progression, and associate 
with poor prognosis in breast cancer patients (Yang and Yee, 2012). Moreover, as already reported 
above, the pharmacological modulation of a system as fundamental for metabolism as it is the one 
comprising insulin and IGFs rises the necessity to analyze in depth the effects of this modulation. 
Preliminary analysis of the oxidative and glycolitic profiles of three cell lines showed in first stance 
an interesting difference at the basal level. MCF-7, in fact, notoriously the less aggressive of the 
three, resulted to have a glycolitic profile closer to normal cells than MDA-231 or T47D, which showed 
an increase in glycolysis even in presence of oxygen, the so called Warburg effect nowadays 
considered a hallmark in cancer. This increase in glycolysis is accompanied by a reduction in the 
oxidative processes, in agreement with literature data. What is even more interesting is the fact that 
when treated with NVP-AEW541 combined with MAB292 all cell lines showed an increase in the 
efficiency of the oxidative phosphorilation. The same result was obtained after treatment with Luteolin. 
Further experiments would be needed to assess the effective impact of these compounds on cellular 
metabolism, as well as the metabolic processes and responses in hypoxia, which could not be 
analyzed in this study. A more specific and in depth analysis also of the glycolitic process is 
necessary to assess the effects of IGF inhibition on metabolism: our preliminary study indeed showed 
98 Analysis of the interaction between the IGF system and HIF: rationale for cotargeting the two systems in breast cancer 
Discussion 
 
modifications also in the glycolitic efficiency that need to be further investigated. 
Overall, we can conclude that the combined inhibition of IGF-1R and HIF-1 appears to result in a 
synergistic effect on the migratory capacity of breast cancer cells in this study and it may therefore be 
a really interesting therapeutic strategy, especially given the close relationship shared by the two 
systems and the consideration that the use of this combined therapy could improve to outcome in 
patients diagnosed with metastases that eventually become unresponsive to systemic therapy. In 
addition to their use in overcoming the resistance to classical therapies, the inhibition of IGF and HIF 
system could be used at the first stages of breast cancer to prevent the progression to MBC. 
Thus, in the present study we have been able to observe that the activation of HIF-1 leads to a 
variation in the levels of transcription of genes of the IGF system involved in proliferation and 
migration (in particular an increase in IGF-2) resulting in the creation of a mechanism of resistance to 
IGF-1R specific inhibition. On the other hand, it is also interesting to observe as a last consideration 
how the activation of IGF-1R as a result of exposure to both ligands lead to an increase in the 
transcription of genes HIF-1 dependent (such as VEGF and PDK1, in addition to the already 
mentioned IGF-2) suggesting the existence of an autocrine loop of survival in the cell lines under 
examination (at least in MDA-231) and thus making it even more interesting to explore the possibility 
to combine the inhibition of the two systems. 
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And here I am, again at the end of a “trip”. Sorry for the ones that are not really fond of 
English, but since all this work was done in English, I think I should finish in the same 
language… 
This time I will be quicker in my acknowledgements than last time, but that doesn’t mean 
they will be less sincere; it’s just a sign of the time passing, and my wisdom -aka age-  
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the students that crossed paths with mine for their stage. There were lots of them, but a 
special mention goes of course to the ones I spent more time with, that now are not just “the 
people of the lab” anymore, but Friends: Elisa, my little “Arciduchessa” and that’s saying all, 
because otherwise I’ll have to write a paper on you my dear; Chiara, my little “Pistonbrilla”, 
and I stop here with you also; SuperI; Gracile Gloria; Simon Binding; ENrika… 
Sorry if I’m not writing down all the things I would like to say, but it would take really too 
long, so I’ll just tell you a very heartfelt THANK YOU for everything. And my only advice for 
the future is… don’t let our “comfort cabinet” become as empty as I found it coming back 
from the USA! 
Talking about USA, a special mention is absolutely needed for the LONG list of people 
working with me in the TML (I know both of you remember it very well!!!): another heartfelt 
THANK YOU to Annamaria and Nikki, for everything you’ve done for me when I was there, 
on the other side of the Ocean, in the lab and outside. I’ll see you soon, you won’t easily free 
yourselves of me…eventually, I’m going to have some babysitting to do! And a big thank you 
also to Erik (don’t worry, I’m not forgetting of you either). 
Coming back to this side of the Ocean, it’s decidedly time to mention the Friends I have 
here: you know who you are. Yes, all of you, that stayed with me through happy and sad 
times (and there had been lots of both of them). To the ones I know since I was a little bit 
older than a toddler (Anto, Sabry, Dany and then Sara and Laura, now with little Sofia!), the 
ones that came later though my life (Sarah, Luisa, Silvia, Angelo, Matteo, Andrea ect…), the 
ones that came with university and similar (Miky, Roby etc…) and the last ones (but not 
really in order of affection) appeared to stay in my life (Vale, Ste etc…). To all of you, that 
have never forgot about me even when I was far away even for so long, THANK YOU. You 
cannot even imagine what you mean to me; let’s just say A LOT. 
And then, of course, the biggest THANK YOU goes to my family; mum, dad, Marco and 
granny. Because, as I already said in other occasions, you’ve always let me take my 
decisions and you supported all of them, always. And that’s the most comfort a person can 
find in her family. THANK YOU again. 
 
At last, only a line to you, that will not be here, but will in fact BE WITH me. Thank you. 
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Okay, okay, here’s the translation…  
Ed eccomi qui, di nuovo alla fine di un "viaggio". Mi dispiace per quelli che non sono 
realmente appassionati di inglese, ma dato che tutto questo lavoro è stato fatto in inglese, 
penso dovrei finire nella stessa lingua ... 
Questa volta sarò più veloce nei miei ringraziamenti dell'ultima volta, ma questo non 
significa che saranno meno sinceri, è solo un segno del tempo che passa, e della mia 
saggezza –o meglio età– che aumenta sempre più! 
La prima menzione va senza alcun dubbio al laboratorio dove ho trascorso questi tre 
anni: a Elena, colei che mi ha dato la possibilità di fare il lavoro che vorrei davvero poter 
continuare a fare anche dopo questa esperienza, e non solo qui, ma anche dall'altra parte 
dell'Oceano, oltre ad avermi dato tutti i consigli di cui avevo bisogno; a Marzia, sempre 
presente quando avevo domande, e non solo di lavoro; a tutti gli studenti che hanno 
incrociato il proprio percorso con il mio per il loro stage. Sono stati tanti, ma una menzione 
speciale va ovviamente a quelli con cui ho trascorso più tempo, che ora non sono solo più 
"quelli del lab", ma Amici: Elisa, la mia piccola "Arciduchessa", e questo è dire tutto, perché 
altrimenti dovrei scrivere un paper su di te, mia cara; Chiara, la mia piccola "Pistonbrilla", e 
mi fermo qui anche con te; SuperI; Gracile Gloria; Simon Binding; Enrika ... 
Scusate se non scrivo tutte le cose che vorrei dire, ma ci vorrebbe davvero troppo tempo, 
quindi mi limiterò a lasciarvi un molto sentito GRAZIE per tutto. E il mio unico consiglio per il 
futuro è ... non lasciate che il nostro "comfort cabinet" diventi vuoti come l’ho trovato di 
ritorno dagli Stati Uniti! 
A proposito di USA, una menzione speciale è assolutamente necessaria per la LUNGA 
lista di persone che hanno lavorato con me in TML (so che voi due ve la ricordate molto 
bene!): un altro sentito GRAZIE ad Annamaria e Nikki, per tutto quello che avete fatto per 
me quando ero lì, dall'altra parte dell'Oceano, in laboratorio e fuori. Ci vediamo presto, non 
sarà facile liberarvi di me ... alla fine, mi aspetta un pò di lavoro da baby-sitter! E un grande 
grazie anche a Erik (non preoccuparti, non mi dimentico nemmeno di te). 
Tornando al di qua dell'Oceano, è decisamente il momento di parlare degli amici che ho 
qui: sapete bene a chi mi riferisco. Sì, voi tutti, che siete rimasti con me nei momenti felici e 
tristi (e ce ne sono stati un sacco di entrambi). Per quelli che conosco da quando ero un pò 
più grande di un cucciolo (Anto, Sabry, Dany e Sara e Laura, ora con la piccola Sofia!), 
Quelli che sono arrivati in seguito nella la mia vita (Sarah, Luisa, Silvia, Angelo, Matteo, 
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...). A tutti voi, che non vi siete mai dimenticati di me, anche quando ero lontano, anche per 
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diciamo solo TANTO. 
E poi, naturalmente, il più grande GRAZIE va alla mia famiglia: mamma, papà, Marco e 
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